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1.1. Bone  
 
Bone is the calcified tissue that provides support to the soft tissues that make 
up a body. It allows for movement, such as walking and chewing, and provides every 
vertebrate creature with their unique shape. The skeleton provides strength, it protects 
the vital organs, and is a storage site for minerals (e.g. calcium, phosphate). But if we 
look closer, it is much more than just a hard, inert structure; it is an interactive and 
vital organ system, sending and receiving molecular signals between its self-contained 
cells and to and from other tissues and organ systems. While bone and bone cells 
change and react in response to molecular signals, they are also sensitive to 
mechanical forces. Mechanical stimulation is sensed by cells deep within the bone, 
triggering the secretion of hormones and growth factors, and ultimately enhancing 
bone production1. Bone hosts, supports, and stimulates the hematopoietic stem cells 
and their differentiation into all of the blood cell lineages. Bone is highly-vascularized, 
allowing for efficient transmission of its embedded minerals, such as calcium, 
hormones and other molecules to the rest of the body, as well as maintaining calcium 
homeostasis in the blood. Furthermore, recent research has also demonstrated the 
endocrine functions of the bone, exemplified by osteocalcin, which is produced by 
osteoblasts and affects multiple organ systems, playing a role in insulin regulation, 
testosterone synthesis, and production of monoamine neurotransmitters2–5.  
 
1.2. Bone tissue and cell types 
 
Bone tissue is composed of an extracellular matrix and bone cells. The 
extracellular matrix primarily consists of type I collagen (90%), with the remaining 
10% being a mix of a large number of non-collagenous proteins (e.g. osteocalcin, 
osteonectin, bone sialoproteins, osteopontin, fibronectin, and various proteoglycans)6–
9. Non-collagenous proteins participate in the process of matrix maturation, 
mineralization9. The bone matrix not only provides support for bone cells, but also 
regulates the activity of bone cells through several adhesion molecules, including 
integrins8,10,11. 
While a great number of cell types are contained within the bone, there are 
three that are most remarkable for their role in bone metabolism: osteoblasts (bone-
forming cells), osteocytes, and osteoclasts (bone resorbing cells) (Fig. 1).  
Osteoblasts are located along the bone surface and comprise 4–6% of the 
total resident bone cells (Fig. 1). Mature osteoblasts are cuboidal cells, containing 
abundant rough endoplasmic reticulum, prominent Golgi apparatus, and various  
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Figure 1. Bone cells. Three main cells types are involved in bone formation and remodeling. The osteoblast is the bone 
building cell, and is derived from the mesenchymal stromal cells. Osteoclasts can further differentiate into osteocytes, 
bone lining cells, or undergo apoptosis. Osteocytes have an important role as mechanical sensors and signal to the other 
bone types. Osteoclasts break down bone and derived from the hematopoietic lineage.  Image adapted from Riddle et 
al.12 
 
secretory vesicles13,14. Osteoblasts come from mesenchymal stromal cells present in 
bone marrow15.  The primary function of osteoblasts is synthesis of bone, which 
includes producing the protein matrix and its subsequent mineralization. Through 
their function in building bone they accomplish a crucial role in the achievement and 
maintenance of a correct bone mass, which is accomplished through a close cross-talk 
with the other bone cells: osteoclasts and osteocytes. 
Osteoblasts play a significant role in regulating osteoclastogensis and bone 
resorption through this cross-talk between the two cells types. Osteoblasts produce 
both macrophage-Colony Stimulating Factor (M-CSF), which promotes osteoclast 
proliferation and differentiation16, and Receptor Activator of Nuclear kappa B Ligand 
(RANKL), that activates the fusion and differentiation of pre-osteoclasts into mature 
osteoclasts17. Osteoblasts also make osteoprotegerin (OPG), which inhibits 
osteoclastogenesis and the subsequent bone resorption by functioning as a decoy 
receptor for RANKL. A correct RANKL/OPG ratio is required to balance bone 
production and breakdown18. Recently a role for the osteoblast in endocrine function 
has also been discovered through their role in producing osteocalcin. Osteocalcin acts 
in the pancreas and adipose tissue to regulate insulin regulation, on the testis for 
testosterone synthesis, and in the brain stimulates the synthesis of monoamine 
neurotransmitters, inhibits gamma-aminobutyric acid (GABA) synthesis, aids in 
learning and memory and decreasing anxiety2–5,19,20. Osteoblasts have also been shown 
to regulate hematopoietic stem cells (HSCs) and HSC progenitors: miRNAs carried by 
osteoblast released extracellular vesicles enhance proliferation of CD34+ 
hematopoietic stem and progenitor cells, constitutive activity of beta catenin in 
osteoblasts induces acute myeloid leukaemia, along with genome instability and 
Bone Matrix
Osteoid
Bone Lining Cells
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chromosome mutations in HSCs, and osteoblasts promote maintenance of the HSC 
niche and/or hematopoietic progenitor populations13,21–23.  
Osteocytes are easily identifiable by their location, being completely 
embedded within the calcified bone matrix (Fig. 1). Osteocytes are derived from 
terminally differentiated osteoblasts. They are the most numerous cell type in the 
bone, as well as the most long-lived, having a lifespan up to 25 years. Each osteocyte 
can have up to 50 long, branched processes that extend through the bone. The 
processes run inside interconnected canals in the bone, called canaliculi. This allows 
the processes of the osteocytes to contact neighboring osteocytes through tight and 
gap-junctions. Their unique shape, distribution and spatial organization optimize them 
for their job in signal transport and sensing of mechanical forces, making osteocytes 
one of the master regulators of bone13,24.  
Bone lining cells, as their name suggests, cover the surface of inactive bone 
and are quiescent, flat-shaped, and also arising from osteoblasts (Fig. 1). Bone lining 
cells functions are not completely understood, but it has been shown that in areas not 
actively undergoing remodeling these cells prevent the direct interaction between 
osteoclasts and the bone matrix, and also participate in osteoclast differentiation, 
producing OPG and the RANKL25,26. These cells have been seen to have processes 
extending into bone canaliculi suggesting they are in communication with 
osteocytes27,28. Recent evidence also suggests that in adult bone, bone lining cells can 
be reactivated to act as mature osteoblasts and osteoblast precursors, ultimately 
capable of producing a mineralized bone matrix29–31. 
Osteoclasts are a member of the monocyte/macrophage family originating 
from haematopoietic stem cells (Fig. 1). Mature, bone resorbing osteoclasts are large 
multinucleated cells formed by cell–cell fusion of mononuclear preosteoclasts9. 
Osteoclasts are highly polar cells, displaying a ruffled border, where there is folding of 
the plasma membrane in the area facing bone matrix. This ruffled border is required 
for their ability to degrade bone32,33. In order to resorb mineralized bone tissue, 
osteoclasts attach to the bone surface and form a seal around the area to be resorbed 
by binding their integrins with the bone protein, vitronectin. The ruffled border of the 
osteoclast incorporates a vacuolar-type H+ pump that acidifies the bone matrix 
beneath the osteoclast. Lysosomal proteases and acid phosphatases are released by the 
osteoclast to break down the calcified tissue34,35. Just as osteoblasts are key regulators 
of osteoclasts, osteoclasts also influence osteoblasts. Through osteoclast-mediated 
bone resorption, factors that are known to be strong osteoblast anabolic agents 
(including transforming growth factor-ß (TGFß), Bone Morphogenetic Proteins 
(BMPs), Fibroblast Growth Factors (FGFs) and Insulin-like Growth Factor I (IGF-I) 
are released, leading to recruitment of osteoblast precursors to the site, and activating 
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matrix deposition and mineralization. Osteoclasts also directly release molecules, 
termed clastokines, that influence osteoblasts. Interestingly, the clastokines released by 
osteoclasts both positively (Tartrate-resistant acid phosphatase (TRAcP), Sphingosine-
1-Phospahte (S1P), BMP6, Wingless-type 10b (Wnt10b), Hepatocyte Growth Factor 
(HGF), Collagen Triple Helix Repeat-Containing Protein 1 (CTHRC1)) and negatively 
(Platelet Derived Growth Factor BB (PDGF BB)) regulate osteoblast recruitment, 
differentiation, matrix deposition and mineralization. This likely aids in maintaining a 
balanced ratio between activation and inhibition of bone formation32,36.  
Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, 
marrow stromal cells, and skeletal stem cells, are a multipotent cell with fibroblast 
spindle-like appearance. They are defined through their ability to differentiate into 
mesenchymal lineages, including osteoblasts, chondrocytes, and adipocytes (Fig. 2), in 
vitro and in vivo, and for their colony forming capacity, adherence to plastic, and ability 
of self-renewal37,38. It is generally agreed that human MSCs can be identified through 
expression of specific surface markers being STRO-1, CD44, CD73, CD90, CD105, 
and CD106 positive and negative for haematopoietic surface markers (CD34, CD45, 
CD14)9,39,40; however, conclusive cell surface markers specific for MSCs are not yet 
determined and agreed upon and identification of these markers is needed, as has 
been done for hematopoietic stem cells.  Apart from their role in maintaining the 
populations of mesenchymal lineage cells, MSCs also modulate immune response 
through secretion of pro- and anti-inflammatory chemokines, organize vascular 
networks via their interaction with endothelial cells, and support hematopoietic stem 
cells37. MSCs are traditionally found in the bone marrow; however, studies have 
shown these cells can also be found in other tissues including peripheral blood, 
umbilical cord blood, synovial membrane, deciduous teeth, amniotic fluid, and 
adipose tissues. While these varying MSC populations share common properties and 
the ability to differentiate into osteoblasts, chondrocytes, and adipocytes, some differ 
in their gene expression profile in ways that reflect their tissue of origin9,39. 
 
1.3. Osteoblast differentiation 
 
1.3.1 Mesenchymal stromal cell (MSC)-derived lineages 
Osteoblasts are derived from the bone marrow MSCs and, following their 
activity as osteoblasts, undergo differentiation to form osteocytes, bone line cells or 
undergo apoptosis41. Besides osteoblasts, MSCs give rise to other cell types, including 
adipocytes and chondrocytes42 (Fig. 2). Significant strides have been made in 
identifying the molecular mechanisms underlying lineage commitment within the  
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Figure 2. Mesenchymal stromal cell differentiation. MSCs reside within the bone marrow and have the capacity to 
differentiate into a variety of cell types including osteoblasts, chondrocytes, and adipocytes. Lineage commitment 
requires expression of a master transcription factor. 
 
mesenchymal lineages. Control over the differentiation of MSCs towards the different 
lineages consists of a cascade of transcription events driven by specific transcription 
factors that control each other’s phenotype-specific gene expression. It has been 
found that a master gene, one transcription factor, that can induce and start a cascade 
that leads to the sequential expression of other transcription factors and of 
phenotype-specific genes, is required for MSC commitment to each of the lineages 
(Fig. 2). Runt-related transcription factor 2 (RUNX2), also known as core-binding 
factor subunit alpha-1 (CBFA1), is considered the master regulator of osteoblast 
differentiation. The significance was Runx2 demonstrated by the fact that Runx2-null 
mice are devoid of all osteoblasts, born with only a cartilaginous template and no 
bone43,44. In the adipocyte lineage Peroxisome proliferator-activated receptor-gamma 
2 (PPAR-γ2) is the master regulator of differentiation, together with other 
transcription factors, including the CCAAT/enhancer binding (C/EBP) protein 
family, plays a key role in adipocyte differentiation45. The transcription factor Sex 
determining region Y-box 9 (SOX9) is essential for chondrocyte differentiation, and 
regulates downstream expression of various chondrocyte genes, and cartilage 
formation46. Interestingly, SOX9 is also crucial in embryonic endochondral bone 
development. SOX9 mediates the condensation of mesenchymal cells into 
chondrogenic progenitors, which is a necessary step in commitment of the osteoblast 
precursors. Ablation of Sox9 in mice leads to a lack expression of Runx2 in the axial 
skeleton, producing mice born with heads, but without limbs; however, if Sox9 is 
selectively ablated in precursors after mesenchymal condensation, Runx2 expression 
and osteoblastogenesis take place47. It should be noted that these differentiation 
process are highly complex and each of these master regulators may play more subtle 
roles within the converse lineages48–51.  
 
 
Bone Marrow
MSCs
Osteoblast
Chondrocyte
Adipocyte
RUNX2
SOX9
PPAR-γ2
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1.3.2 Signaling pathways in osteoblast differentiation 
 Maintaining a proper bone mass requires an intricate network of signaling 
pathways and molecular cascades. Each pathway feeds back to others and creates a 
web of positive and negative controls. Over the past several decades a great deal of 
insight has been gained into the genes and signaling pathways controlling osteoblast 
differentiation and controlling bone formation. Some examples of the complex 
signaling networks involved in osteoblast differentiation are described herewith. 
Members of the TGFß family stimulate RUNX2 expression and matrix protein 
production and deposition. BMPs can enhance, and in some cases induce, osteoblast 
differentiation through expression of RUNX2 and Osterix (OSX, encoded by SP7)52. 
Wnt family members are essential in regulating commitment of MSCs towards the 
osteoblast lineage and further osteoblast differentiation. Canonical Wnt signaling 
regulates osteoblast differentiation and bone formation through beta-catenin 
stabilization, allowing translocation into the nucleus where it regulates the 
transcription of Wnt target genes13,53. And notably, Wnt co-receptor, Low-Density 
Lipoprotein (LDL) receptor related protein 5 (Lrp5), regulates bone mass through 
changes in osteoblast activity38. Notch signaling is important in regulating osteoblast 
differentiation via its role as a negative regulator of osteoblast formation, targeting the 
stage of MSC differentiation via RUNX2 transcriptional activity53. Liver-secreted 
insulin-like growth factors (IGFs) can enhance OSX expression, trigger osteoblast 
proliferation, and increase collagen synthesis52. Hedgehog (Hh) family members 
encourage osteoblast differentiation at the progenitor stage via Gli transcription 
factors that stimulate expression of Runx254. Vascular endothelial growth factors 
(VEGF) promote differentiation of osteoblasts, increase bone mineralization, regulate 
osteoclast differentiation and activity, and induce vascularization of developing bones, 
which is essential for bone growth55,56. 
 
1.3.3 Stages of osteoblast differentiation 
 Osteogenic differentiation of MSCs into osteoblasts is a tightly regulated 
process that progresses through several phases, portrayed in Fig. 3. In the first phase 
of differentiation MSCs are driven to the osteogenic lineage by expression of the 
osteoblast-specific transcription factors, with RUNX2 and OSX being the most 
critical43,44,57. As described in the previous section, RUNX2 is integral to osteoblast 
differentiation and bone development. Mutations in RUNX2 in humans leads to a 
variety of defects resulting in cleidocranial dysplasia58,59. In addition to being required 
for osteoblast differentiation, RUNX2 is also necessary for the proper function of 
mature osteoblasts, including the synthesis of extracellular matrix (ECM), through its 
ability to regulate a number of osteoblast-related genes, including osteopontin (SPP1),  
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Figure 3. Stages of osteoblast differentiation. Osteoblast differentiation is tightly regulated process that involves 
several stages, each controlled by a number of genes, cytokines, growth factors, and ECM proteins.  
 
bone sialoprotein (IBSP), osteocalcin (BGLAP), OPG, RANKL, collagen type I alpha 
1 chain (COL1A1), and alkaline phosphatase (ALPL)8,53,54. A high degree of cross talk 
exists between the varying signaling pathways affecting osteoblast differentiation and 
bone formation. RUNX2 is at the center of this, acting as the master controller of 
osteoblast differentiation, and a large number of positive and negative checks are 
centered around it. Many transcription factors (Table 1) have been shown to 
synergize with RUNX2 to promote osteoblast differentiation by either stimulating 
RUNX2 expression, enhancing RUNX2 activity or acting as co-activators. On the 
other hand, a number of other factors (Table 1) suppress RUNX2 levels or by 
blocking RUNX2 DNA binding, nuclear translocation, or protein expression. 
Osterix (Osx/SP7), a zinc-finger transcription factor downstream of 
RUNX2, is necessary for both commitment of MSCs to the osteoblast lineage and 
further osteoblast differentiation. Osx was discovered as a Bmp-inducible gene in 
murine C2C12 cells, whose deletion in mice resulted in complete absence of 
osteoblasts in embryos, despite relatively normal expression of Runx260. In addition, 
these mice displayed very little Col1a1, and no expression of IBSP, osteonectin 
(SPARC), or SPP1. OSX expression is stimulated by BMPs and IGF1, and although it 
is downstream of RUNX2, its activation via BMPs follows both RUNX2-dependent 
and -independent pathways. Osterix also serves as a negative regulator of Wnt 
signaling13,54 and it controls transcriptional expression of the transcription factor 
Special AT-rich Binding 2 (SATB2)61, which is important in craniofacial development 
and osteoblast differentiation62. SATB2 interacts with both RUNX2 and Activating 
Transcription Factor 4 (ATF4) to positively regulate osteoblast markers COL1A1, 
IBSP, and OCN, at the later stage of osteoblast differentiation63.  
 
 
MSC Osteoprogenitor Early osteoblast Mature
Osteoblast
Lining Cell
Osteocyte
Apoptosis
Lineage commitment
RUNX2, SP7 (Osterix)
BMP, WNT, DLX5 
Proliferation
Low ALP
RUNX2, SP7, COl1A1, 
FN, TGFB, IGF1, SPP1
ECM production
High ALP
COL1A1, SPP1, IBSP, 
ALP, FGF2, BMP2, 
TGFB
Matrix Maturation 
and Mineralization
BGLAP, OPN
Calcium, Phosphate
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Table 1: Transcription factors acting on or with RUNX2 to affect osteoblast differentiation 
Transcription factor name Gene symbol Effect on 
RUNX2 
Ref 
v-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog 
MAF Enhances 64 
tafazzin TAZ Co-activator 65,66 
special AT-rich sequence-binding protein 2 SATB2 Stimulates 62 
retinoblastoma protein RB Enhances 67,68 
GLI family zinc finger 2 GLI2 Stimulates, 
Enhances 
69 
distal-less homeobox 5 DLX5 Stimulates 70,71 
Msh homeobox 2 MSX2 Stimulates 72 
bagpipe homeobox homolog 1 NKX3-2 Stimulates 73 
Twist-related protein 1 TWIST1 Inhibits  74 
Heart- and neural crest derivatives-expressed protein 2 HAND2 Inhibits binding 75 
Human Immunodeficiency Virus Type I Enhancer 
Binding Protein 3 
HIVEP3 
(Schnurri-3) 
Facilitates 
degradation 
76 
GLI Family Zinc Finger 3 GLI3 Inhibits binding 77 
Homeobox A2 HOXA2 Downregulates 78 
Hes Family BHLH Transcription Factor 1 / Hes 
Related Family BHLH Transcription Factor With 
YRPW Motif 1 
HES1/ 
HEY1 
Inhibits activity 79,80 
 
 Following activation of RUNX2 and OSX, osteoprogenitors undergo a 
proliferation phase and begin to show alkaline phosphatase (ALP) activity. Through 
this proliferation phase the cells upregulate expression of genes encoding matrix 
protein and stimulating osteoblast differentiation, including fibronectin (FN), collagen 
I, TGFβ, TGFβ receptor, VEGF, PDGF, IGF-1, and SPP18,13,54,81. 
In the next stage of differentiation early osteoblasts (or pre-osteoblasts) are 
actively engaged in energy demanding process of ECM production and maturation. 
Osteoblasts secrete collagen proteins (mainly type I), non-collagenous proteins (OCN, 
osteonectin, bone sialoproteins, osteopontin), and proteoglycans (including decorin 
and biglycan), forming the bone matrix (osteoid) onto which the mineral will later be 
deposited82. This stage of differentiation is characterized by peak transcription and 
protein expression of ALP83. These matrix producing osteoblasts are characterized by 
expression of COL1A1, SPP1, IBSP, ALP, FGF2, BMP2, TGFß, and PDGF13,81,83. 
The morphology of the osteoblast is also changing at this time and by the beginning 
of the mineralization phase (next) osteoblasts have adopted their characteristic large, 
cuboidal shape53. 
 In the final stage of osteoblast differentiation, matrix mineralization occurs, 
which is characterized by high expression of osteocalcin (BGLAP) and osteopontin 
(OPN), followed by calcium and phosphate deposition81,84. Production of osteocalcin 
is so high at this point that it is in fact the most abundant non-collagenous protein in 
bone, after collagen85. Mineralization of bone matrix takes place beginning with the 
osteoblasts releasing matrix vesicles from their apical membrane domain into the 
newly formed matrix, where the vesicles bind to proteoglycans and other organic 
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components in the matrix. Calcium phosphate crystals begin forming inside the 
matrix vesicles and grow through the influx of Ca2+ and PO43−, by means of the 
membrane transporters and enzymes (including ecto-nucleotide 
pyrophosphatase/phosphodiesterase 1 (ENPP1), ankylosis (ANK), and ALP. The 
calcium phosphate crystals (hydroxyapatite) elongate and penetrate the matrix vesicle’s 
membrane, finally growing out of the vesicles to form calcifying nodules. The 
calcifying nodules continue growing, finally leading to collagen mineralization in the 
surrounding matrix8,86. 
 After osteoblasts fulfill their primary role in bone production three possible 
fates exist for these cells. The osteoblasts either (1) undergo apoptosis, (2) transform 
into osteocytes embedded within the bone matrix, or (3) become quiescent bone 
lining cells covering the bone surface. The mechanisms that control final osteoblast 
fate are still largely yet unknown. 
 
1.4. Bone formation, modeling, and remodeling 
 
Throughout life bone is constantly changing, and undergoing continuous 
turnover to maintain its strength and mass. Bone structure and mass are created or 
altered in one of three ways: osteogenesis (embryonic bone formation), bone 
modeling and bone remodeling.  
During embryogenesis, osteogenesis occurs either by intramembranous or 
endochondral ossification. Intramembranous ossification occurs in parts of the skull 
or craniofacial skeleton, clavicles and scapulae where mesenchymal cells condense, 
differentiate, and directly produce membranous bone. In endochondral, or indirect, 
ossification first a cartilaginous template is produced, which slowly is replaced by 
mineralized bone, and occurs in the long bones and the rest of the skeleton9. 
 Once bone is formed, substantial changes in structure and geometry of the 
bones occur through bone modeling. Throughout development, childhood and even 
into adulthood adaptation to strain leads to modeling of bone. Examples of this 
include tibial modeling after removal of fibula for reconstructive surgery87. In bone 
modeling the activities of the osteoblasts and osteoclasts may occur independently88. 
 Bone remodeling is the process of removing mature bone tissue followed by 
subsequent formation of new bone tissue. In healthy adults, bone undergoes constant 
remodeling, balancing bone formation and bone resorption, with the actions of 
osteoblasts and osteoclasts being linked, a process known as coupling. This allows 
bone resorption and then formation to occur at the same location on the bone surface 
consecutively and maintenance of a healthy bone mass. It has been estimated that the 
human adult skeleton is renewed by remodeling every 10 years and that 1 million  
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bone remodeling units (BRUs) are actively engaged in bone turnover at any time89. 
BRUs are made up of osteoblasts and osteoclasts, together with their precursor cells 
and associated cells (e.g. endothelial cells, nerve cells), with coordinated actions 
between the cells required for proper bone remodeling to take place9. Remodeling is 
essential for removal of microcracks, that can endanger the integrity of the bone, as 
well as for maintaining mineral homeostasis in the skeleton and throughout the body. 
Bone remodeling also plays a role in the maintenance of acid/base balance, and the 
release of growth factors embedded in bone that are required for the bone remodeling 
process and attract osteoblast precursors and enhance osteoblast proliferation and 
differentiation34,88,91,92. Remodeling is a process characterized by four phases: (1) the 
activation phase when the osteoclasts are recruited; (2) the resorption phase, when the 
osteoclasts digest the underlying bone mineral matrix; (3) the reversal phase, where 
the osteoclasts undergo apoptosis, the eroded bone surfaces are colonized by reversal 
cells, and osteoblasts are recruited; and (4) the formation phase, where the osteoblasts 
lay down new organic bone matrix that subsequently mineralizes (Fig. 4). This process 
is driven by complex actions of the various cell types and biochemical factors, and it is 
sensitive to the loads applied onto the skeleton92. Interestingly, a great deal of research 
recently has focused on the reversal phase, in particular the reversal cells (recently 
described as identical to osteoprogenitors) that are thought to be key in linking bone 
formation to resorption93,94.  
 
 
Figure 4. Bone remodeling. Bone remodeling is carried out through a series of steps: (1) osteoclast precursors are 
recruited to the bone surface. (2) mature osteoclasts resorb the bone mineral matrix. (3) a reversal phase where 
osteoclasts undergo apoptosis and reversal cells and osteoblast precursors are recruited. (4) mature osteoblasts create a 
new matrix that is mineralized. Adapted from Tou.90 
 
1.5. Osteoporosis 
 
Osteoporosis, the word itself meaning porous bones, is a common and 
devastating bone disease that is characterized by low bone mass and deterioration of 
bone microstructure, which leads to increased bone fragility and susceptibility to 
fractures (Fig. 5). Osteoporosis has become a major-medical problem and is now  
 
       Pre-            Active    Reversal Cells /    Active    Osteoblast apoptosis
osteoclasts               osteoclasts    Pre-osteoblasts        Osteoblasts       Bone Lining Cells
                       Osteocytes
        Osteoclast apoptosis
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Figure 5. Depiction of healthy versus osteoporotic bone structure. Trabecular bone from healthy individuals 
(left) has a higher mineral density than bone of individuals with osteoporosis (right). Adapter from Ringer98. 
 
estimated to affect approximately 50 percent of women and 20 percent of men over 
50 years of age95. The acute clinical concern of osteoporosis is fractures and their 
subsequent consequences for health; osteoporosis-related fractures, vertebral and hip, 
are associated with morbidity and increased mortality96,97. It is estimated that an 
osteoporotic fracture occurs once every 8 seconds worldwide99 and direct healthcare 
costs in Europe alone are at least €31.7 billion annually100.  
During osteoporosis the coupling process is disturbed, leading to a disruption 
in bone remodeling where resorption overtakes bone formation101. The exact cause of 
this dysregulation in osteoblast and osteoclast balance and development of 
osteoporosis is still being unraveled. Diagnosis of osteoporosis itself is usually based 
upon measuring bone mineral density (BMD) through use of a bone densitometer 
(most common is a Dual energy X-ray absorptiometry (DXA)). Bone density test 
results are reported as a number called a T-score that indicates the number of units 
(standard deviations) that a patient’s bone density is above or below the average. 
Patients with T-scores of -2.5 and below are characterized as having osteoporosis. 
The cause of osteoporosis is due to a combination of factors, which include genetics, 
nutrition, lifestyle, estrogen deficiency, calcium and vitamin D deficiency, secondary 
hyperparathyroidism, impaired stem cell renewal, decreased growth factors, cytokines 
and inflammation, neural and muscular impairment, drugs affecting balance and 
coordination, and environmental hazards102. Great effort has been put into 
discovering genetic polymorphisms that can affect bone mass and bone fragility. Most 
notably a number of polymorphisms have been found that affect the collagen1α1 
gene, leading to poor bone quality102. Estrogen deficiency is one of the most well-
known contributors to osteoporosis, although the precise mechanisms are still being 
studied. Estrogens act on osteoblasts, osteocytes, and osteoclasts to regulate bone 
remodeling and maintain bone formation9,103. Estrogen deficiency is associated with 
increases in bone resorption due to increased osteoclast numbers and increased 
osteoclast activity89. The increase in bone resorption following estrogen deficiency is 
associated with an increase in bone formation (coupling), but the rate of formation is 
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not able to keep up with the rate of resorption, resulting in a net loss of bone103. 
Other age-related changes, such as reduced levels of growth factors and increases in 
inflammation are likely affecting the homeostatic bone balance. Increases in the 
cytokine Tumor Necrosis Factor alpha (TNFα) can inhibit bone formation while 
stimulating bone resorption102. Another cause for the occurrence of osteoporosis is 
the reduced osteoblastic differentiation capacity of MSCs. It has been seen that with 
aging there is a decrease in bone mass and increased bone fragility, while at the same 
time there is an increase in total and bone marrow adiposity104–106. There is also 
evidence of a high correlation between osteoporosis and bone marrow fat. These 
indicate that there is a shift in the lineage decision-making process of MSCs with 
increasing age contributing to the development of osteoporosis by increased 
preference of adipocyte differentiation as opposed to that of osteoblasts. However, 
despite considerable research for many years, our current understanding of the 
mechanisms that disrupt osteoblast/osteoclast coupling during bone homeostasis and 
remodeling, and the associated changes in properties of bone during osteoporosis is 
still fragmented due to complex interrelationships between bone cells and structural 
features of bone.  
 
1.6. Current treatments for osteoporosis 
 
At present, most osteoporosis treatments thus far aim at inhibiting bone 
degradation by way of decreasing osteoclast function or production. The treatments 
are termed anti-resorptive and decrease the rate of remodeling and the amount of 
resorption cavities. Essentially, anti-resorptive therapy preserve the existing bone 
mass and structure107. Bisphosphonates are the most common anti-resorptives and 
include alendronate, ibandronate, risedronate, and zoledronic acid. The 50th 
anniversary of the bisphosphonate discovery was celebrated in 2019. Bisphosphonates 
bind with high affinity to the mineral matrix of the bone and inhibit osteoclast 
resorption of the bone, which leads to a decrease in bone turnover107,108. An overall 
increase in BMD is seen with bisphosphonate treatment, likely due to decreased 
formation of new remodeling units by osteoclasts along with relative maintenance, at 
least initially, of osteoblast activity109. All bisphosphonates are reported to be 
associated with a rare complication called osteonecrosis of the jaw108 and, more 
recently, atypical femur fractures110. 
Denosumab is a newer non-bisphosphonate anti-resorptive drug, which has 
also shown to reduce the risk of osteoporotic fracture in women and men. It is a 
human monoclonal antibody against RANKL, the transmembrane protein required 
for the formation, function, and survival of osteoclasts, leading to decreased bone 
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resorption108. In cortical bone, denosumab can improve cortical bone structure, 
increasing cortical thickness and decreasing porosity, and it has been reported that this 
increase in BMD is somewhat greater than with bisphosphonates and lasts longer. A 
possible reason for the gain in bone is that denosumab maintains physiological bone 
modelling88,107,111. Osteonecrosis of the jaw and atypical femur fractures have also 
been reported with denosumab use110,112. 
Selective estrogen receptor modulators Raloxifene and Bazedoxifene are both 
estrogen agonists and antagonists, and act as a weak antiresorptive agent known to 
reduce the risk of vertebral but not non-vertebral or hip fracture in women with 
postmenopausal osteoporosis107. They also have estrogen antagonistic activity on 
breast and uterine tissue. 
Most anti-resorptive treatments can result in modest increases in BMD; 
however, these treatments do not result in a true bone anabolic effect, so patients do 
not regain bone that has been lost at time of diagnosis. Some drugs, especially 
bisphosphonates due to their prolonged activity in bone, even inhibit osteoblast 
activity through the coupling of osteoblast and osteoclast activity, which can result in 
a “frozen bone” state where bone may actually become more brittle as it fails to 
respond to bone remodeling cues, such as microcracks and systemic mineral 
requirements.  
While there is a need and interest in treatments that act by stimulating bone 
formation, so called anabolic drugs, the only currently available treatment to increase 
bone formation is parathyroid hormone. Parathyroid hormone (PTH) is produced 
naturally in the body and regulates the amount of calcium in bone. PTH treatments 
(teriparatide, a truncated version of recombinant human PTH(1-34); and 
abaloparatide, a synthetic analogue of PTH related peptide (PTHrP)) are used to 
stimulate osteoblasts. The majority of the anabolic effect in trabecular bone is 
achieved through enhanced osteoclast activity at remodeling sites, with overfilling of 
remodeling units. By increasing bone production there is also an increased osteoclast 
activity, as the two are linked, but despite this, studies have shown an overall increase 
in BMD. On the downside, PTH treatments must be administered daily by 
subcutaneous injection, are expensive compared to anti-resorptive treatments, appear 
to primarily increase bone forming activity at sites that are still undergoing bone 
remodeling rather than at areas of quiescence, and during the early stages of treatment 
the formation of under-mineralized new bone can occur, which results in little change, 
or a decrease in BMD at sites such as the hip and radius107,113. In addition PTH 
treatment are limited to 2 years of use due to the potential occurrence of 
osteosarcomas (seen in rat studies) and are reserved for patients with severe 
osteoporosis107,114.  
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The search for better treatments continues. In order to bring fragile 
osteoporotic bone back into a healthy state and reduce the risk of new fractures in 
osteoporosis patients there is a need for new treatments that can replace bone that has 
already been lost. The future of osteoporosis treatments may include identification of 
new bone anabolic treatments, but there is also a need to better understand the 
mechanisms of action by existing drugs and the intricacies of the networks involved in 
bone production and remodeling as this could lead to improved use of existing 
treatments.  
 
1.7. Aim of this thesis 
 
Understanding the mechanisms that control the differentiation of osteoblasts 
cells from MSCs is one of the fundamental areas of research of bone biology, and the 
focus of this thesis. While huge leaps have been made in bone research, primarily 
through mouse models and cell lines, there is still a great deal unknown about what 
specific factors stimulate osteoblast differentiation and lead to mineralization of new 
bone, particularly in human cells and during adult bone formation, remodeling and 
repair. A better understanding of the predominant signaling networks, their intricate 
interactions, and what other genes and pathways are involved in human MSC lineage 
decision making, as well as osteoblast differentiation and function, is required to 
develop approaches to enhance bone formation and promote fracture healing for 
patients with disorders such as osteoporosis.  
 
The overall aim of this thesis, through the combined use of bioinformatic, 
genomic, molecular, and proteomic approaches, is to identify novel compounds 
affecting, and genes and processes involved in human osteoblast differentiation and 
bone formation, thus expanding the knowledge of approaches to enhance human 
osteogenesis. The basis for all of the results presented in this thesis come from 
microarray gene expression profiling with high temporal resolution of hMSCs 
undergoing osteoblast differentiation, which identified genes significantly regulated 
during the differentiation process. 
 
In Chapter 2 we combine genomic (gene expression microarray of 
osteogenic differentiating human MSCs) and bioinformatics (the Connectivity Map or 
CMap) tools to identify a novel bone anabolic compound, Parbendazole, that induces 
osteoblast differentiation in a subset of the hMSC population through cytoskeletal 
changes and increased bone morphogenetic protein 2 activity in vitro. 
 
| Chapter 1 
 22 
Using the same approach as in the previous chapter, in Chapter 3 we use the 
CMap to identify additional compounds that both positively and negatively affect in 
vitro human osteoblast differentiation and delve into the important genes mitigating 
their effects. 
 
Chapter 4 identifies Chloride Intracellular Channel 3 (CLIC3) as new gene 
regulated specifically during osteoblast differentiation based on differential 
transcriptional programming of hMSC differentiated towards osteogenic versus 
adipogenic cell lineages, and examines its crucial function in promoting 
mineralization. 
 
Mucin1 (MUC1) was also identified as a novel, lineage specific gene based on 
microarray expression profiling of hMSCs undergoing osteogenic and adipogenic 
differentiation. Chapter 5 details the in vivo role of Muc1 in bone through a Muc1 
deficient mouse model. Longitudinal studies of these mice allowed us to identify mild 
temporal changes in the femurs of female mice during aging. 
 
 Finally, in Chapter 6, the conclusions of the work presented in this thesis are 
defined. I describe the key findings, discuss their significance in the field of bone 
biology, and give recommendations for future work.  
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Abstract 
Osteoporosis is a common skeletal disorder characterized by low bone mass leading 
to increased bone fragility and fracture susceptibility. In this study, we have identified 
pathways that stimulate differentiation of bone forming osteoblasts from human 
mesenchymal stromal cells (hMSCs). Gene expression profiling was performed in 
hMSCs differentiated towards osteoblasts (at 6h). Significantly regulated genes were 
analyzed in silico and the Connectivity Map (CMap) was used to identify candidate 
bone stimulatory compounds. The signature of parbendazole matches the expression 
changes observed for osteogenic hMSCs. Parbendazole stimulates osteoblast 
differentiation as indicated by increased alkaline phosphatase activity, mineralization, 
and upregulation of bone marker genes (alkaline phosphatase/ALPL, 
osteopontin/SPP1, and bone sialoprotein II/IBSP) in a subset of the hMSC 
population resistant to the apoptotic effects of parbendazole. These osteogenic effects 
are independent of glucocorticoids because parbendazole does not upregulate 
glucocorticoid receptor (GR) target genes and is not inhibited by the GR antagonist 
mifepristone. Parbendazole causes profound cytoskeletal changes including 
degradation of microtubules and increased focal adhesions. Stabilization of 
microtubules by pretreatment with taxol inhibits osteoblast differentiation. 
Parbendazole upregulates bone morphogenetic protein (BMP)-2 gene expression and 
activity. Co-treatment with the BMP-2 antagonist DMH1 limits, but does not block 
parbendazole-induced mineralization. Using the CMap we have identified a novel, 
lineage specific, bone anabolic compound, parbendazole, which induces osteogenic 
differentiation through a combination of cytoskeletal changes and increased BMP-2 
activity. 
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2.1 Introduction 
Osteoporosis is a common and devastating bone disease characterized by 
reduced bone mass and increased fragility and fracture risk. It has been estimated that 
an osteoporotic fracture occurs once every 8 seconds worldwide1 and direct 
healthcare costs in Europe alone are at least €31.7 billion annually2.   Osteoporosis 
means porous bones and occurs when bone remodeling is disrupted. Bone 
remodeling is a balancing act between removal of old bone and formation of new 
bone, which is achieved by two distinct cells, the osteoclast and osteoblast, 
respectively. When uncoupling of these two processes takes place, bone resorption 
can overtake bone formation resulting in osteoporosis. Most osteoporosis treatments, 
such as bisphosphonates, reduce bone resorption and result in modest increases in 
bone density; however, these treatments do not result in a true bone anabolic effect so 
patients do not regain bone that has been lost at time of diagnosis. An ideal treatment 
would stimulate bone formation as well, to help repair the damage already done to the 
bone microarchitecture and strength. With this in mind, our goal was to search for 
novel molecules and/or mechanisms that stimulate human osteoblast differentiation 
and bone formation. 
The connectivity map (CMap) is a web-based tool that allows for screening of 
compounds against a genome-wide disease or physiological gene signature3,4. This is 
achieved by comparing microarray data from over 1300 small molecules to a user’s 
selected gene signature of the phenotype of interest using a pattern-matching 
algorithm with a high level of resolution and specificity. This results in a list of 
compounds with a highly correlating gene expression pattern to that of the phenotype 
of interest, which has the potential to aid in finding a novel treatment for a disease or 
to identify novel pathways or genes involved in a complex biological process. To date, 
the CMap has been successfully used to identify compounds and combination 
therapies that show promise in the treatment of osteoarthritic pain5, adenocarcinoma6, 
kidney disease7, gliomas8, and NK cell neoplasms9. 
Our aim was to identify novel anabolic therapeutic targets by genomic, 
proteomic and bioinformatic dissection of human mesenchymal stromal cell (hMSC)-
derived osteoblasts. Therefore, we utilized the CMap to identify compounds with a 
matching gene expression profile to human mesenchymal stem cells undergoing 
osteogenic differentiation. By following this approach, we aimed to not only discover 
novel compounds that stimulate osteogenic differentiation, but also novel processes 
underlying this process.  
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2.2 Results 
 
Parbendazole has the strongest correlating gene signature to hMSCs undergoing osteoblast 
differentiation 
Using a pattern-matching algorithm, the CMap links compounds with disease 
or physiological phenotypes by measuring similarities in gene expression3. To identify 
compounds that may exert bone anabolic effects due to their ability to stimulate genes 
regulated during osteoblast differentiation, we performed a CMap analysis in which 
we searched for drugs that have a gene expression pattern positively correlating to 
hMSCs differentiating towards osteoblasts (Appendix C, Table A1). Multiple drugs 
were identified that have a significantly correlating gene expression pattern to that of 
differentiating human osteoblasts, including dexamethasone (dex) and a number of 
other corticosteroids (Table 1). These results demonstrate the validity of the CMap, 
because dex is the compound that we originally used to stimulate osteoblast 
differentiation and glucocorticoid (GC)-mediated activation of the glucocorticoid 
receptor (GR) is the classical stimulus for in vitro human osteoblast differentiation. As 
our aim was to identify novel compounds/pathways that stimulate osteoblast 
differentiation, we excluded any corticosteroid compound for further testing. We 
found that the strongest correlating compound (p < 0.0001) (Table 1), and only non-
corticosteroid in the top 8 compounds, is the benzimidazole anthelmintic 
parbendazole. Based on these results we chose to scrutinize the effects parbendazole 
has on hMSCs in regard to its osteogenic potential. 
 
Table 1: CMap permuted results showing compounds with significant positive correlation to the 
osteogenic hMSCs gene. 
Rank Compound Name Cell  Line 
Mean CMap  
Score n p-value 
1 Parbendazole PC3 0.855 2 <0.00001 
2 Dexamethasone PC3 0.913 2 <0.00001 
3 Fludrocortisone PC3 0.768 2 0.00002 
4 Halcinonide PC3 0.788 2 0.00002 
5 Fludroxycortide PC3 0.775 2 0.00002 
6 Flumetasone PC3 0.854 2 0.00002 
7 Flunisolide PC3 0.718 2 0.00002 
8 Fluocinonide PC3 0.72 2 0.00002 
Top matching compounds from the Connectivity Map based on the average of the replicates of a single compound 
for each cell line. Shading indicates a glucocorticoid. Top matching compound and only non-glucocorticoid, 
parbendazole, in white. Rank is based on the p-value calculated from the CMap scores all of the replicates of a single 
compound in a single cell line. Score is based on the relative strength of a given signature in an instance from the total 
set of instances calculated upon execution of a query. 
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Parbendazole induces osteoblast differentiation of hMSCs in vitro 
Similar to the known stimulator of osteogenic differentiation, dex, 
parbendazole treatment stimulated alkaline phosphatase (ALP) activity after 1 week of 
culture and mineralization after 3 weeks of culture, dose-dependently up to 4 µM (Fig. 
1A and B, respectively). We confirmed the dose-dependent parbendazole-induced 
mineralization by alizarin red staining (Fig. 1C). These results show that parbendazole 
induces biochemical changes in hMSCs leading to osteoblast differentiation and 
mineralization.  
 
 
Figure 1. Parbendazole induces osteogenic differentiation of hMSCs. Results of ALP activity after 1 week of 
culture (A) and mineralization after 3 weeks of culture (B) in hMSCs treated with 1 µM parbendazole (light gray bar), 
4µM parbendazole (dark gray bar) compared to negative control (control medium) (white bar) or positive control (0.1 
µM dex) (black bar) treated cells. (C) Dose dependent induction of mineralization was confirmed by alizarin red 
staining after 3 weeks of culture. mRNA expression levels of ALPL (D), IBSP (E) and SPP1 (F) 7 days after the start 
of treatment with control medium (white bar), 4 µM parbendazole (gray bar) or 0.1 µM dex (black bar) as assessed by 
quantitative PCR. For biochemistry n=12. For PCRs n=6. * p < 0.05, ** p < 0.01, *** p < 0.001. Results are 
presented relative to control.  
 
We also examined if the most effective dose of parbendazole, 4µM, induces 
expression of well-known osteoblast marker genes by performing quantitative PCRs 
on hMSCs treated with parbendazole for 7 days. Parbendazole significantly increased 
   -    1 μM        4 μM         0.1 μM
       Parbendazole            Dex
A         B           
          C
D        E                   F
Figure1
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the expression of alkaline phosphatase (ALPL) (Fig. 1D) as well as the genes 
encoding the matrix proteins bone sialoprotein (IBSP) and osteopontin (SPP1) (Fig. 
1E-F).  
Simian virus-immortalized human fetal osteoblasts (SV-HFO), a human pre-
osteoblastic cell line, treated with parbendazole did not mineralize (Fig. 2A) and total 
protein was decreased by parbendazole (Fig. 2B) at the doses stimulating osteogenesis 
in the hMSCs. 
Taken together, these results demonstrate that parbendazole induces 
osteogenic differentiation of hMSCs independent of the known osteogenic stimulus, 
dexamethasone. 
 
 
Figure 2. Parbendazole does not induce osteogenic differentiation in human pre-osteoblast cells (SV-HFOs), 
but does reduce total protein. Results of mineralization (A) and total protein content (B) after 3 weeks of culture in 
SV-HFOs treated with 1 µM parbendazole (light gray bar), 100 nM parbendazole (medium gray bar), and 10 nM 
parbendazole (dark gray bar) compared to negative control (control medium) (black bar) or positive control (100 nM 
dex) (darkest gray bar) treated cells. n=3. Results are of 1 representative experiment.  
 
Parbendazole increases both apoptosis and proliferation 
To determine how parbendazole may affect hMSC viability we used 
Fluorescence-Activated Cell Sorting (FACS) analysis to look at apoptosis and 
proliferation. Parbendazole increased apoptosis at day 5 and 8 of culture compared to 
control-treated hMSCs (44.8-58.5% vs. 15.8-17.9%, respectively) (Fig. 3A). We also 
found that at days 5 and 8 of culture, parbendazole significantly increased 
proliferation compared to control-treatment (24.7-26.1% vs. 9.1-10.4% Ki67+, 
respectively) (Fig. 3B). To verify the overall viability of hMSCs treated with 
parbendazole, we performed a PrestoBlue assay, a metabolism-based assay as a read 
out for cell viability. Parbendazole treatment led to a decrease in cell viability 
compared to both controls and dex-treated hMSCs starting at day 4 of culture (Fig. 
3C). These findings reveal that parbendazole is capable of increasing both 
proliferation and apoptosis in hMSCs and because apoptosis (i.e., increased cell death 
and decreased cell survival) exceeds proliferation conditions, the total accumulation of 
cells is reduced in parbendazole-treated cells. 
Fig. S2
A         B           
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Figure 3. Parbendazole treatment decreases cell viability by increasing apoptosis. (A) FACS assessment of 
hMSCs treated with control medium (white bar), 4 µM parbendazole (gray bar), or 0.1 µM dex (black bar) and stained 
with annexin to determine combined early and late apoptosis. (B) FACS assessment of hMSCs treated with control 
medium (white bar), 4 µM parbendazole (gray bar), or 0.1 µM dex (black bar) and stained with Ki67 to determine 
proliferation (n = 7). (C) Relative cell viability was assessed by PrestoBlue assay as represented by the relative 
fluorescence units (RFU). *P < 0.05, **P < 0.01, ***P < 0.001. Results are presented relative to control at each time 
point. 
 
 
Figure 4: Parbendazole induced osteoblast differentiation is independent of glucocorticoid receptor 
signaling. (A,B,C) Quantitative PCR results from hMSCs incubated with parbendazole and from control hMSCs 
either undifferentiated or differentiated with dex. Relative gene expression of direct glucocorticoid receptor signaling 
targets, ZNF145 (A), GILZ (B) and FKBP51 (C) of hMSCs treated with control medium (white bar), 4 µM 
parbendazole (gray bar) or 0.1 µM dex (black bar) for 24 hours. Biochemical assays for ALP (Day 6) (D) and 
mineralization (week 3) (E) of hMSCs treated with control medium (white bar), 4 µM parbendazole (gray bar) or 0.1 
µM dex (black bar) with (patterned bars) or without (solid bars) the GR antagonist, mifepristone, throughout the 
culture period. n=6.  ** p < 0.01, *** p < 0.001. Results are presented relative to control at each time point.  
 
 A          B                C
   D           E
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Parbendazole induces osteoblast differentiation independent of glucocorticoid receptor signaling 
To determine if parbendazole induces osteogenic differentiation through 
direct GR–mediated stimulation of osteoblast marker genes, similar to dex, we 
performed quantitative gene expression analyses for known GR target genes following 
parbendazole treatment. Dex-induced osteoblast differentiation strongly upregulated 
the GR target genes ZNF145, GILZ, and FKBP51 (up to 10,000 fold), while 
parbendazole treatment did not (Fig. 4A-C), implicating that parbendazole acts 
independent of GR signaling. We then cultured dex- or parbendazole-treated hMSCs 
in combination with the GR antagonist mifepristone (RU486), which blocks signaling 
through the GR, and performed biochemical assays for osteoblast differentiation. 
Whereas mifepristone had no effect on induction of ALP activity (Fig. 4D) or 
mineralization (Fig. 4E) by parbendazole, it completely abolished dex-induced 
increases in ALP activity (Fig. 4D) and mineralization (Fig. 4E). These results prove 
that parbendazole induces human osteoblast differentiation independent of GR 
signaling. 
 
Parbendazole inhibition of microtubule polymerization is required for parbendazole-induced osteogenic 
differentiation   
Parbendazole is known to be an inhibitor of microtubule formation10 and we 
confirmed this in our hMSCs. In control (Fig. 5A,D,J) and dex-treated (Fig. 5C,F,L) 
cultures, both the actin and microtubule structures are similarly distributed 
throughout the cell, while in parbendazole treated hMSCs the microtubule structure is 
severely degraded, leaving only short strands of microtubule filaments surrounding 
the nucleus (Fig. 5E,K). However, we observed numerous thick, crossing actin stress 
fibers present in cells treated with parbendazole (Fig. 5B), while in control treated 
cells the actin filaments were primarily organized parallel to the cell axis (Fig. 5A). To 
determine whether degradation of the microtubule structure is required for 
parbendazole-induced osteogenic differentiation we used the microtubule stabilizing 
agent paclitaxel (taxol). Taxol completely abolished the parbendazole-induced 
mineralization of hMSCs (Fig. 6). These results clearly demonstrate that inhibition of 
microtubule formation is required for parbendazole to elicit osteogenic differentiation 
of hMSCs. 
 
Parbendazole increases focal adhesions 
Based on the evidence that cytoskeletal changes are induced by parbendazole 
during hMSC osteogenic differentiation, and previous evidence that cytoskeletal 
changes and integrin binding and signaling play a significant role in osteoblast  
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Figure 5. Parbendazole inhibits microtubule polymerization. hMSCs were incubated with control medium 
(A,D,G,J), 4 µM parbendazole (B,E,H,K), or 0.1 µM dex (C,F,I,L) for 4 days and then the actin and tubulin 
cytoskeleton were visualized by immunofluorescence microscopy using phalloidin and β-tubulin antibodies. 
Parbendazole treatment inhibits microtubule formation (E,K), with only small microtubules remaining perinuclear 
(white arrow). Crossing of the actin microfilaments can also be seen in parbendazole treated cells (white asterisks). 
630x magnification.  
 
 
Figure 6. Parbendazole inhibition of microtubule polymerization is required for parbendazole induced 
osteogenic differentiation. Mineralization in hMSCs treated with control medium (white bar) or 4µM parbendazole 
(gray bar) in combination with (striped bars) or without (solid bars) the microtubule stabilizing drug taxol. n=6 *** p 
< 0.001. Results are presented relative to control.  
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differentiation11-13, we investigated whether focal adhesions (FAs) are also affected by 
parbendazole. Analysis of immunofluorescent images show that FAs appear to be 
longer and more numerous following parbendazole treatment (Fig. 7E,K,N) 
compared to control treatment (Fig. 7D,J,M). Quantification of the FAs revealed that 
parbendazole treatment significantly increased the number of focal adhesions 
compared to both control and dex treatment (Fig. 8A) and increased their length 
compared to control (Fig. 8B) after 24 hours of treatment.  
 
 
Figure 7. Parbendazole affects focal adhesions. hMSCs were incubated with control medium (A,D,G,J,M), 4 µM 
parbendazole (B,E,H,K,N), or 0.1 µM dex (C,F,I,L,O) for 24 hours and actin microfilaments and FAs were visualized 
by immunofluorescence microscopy using phalloidin and vinculin antibodies. FAs are identified by the filled arrow 
heads. Crossing of the actin microfilaments can also be seen in parbendazole treated cells (star). 20µM scale bar. 400x 
magnification. 
A     B           C
D     E           F
G     H           I
J     K           L
    M         N         O
  
     
Fig. S3
CMap discovery of parbendazole as an osteogenic compound | 
 37 
 
Figure 8. Parbendazole increases number and length of focal adhesions. Quantification of the number of (A) 
length (B) of focal adhesions was performed on control, parbendazole and dex treated hMSCS. n=28-30 cells. * p < 
0.05 **, p < 0.01 ***, p < 0.001. 
 
Parbendazole increases BMP-2 expression and activity 
It has previously been demonstrated that microtubule inhibitors stimulate 
osteoblast differentiation and increase bone mass in mice through elevated levels of 
BMP-214,15. We show that parbendazole significantly increased BMP2 expression (Fig. 
9A), while dex significantly inhibited BMP2 expression compared to control treated 
cells. To determine BMP bioactivity stimulated by parbendazole we employed a 
C2C12-BRE-Luc reporter cell line16,17. Incubation with conditioned media from 
hMSCs treated with parbendazole for 48 hours significantly increased luciferase 
activity (Fig. 9B), while conditioned medium from control and dex treatment had no 
effect. These results show that parbendazole stimulates BMP-2 signaling in hMSCs. 
 
Inhibiting BMP-2 signaling limits parbendazole induced osteogenic hMSCs differentiation 
To determine whether BMP-2 is involved in the osteogenic effect of 
parbendazole, we used the BMP-specific antagonist DMH118. These studies 
demonstrated significant interaction between parbendazole and DMH1 resulting in 
limitation of osteogenic differentiation following the co-treatment of parbendazole 
and DMH1 compared to parbendazole or DMH1 alone (Fig. 9C). This reveals that 
BMP-2 signaling is involved in the effect of parbendazole on osteoblast 
differentiation of hMSC. In the control condition, DMH1 induced mineralization in 
hMSCs cultures, which is consistent with the results of Rifas19 showing that inhibition 
of BMP signaling by another BMP antagonist noggin resulted in osteogenic 
differentiation of hMSCs.  
 
 
A            B
Fig. 5
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Figure 9. Parbendazole regulates BMP-2 expression and activity. (A) Gene expression of BMP2 after treating 
hMSCS for 24 hours with control medium (white bar), 4 µM parbendazole (gray bar), or dex (black bars). (B) 
Luciferase reporter assay for BMP signaling reporter BRE-Luc of control medium (solid white bar), conditioned 
medium from hMSCs treated from control (white patterned bar), 4 µM parbendazole for 48 hours (gray patterned 
bar), or 0.1 µM dex (black patterned bar) for 48 hours, and the positive control, recombinant BMP-2 protein (black 
bar). (C) Pretreatment of hMSCs with the BMP inhibitor DMH1 (patterned bars) enhances mineralization. Relative 
mineralization in hMSCs cultures following control (white bar), DMH1 (white patterned bar), parbendazole (gray bar), 
and parbendazole + DMH1 (gray patterened bar) treatment.  n=6. *** p < 0.001 by one-way ANOVA. ### p < 
0.001 by two-way ANOVA. Results are presented relative to control. 
 
2.3 Discussion 
Using the CMap, we were able to identify a compound with a highly 
significant positively correlating gene expression profile to that of differentiating 
human osteoblasts. As expected, the top of the list of compounds was dominated by 
glucocorticoids, including dexamethasone; however, the top resulting compound was 
found to be parbendazole. We confirmed the validity and power of the CMap 
approach by demonstrating that parbendazole, independent of an additional 
osteogenic stimulus such as dexamethasone, is able to stimulate human osteoblast 
differentiation as evidenced by increased ALP activity, mineralization and up-
regulation of genes known to be important in osteoblast differentiation and function. 
Mechanistically, we showed that the osteogenic effect of parbendazole occurs 
independent of glucocorticoid receptor signaling, but rather via affecting microtubule 
formation and cytoskeletal organization. Overall, our findings demonstrate that by 
C       
A                B BMP2 Expression                                                           BRE Reporter Assay
Mineralization
Figure6
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using the CMap, we identified a novel compound that independently stimulates 
human osteogenic differentiation. 
The web-based resource CMap was created to identify compounds that 
induce a similar or opposite effect on the physiological processes or diseases of 
interest; as a consequence, it is a bioinformatics tool to identify novel applications for 
established drugs. The CMap uses several human tumor cell lines, including PC3, 
MCF7, and HL60, to generate gene expression profiles of more than 1300 
compounds. Interestingly, all of the top eight compound profiles most strongly 
correlating with our human osteoblast expression profile are derived from the PC3 
cell line, a cell line originating from a bone metastasis of a prostate tumor20. An 
explanation for this intriguing observation is lacking, but it is tempting to hypothesize 
that, based on our CMap results, there must be a resemblance in the genomic profile 
of both osteogenic hMSCs and the bone metastatic PC3 cells, which is potentially 
linked to both of their abilities to thrive in the bone environment. A prerequisite of 
the CMap approach for discovering bone anabolic compounds is that one has to 
assume similarities in how different cell types respond to the same compound 
regarding gene expression. However, the evidence presented here and the growing 
evidence from other groups5-9, strongly supports the concept that CMap is a potent 
tool for identification of compounds with medicinal benefit for a wide range of 
diseases. 
Benzimidazoles, including parbendazole, are a class of compounds that 
consist of the fusion of benzene and imidazole rings and are primarily used as 
anthelminthics21. The majority of these family members have a similar mechanism of 
action-namely, preventing tubulin polymerization through specific binding to 
tubulin22,23. Parbendazole is no exception: it binds the tubulin dimer with a mol:mol 
stoichiometry and microtubules withdraw from the peripheral area of the cell within 
30 min of treatment with parbendazole10. Our immunocytological findings in 
osteogenic hMSC are consistent with the findings by Havercroft and coworkers. 
Disassembly of microtubules in other cell types has been associated with blebbing of 
the plasma membrane, indicative of apoptosis. Our FACS results showing that 
parbendazole treatment increases the number of annexin V positive cells in our 
cultures supports the idea that microtubule inhibition leads to increased apoptosis. 
However, Havercroft et al.10 also showed that after 1 day of parbendazole treatment, 
cells flattened out without any signs of plasma membrane blebbing, despite absent 
microtubules. This morphology correlates to our observation that a subset of 
parbendazole-treated hMSCs displays a flattened, widespread morphology. 
Interestingly, although we do see an increase in apoptosis, we also observe an increase 
in the proliferation marker Ki67 at day 5 and 8 in hMSCs treated with parbendazole, 
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which indicates that there are at least two populations of MSC in the bone marrow 
with different sensitivity to parbendazole. One population, likely the true stem cells, is 
resistant to the apoptotic effects of parbendazole and are induced to proliferate and 
eventually differentiate and mineralize, and another population, the pre-committed 
cells, that undergoes apoptosis. Taking the hMSC FACs data together with the 
biochemical results in the SV-HFOs we propose that parbendazole acts at the stage of 
lineage allocation in hMSCs. 
Microtubules are highly dynamic cytoskeletal elements that undergo 
continuous assembly and disassembly to maintain normal function24,25; they play an 
essential role in a variety of cellular processes including mitosis, cell motility, and 
intra- and intercellular trafficking26, but are also taking part in various signaling 
pathways including those involving sonic hedgehog, Wnt, and MAPK24,27. 
Microtubules act as binding sites for a number of proteins and transcription factors, 
including RUNX2; and in the case of RUNX2, modulate transcriptional activity by 
acting as a shuttle between the nucleus and cytoplasm28. It has been shown previously 
that taxol treatment leads to depletion of nuclear levels of RUNX228, this could also 
be one explanation for our results demonstrating that taxol pretreatment blocks the 
osteogenic effect of parbendazole. Chang, et al.29 observed that short-term treatment 
of MSCs with a related compound, nocodazole, increased cell contractility and 
cytoskeletal tension followed by enhanced osteoblast differentiation. Cytoskeletal 
tension rises, and perhaps even directly stimulates, osteoblast differentiation through 
changes in the actin cytoskeleton13,30-33. In addition, disruption of the tubulin 
organization also affects the kinetics of actin organization13, indicating a regulatory 
role for microtubules in actin reorganization. Cytoskeletal rearrangements may also 
affect osteoblast differentiation through enhanced integrin signaling. FA complexes 
and integrins are known to directly interact with extracellular matrix proteins, 
including SPP1 and IBSP, which play a critical role in osteoblast survival and 
differentiation11,30,34,35. An increased number of FAs is proposed to increase adhesion 
to the extracellular matrix35,36, which may also contribute to osteogenic differentiation. 
The fact that parbendazole treated hMSCs display a widespread, flattened 
morphology, prominent and rearranged actin fibers, increased focal adhesion 
complexes, and higher expression of SPP1 and IBSP, supports the idea that 
cytoskeletal rearrangements contribute to osteoblast differentiation through enhanced 
integrin signaling and/or matrix binding. Liu et al.14 demonstrated a role for 
microtubule inhibitors as a bone anabolic drug by showing that stathmin, a 
ubiquitously expressed protein that inhibits microtubule assembly, promotes 
osteoblast differentiation and inhibits osteoclast activity; and mice lacking stathmin 
are osteopenic as a consequence of decreased osteoblast numbers and differentiation, 
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and increased numbers of osteoclasts. Our results, demonstrating that changes in the 
balance between the tension forces of the microfilaments and the compression forces 
of the microtubules elicit changes in the cellular shape, function and cell fate, are in 
line with the cellular tensegrity model37,38 and with previous findings that changes in 
cell shape and cytoskeleton can strongly influence hMSC lineage decision-making39. 
There is growing evidence that microtubule inhibitors have a positive effect 
on bone formation and osteoblast differentiation through increased BMP signaling. 
Zhao et al.,15 showed that several types of microtubule inhibitors, including 
nocodazole and TN16, increased Bmp2 expression and ALP activity in murine 
osteoblasts; additionally, the authors showed that short-term administration of TN16 
locally over the calvaria or systemically in mice lead to increased calvarial periosteal 
bone formation and trabecular volume in long bones, respectively. It was shown in 
murine osteoblasts that the osteogenic effect of the inhibition of microtubule 
assembly is due to increased cytoplasmic Gli2 protein concentration through 
disassociation of the microtubule-Gli-Ci complex that would otherwise lead to 
proteasomal degradation of Gli2 (15). Gli2 enhances Bmp2 expression through BMP 
promoter binding40. Bmp-2 is known to be a potent stimulator of osteoblast 
differentiation in murine cells41,42, reviewed by 43, but the evidence for BMP-2 effects on 
human osteogenic differentiation in vitro is conflicting, ranging from strongly 
enhancing osteogenic differentiation44,45 to having no positive effect46,47. This may be, 
in part, due to differences in the BMP receptor expression profiles by the various 
osteoblast precursors and hMSC donors44,47. Clinical trials looking at the efficacy of 
BMP-2 in fracture healing and fusions are mixed; two recent independent meta-
analyses of human clinical trials comparing recombinant human BMP-2 to autologous 
bone grafts in spinal fusions found no significant difference in healing or pain48,49. In 
this study we found that parbendazole treatment induces both BMP2 expression and 
BMP activity as evidenced by our gene expression and reporter assay data. In support 
of this, the BMP inhibitor DMH118 seems to limit the parbendazole-induced 
osteoblast mineralization in our hMSC cultures, but does not completely block it. 
Thus, our data confirms a parbendazole-induced human osteogenic pathway through 
inhibition of microtubule assembly and increased BMP-2 activity. 
In summary, we conclude that the CMap identified compound parbendazole 
is a novel compound that stimulates human osteoblast differentiation in vitro. We have 
proven that parbendazole, independent of additional osteogenic stimulus, stimulates 
ALP activity and mineralization, and up-regulates genes important in osteoblast 
differentiation and extracellular matrix production in a subset of hMSCs resistant to 
its apoptotic effects. In line with previous reports of other microtubule inhibitors, the 
stimulatory effect of parbendazole is partly due to increased BMP-2 activity; however, 
| Chapter 2 
 42 
additional cytoskeletal driven mechanisms, such as cytoskeletal associated proteins 
and transcription factors, and integrin signaling, are likely to be of equal or greater 
importance in stimulating osteogenic differentiation of hMSCs. Though we do not 
propose parbendazole itself to be the ideal bone anabolic drug for treatment of 
osteoporosis in humans, the evidence presented here significantly strengthens the 
concept that cytoskeletal changes strongly influence hMSC lineage allocation and 
osteoblast differentiation. We envisage that cytoskeletal manipulation, or the 
downstream processes that results from it, hold promise as novel anti-osteoporotic 
treatments, but this will need to be studied further.  We have also clearly 
demonstrated the power of the CMap as an effective tool to discover novel bone 
anabolic compounds. 
 
2.4 Materials and Methods 
Materials 
MSCs were purchased from Lonza (MSC; PT-2501, Walkersville, MD). 
αMEM was purchased from Gibco BRL, Life Technologies (Paisley, UK). 
Dexamethasone, β-glycerophosphate, mifepristone, paclitaxel (taxol), DMH1. The 
calcium assay kit, alizarin Red S, ethanolamine, triton X-100, mouse monoclonal anti-
b-tubulin antibody, and oligonucleotide primer pairs were purchased from Sigma–
Aldrich (St. Louis, MO, USA). TRIzol, PrestoBlue cytotoxicity assay reagent, and 
rabbit monoclonal ABfinity anti-vinculin antibody were purchased from Invitrogen 
(Carlsbad, CA, USA). Illumina Human HT-12 v3 BeadChip arrays, iScan, 
GenomeStudio V2010.1 (Gene Expression Module 1.6.0) were obtained from 
Illumina Inc. (Eindhoven, The Netherlands). 2100 Bioanalyzer from Agilent 
Technologies (Santa Clara, CA, USA). Illumina TotalPrep RNA Amplification Kit was 
purchased form Ambion (Austin, TX, USA). Streptavidin-Cy3 was purchased form 
GE Healthcare (Piscataway, NJ, USA). BCATM protein assay reagent A and B were 
purchased from Pierce (Rockford, IL). Victor2 plate reader and Steady Lite Plus 
Luciferase reagent was purchased from PerkinElmer Life and Analytical Science. All 
FACS antibodies, the Accuri C6 Personal Flow Cytometer and BD Accuri C6 
software analysis program were obtained from Beckon Dickinson (Breda, The 
Netherlands). Alexa Fluor® 488 Goat Anti-Mouse IgG, rhodamine–conjugated 
phalloidin, and Alexa Fluor® 488 Goat Anti-Rabbit IgG were purchased from 
Molecular Probes. Vectashield mounting medium containing DAPI was from Vector 
Laboratories (Burlingame, CA, USA).  
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Cell culture 
Human bone marrow-derived Mesenchymal Stromal Cells were cultured as 
described previously50,51. For osteogenic differentiation, MSCs were cultured in 
αMEM medium containing 10% heat-inactivated fetal calf serum supplemented with 
100 nM dexamethasone (dex) or with various concentrations (ranging from 0.1 to 4 
µM) of parbendazole, both in combination with 10 mM β-glycerophosphate. Where 
applicable hMSCs were treated with 10µM mifepristone, 0.1 µM paclitaxel (taxol) or 
0.5µM DMH1, a highly selective dorsomorphin analogue, in β-glycerophosphate 
containing medium alone or 30 minutes prior to adding parbendazole or dex. Cell 
extracts were harvested at different time points during culture by scraping the cells in 
PBS/triton and storing at -80ºC for biochemical analyses or in TRIzol and stored at -
20ºC for gene expression analyses. Alternatively, cells were fixed in 4% phosphate-
buffered paraformaldehyde for immunocytochemical procedures or 70% ethanol for 
alizarin red staining. 
 
Illumina gene chip–based gene expression 
For analysis of whole human genome expression, we used Illumina Human 
HT-12 v3 BeadChip arrays. Human MSCs (in triplicate) were treated for 6 hours with 
dexamethasone and next RNA was isolated as previously described51. RNA integrity 
of isolated RNA was assessed by RNA 6000 Nano assay on a 2100 Bioanalyzer. The 
Illumina TotalPrep RNA Amplification Kit was used for RNA amplification of each 
sample according to manufacturer's instructions. In short, T7 oligo(dT) primer was 
used to generate single-stranded cDNA, followed by a second-strand synthesis to 
generate double-stranded cDNA. Biotin-labeled cRNA was synthesized using T7 
RNA polymerase. The cRNA was column-purified and checked for quality by RNA 
6000 Nano assay. A total of 750 ng of cRNA was hybridized for each array using the 
standard Illumina protocol, using streptavidin-Cy3 for detection. Slides were scanned 
on an iScan and analyzed using GenomeStudio. 
 
Microarray analysis 
Background was subtracted from the raw data using GenomeStudio V2010.1 
(Gene Expression Module 1.6.0), and data were processed, using the Bioconductor 
R2.10.0 Lumi package (www.bioconductor.org)52. Data were transformed by variance 
stabilization and quantile normalization. Probes that were detected at least once in the 
experiments (Illumina detection p-value < 0.01) were considered to be expressed and 
were further analyzed. Differentially expressed probes were identified using 
Bioconductor Package Limma (www.bioconductor.org)53 with p-values adjusted to 
reduce the false discovery rate (FDR; p <0.001).  
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Connectivity map query 
To find compounds that have similar gene expression patterns compared to 
our human osteogenic differentiation-induced gene expression patterns, we generated 
gene signatures from microarray gene expression analyses of bone marrow-derived 
hMSCs treated with dex to stimulate osteogenic differentiation. We identified the 100 
most significantly (Z<0.001) up- and downregulated probes based on log ratio of 
gene expression during osteogenic differentiation at 6 hours following the start of 
differentiation treatment, compared to time 0. We chose this time point to be able to 
temporally match it with the time of incubation of each compound within the CMap. 
Illumina probe IDs were converted to Affymatrix probe IDs, which are required for 
input into the CMap. After removal of duplicates we ended up with 77 up-regulated 
genes and 66 down-regulated genes (Apendix A, Table A1) that we submitted 
simultaneously for our CMap query (build02, http://www.broadinstitute.org/cmap/). 
Each signature was queried against the CMap using the gene set enrichment analysis 
algorithm described by Lamb et al.3. 
 
Alkaline phosphatase, mineralization and protein assays 
Alkaline phosphatase (ALP) and calcium measurements were performed as 
described previously54. Briefly, ALP activity is determined by an enzymatic reaction, 
where the ALP-mediated conversion of PNPP to PNP during 10 min at 37°C is 
measured. For calcium measurements, cell lysates were incubated overnight with 
0.24 M HCl at 4°C. Calcium content was determined colorimetrically with a calcium 
assay kit according to the manufacturer's description. ALP results were adjusted for 
protein content of the cell lysates. For protein measurement, 200 µl of working 
reagent was added to 10 µl of sonicated cell lysate. The mixture was incubated for 
30 min at 37°C, cooled down to room temperature (RT) and absorbance was 
measured at 595 nm. All measurements were performed using a Victor2 plate reader. 
Staining for mineralization was performed as described previously51. Briefly, cells were 
fixed with 70% ethanol and after washing they were stained for 10-20 min with 
alizarin Red S solution.  
 
Quantification of mRNA expression 
Cultures continuously treated with control, 100 nM dex or 4 µM 
parbendazole were harvested during the early or middle differentiation period (6 
hours, 24 hours, and 7 days). RNA isolation, cDNA synthesis and PCR reactions were 
performed as described previously51. Oligonucleotide primer pairs were designed to 
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be either on exon boundaries or spanning at least one intron (Table 2). Gene 
expressions were corrected for the housekeeping gene GAPDH.  
 
Table 2: Sequences of primer sets used for quantitative PCR in this study.  
Gene Forward Primer Reverse Primer 
GAPDH CCGCATCTTCTTTTGCGTCG CCCAATACGACCAAATCCGTTG 
ALPL TAAAGCAGGTCTTGGGGTGC GGGTCTTTCTCTTTCTCTGGCA 
SPP1 AGGCATCACCTGTGCCATAC CACAGCATTCTGCTTTTCCTCA 
IBSP TGCCTTGAGCCTGCTTCC GCAAAATTAAAGCAGTCTTCATTTTG 
Probe FAM-TAMRA: CTCCAGGACTGCCAGAGGAAGCAATCA 
ZNF145 GCGGTTCCTGGATAGTTTGC TGATCACAGACAAAGGCTTTGG 
Probe FAM-TAMRA: ATGCACTTACTGCGTCATTCAGCGGG 
FKBP51 CGGAAAGGAGAGGGATATTCAA TCTGCAGTCAAACATCCTTCCA 
GILZ GCACAATTTCTCCATCTCCTTCTT TCAGATGATTCTTCACCAGATCCA 
BMP2 ACGGACTGCGGTCTCCTAA GGAAGCAGCAACGCTAGAAG 
Most genes were detected using SYBR green; IBSP and ZNF145 PCRs were performed with a specific probe (FAM-
TAMRA). 
 
Flow cytometric analysis of proliferation and apoptosis  
To measure apoptosis or proliferation, hMSCs were treated with 100nM dex 
or 4µM parbendazole for 1, 5, or 8 days (n=7).   
To measure apoptosis cells were trypsinized, collected in media and washed 
once in PBS before being resuspended in 50µL binding buffer and 2.5µl annexin V 
and 2.5µl 7-Aminoactinomycin D (7AAD). Cells were incubated in the dark for 15 
minutes before an additional 75µl binding buffer was added and cell were analyzed by 
flow cytometry. The percentage apoptotic cells was measured by flow cytometry after 
staining with phyco-erythrin (PE)-conjugated annexin V and 7AAD (annexin V+, 
7AAD+). We scored viable cells as those that are negative for annexin V and 7AAD. 
Irrelevant isotype-matched immunoglobulin was used as a control. Fold induction of 
apoptosis was calculated from the increase in the percentage of apoptotic cells 
between the treated and untreated samples. The amount of necrotic cells (annexin V–, 
7AAD+) was always minimal. 
For analysis of proliferation, hMSCs were trypsinized, collected in media and 
after centrifugation, 5ml of ethanol was added drop wise to the cells after which they 
were incubated at -20°C for 30 min. Cells were then centrifuged and resuspended in 
1ml PBS plus 1% BSA before being centrifuged again. Supernatant was discarded and 
55µl PBS containing 5% serum plus 2.5µl Pe-Cy7-conjugated Ki67 antibody was 
added. Cells were incubated 30 min in the dark at RT. After incubation, 1ml PBS 
containing 5% serum was added and centrifuged again. Supernatant was discarded and 
the pellet was dissolved in 100µl PBS containing 5% serum. Proliferating cells were 
identified as being Ki67 positive. Stained cells were analyzed using a BD Biosciences 
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Accuri C6 Personal Flow Cytometer and analyzed with BD Accuri C6 software 
analysis program. For each sample, a minimum of 10,000 events was collected. 
 
Presto blue assay for cell survival analysis  
For analysis of cell survival, hMSCs were cultured in 96 well tissue culture 
plates. Following incubations with control media, 100nM dex or 4µM parbendazole, 
cell viability was assayed at 1, 5, 8 and 14 days (n=6), using a PrestoBlue cytotoxicity 
assay following the manufacturers protocol. Briefly, 10µl of PrestoBlue reagent was 
added to each well and after a one hour incubation the plate fluorescence was 
measured at excitation 530nm / emission 590nm wavelength using a Victor2 plate 
reader. Date was corrected for background fluorescence of presto blue in media 
alone. 
 
Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline 
(PBS) for 15 minutes at RT, washed in PBS, and excess aldehyde quenched with 10 
mM ethanolamine in PBS for 5 min. Cells were then permeabilized with 0.5% Triton-
X-100 in PBS for 10 minutes and blocked for 30 minutes at room temperature in PBS 
supplemented with 1.5% bovine serum albumin (BSA) and 0.02% Triton-X-100. For 
visualization of microtubules cells were labeled for 1 hour with mouse monoclonal 
anti-b-tubulin antibody at 1:60 dilution at RT, followed by secondary Alexa Fluor® 
488 Goat Anti-Mouse IgG at 1:400 dilution for a total of 1 hour, with the addition of 
rhodamine–conjugated phalloidin at 1:100 dilution for the last 20 minutes. For 
visualization and quantification of focal adhesions cells were labeled for 1 hour with 
rabbit monoclonal ABfinity anti-vinculin antibody at 1:200 dilution at RT, followed by 
secondary Alexa Fluor® 488 Goat Anti-Rabbit IgG at 1:400 dilution for a total of 1 
hour, with the addition of rhodamine–conjugated phalloidin at 1:100 dilution for the 
last 20 minutes. Slides were mounted using Vectashield mounting medium containing 
DAPI and pictures were taken on a Zeiss Axiovert 200 MOT microscope. 
Quantitative morphometric analysis (length and number of focal adhesions per cell) 
was performed using image analysis soft-ware, ImageJ (NIH, Bethesda, Maryland, 
USA, available online at http//rsb.info.nih.gov.ij) as described previously55. 
 
BMP reporter assay 
We used a previously reported C2C12 cell line stably transfected with a 
reporter plasmid consisting of BMP-responsive elements from the Id1 promoter 
fused to a luciferase reporter gene (C2C12-BRE-Luc) to detect BMP activity16,17 
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following treatment with conditioned media from hMSCs exposed to parbendazole.  
C2C12-BRE-Luc cells were seeded into white walled 96 well culture plates at a density 
of 40,000 cells/well in 50µl of media. After 30 minutes 50µl of conditioned media 
from hMSCs treated with parbendazole (4µM), dex (0.1µM), or control media was 
then added to the cells. After 24 hours, the media was removed from the cells and 
100µl of the combined lysis buffer and luciferin reagent (Steady Lite Plus) was added 
to each well. The plates were shaken for 15 minutes in the dark and then 
luminescence was quantified using a Victor2 plate reader. 
 
Cell culture of SV-HFOs 
SV-HFO cells56 were cultured as described previously54. 
 
Statistics 
The data provided here are based on at least two independent experiments 
performed in at least triplicate. Values displayed are mean ± SEM. Significance was 
calculated using either the Student's t-test, the one-way ANOVA with Tukey’s or 
Dunn’s post-hoc test, or two-way ANOVA where appropriate, using GraphPad prism 
6.0. P-values <0.05 were considered significant. 
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Abstract 
Osteoporosis is a common skeletal disorder characterized by low bone mass leading 
to increased bone fragility and fracture susceptibility. Identification of factors 
influencing osteoblast differentiation and bone formation is very important. 
Previously, we identified parbendazole to be a novel compound that stimulates 
osteogenic differentiation of human mesenchymal stromal cells (hMSCs), using gene 
expression profiling and bioinformatic analyses, including the Connectivity Map 
(CMap), as an in-silico approach. The aim for this paper is to identify additional 
compounds affecting osteoblast differentiation using the CMap.  
Gene expression profiling was performed on hMSCs differentiated to osteoblasts 
using Illumina microarrays. Our osteoblast gene signature, the top regulated genes 6-
hours after induction by dexamethasone, was uploaded into CMap 
(www.broadinstitute.org/cmap/). Through this approach we identified compounds 
with gene signatures positively correlating (withaferin-A, calcium folinate, amylocaine) 
or negatively correlating (salbutamol, metaraminol, diprophylline) to our osteoblast 
gene signature. All positively correlating compounds stimulated osteogenic 
differentiation, as indicated by increased mineralization compared to control treated 
cells. One of three negatively correlating compounds, salbutamol, inhibited 
dexamethasone-induced osteoblastic differentiation, while the other two had no 
effect. Based on gene expression data of withaferin-A and salbutamol, we identified 
HMOX1 and STC1 as being strongly differentially expressed. shRNA knockdown of 
HMOX1 or STC1 in hMSCs inhibited osteoblast differentiation. These results 
confirm that the CMap is a powerful approach to identify positively compounds that 
stimulate osteogenesis of hMSCs, and through this approach we can identify genes 
that play an important role in osteoblast differentiation and could be targets for novel 
bone anabolic therapies. 
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3.1 Introduction 
Osteoporosis is a common bone disease characterized by reduced bone mass 
and deterioration of the bone microstructure leading to increased fragility and 
susceptibility to fracture. It has been estimated that one osteoporotic fracture occurs 
every 8 seconds worldwide1 and direct healthcare costs in Europe alone exceed €31 
billion annually2. Bone remodeling is a balancing act between removal of old bone and 
formation of new bone, which is achieved by two distinct cells, the osteoclast and 
osteoblast as well as its terminally differentiated form the osteocyte. When uncoupling 
of these two processes takes place, bone resorption can overtake bone formation 
resulting in osteoporosis. Most currently available osteoporosis treatments, such as 
bisphosphonates, reduce bone resorption and result in modest increases in bone 
density; however, these treatments do not result in a true bone anabolic effect or 
improve bone microarchitecture so patients do not regain bone that has been lost at 
time of diagnosis. An ideal treatment would stimulate bone formation as well, to help 
repair the damage already done to the bone microarchitecture and strength. With this 
in mind, our goal is to search for novel molecules and/or mechanisms that stimulate 
human osteoblast differentiation and bone formation. 
The connectivity map (CMap) is a web-based tool that allows for screening of 
compounds against a disease or physiological gene signature3,4. This is achieved by 
comparing microarray data from over 1300 small molecules to a user’s selected gene 
signature of a phenotype of interest using a pattern-matching algorithm with a high 
level of resolution and specificity. This results in a list of compounds ranked from 
highly positively correlated (similar gene pattern to that of the phenotype of interest) 
to strongly negatively correlated (inverse gene expression pattern to that of the 
phenotype of interest). These compounds hold the potential to deliver a novel 
treatment for a disease or to identify novel pathways or genes involved in a complex 
biological process. To date, the CMap has been successfully used to identify 
compounds and combination therapies that show promise in the treatment of 
osteoarthritic pain5, adenocarcinoma6, skeletal muscle atrophy7,8, emphysema-related 
lung disease9, kidney disease10, gliomas11, NK cell neoplasms12, Parkinson's disease 
related neurodegeneration13 and medulloblastomas14. 
 Recently we have successfully used the CMap to identify a novel compound, 
parbendazole, that independently stimulates osteoblast differentiation of human 
mesenchymal stem cells (hMSCs) and elucidate a targetable osteogenic pathway15. Our 
aim of the current study was to determine if we can use the CMap to detect additional 
molecules that modulate human osteogenesis, both positively or negatively. By doing 
so we may identify novel bone anabolic agents for the treatment of bone diseases 
such as osteoporosis, or to help us distinguish and understand the processes 
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underlying the process of osteoblast differentiation and bone formation and identify 
therapeutic candidate targets. 
 
3.2 Results 
 
3.2.1 Identification of compounds with the most positively and negatively correlated gene signatures. 
To identify compounds that may either stimulate or inhibit bone formation, 
due to their ability to enhance or repress genes regulated during osteoblast 
differentiation, we performed a CMap analysis. For this analysis we uploaded our gene 
signature of hMSCs differentiating to osteoblasts (Appendix C, Table A1) into the 
CMap and focused on compounds tested in the PC3 cell line as we found in our 
previous work15 that the strongest and most consistent correlating gene signatures 
came from this cell line. 
Multiple compounds were identified that have a significant positively 
correlating gene expression pattern to that of differentiating hMSCs, including 
dexamethasone (dex) and a number of other corticosteroids, as well as the previously 
described novel osteogenic compound, parbendazole15 (Table 1). The large number 
of glucocorticoid receptor (GR) binding ligands, including dex, was expected, as dex is 
the compound that we used to stimulate osteoblast differentiation and glucocorticoid-
mediated activation of the glucocorticoid receptor is the classical stimulus for human 
osteoblast differentiation in vitro. To select novel compounds that may stimulate 
osteoblast differentiation we excluded any GR-ligand. We also excluded several 
compounds that we were unable to obtain (CP-690334-01, MG-262, F0447-0125). In 
addition, we considered both the mean CMap score and p-value when selecting 
compounds to test. Based on these criteria we selected three top positively correlating 
compounds, withaferin A, calcium folinate, and amylocaine for further downstream 
analyses (Table 1).  
In a similar approach we identified compounds that had an opposite gene 
signature (negatively correlating) to that of osteoblasts differentiating from hMSCs in 
order to identify compounds that may inhibit osteoblast differentiation and/or 
gene/protein targets or (signaling) pathways that negatively affect bone formation. 
The top ranking negatively correlated compounds identified by the CMap are shown 
in Table 2. The top three negatively correlated compounds, salbutamol, metaraminol, 
and diprophylline, were selected for further testing (Table 2).  
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Table 1: Positively correlated compounds from the CMap 
Rank Compound Name Mean CMap Score n p-value 
1 Parbendazole 0.855 2 <0.00001 
2 Dexamethasone 0.913 2 <0.00001 
3 Fludrocortisone 0.768 2 0.00002 
4 Halcinonide 0.788 2 0.00002 
5 Fludroxycortide 0.775 2 0.00002 
6 Flumetasone 0.854 2 0.00002 
7 Flunisolide 0.718 2 0.00002 
8 Fluocinonide 0.72 2 0.00002 
9 Withaferin A 0.687 2 0.00002 
10 CP-690334-01 0.473 4 0.00002 
11 Triamcinolone 0.736 2 0.00004 
12 Calcium Folinate 0.627 2 0.00018 
13 MG-262 0.566 2 0.00028 
14 Medrysone 0.514 2 0.00070 
15 Monensin 0.492 2 0.00145 
16 Semustine 0.479 2 0.00221 
17 Pioglitazone 0.376 5 0.00513 
18 Tropicamide 0.452 2 0.00626 
19 F0447-0125 0.491 2 0.00710 
20 Amylocaine 0.548 2 0.00793 
CMap permuted results showing compounds with significant positive correlation to the osteogenic hMSCs gene. Top 
matching compounds from the Connectivity Map based on the average of the replicates of a single compound in only 
the PC3 cell line. Compounds in bold were chosen for further testing. Compounds in italic are corticosteroids. Rank is 
based on the p-value calculated from the CMap scores all of the replicates of a single compound in a single cell line. 
Score is based on the relative strength of a given signature in an instance from the total set of instances calculated 
upon execution of a query. 
 
Table 2: Negatively correlated compounds from the CMap 
Rank Compound Name Mean CMap Score n p-value 
1 Salbutamol -0.733 2 0.00048 
2 Metaraminol -0.834 2 0.00074 
3 Diprophylline -0.652 2 0.00519 
4 0175029-0000 -0.409 4 0.00627 
5 Morantel -0.601 2 0.00861 
6 Isoxicam -0.575 2 0.00984 
7 Acetylsalicylic	Acid -0.673 2 0.01181 
8 PHA-00816795 -0.606 2 0.01515 
9 Chloramphenicol -0.627 2 0.01604 
10 Isocarboxazid -0.530 2 0.02946 
CMap permuted results showing compounds with significant negative correlation to the osteogenic hMSCs gene. 
Compounds in bold were chosen for further testing.  Top matching compounds from the Connectivity Map based on 
the average of the replicates of a single compound in only the PC3 cell line. Rank is based on the p-value calculated 
from the CMap scores all of the replicates of a single compound in a single cell line. Score is based on the relative 
strength of a given signature in an instance from the total set of instances calculated upon execution of a query. 
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3.2.2 The positive correlating compounds, withaferin A, calcium folinate and amylocaine, induce 
osteoblast differentiation of hMSCs in vitro 
To determine if the identified correlated compounds, withaferin A, calcium folinate, 
and amylocaine, are able to stimulate osteoblast differentiation of hMSCs we cultured 
the cells with various concentrations of each compound. We then performed 
biochemical assays to determine if classical biological indicators of osteoblast 
differentiation, alkaline phosphatase (ALP) and mineralization, were induced. 
Withaferin A stimulated ALP activity (Fig. 1A) after one week of culture, compared to 
control treated cells, and mineralization was induced (Fig. 1B) after three weeks of 
culture. Calcium folinate had no effect on ALP activity (Fig. 1C) after one week of 
culture, but did induce mineralization (Fig. 1D) after three weeks of culture. Similar to 
calcium folinate, amylocaine also had no effect on ALP activity (Fig. 1E), but did 
stimulate mineralization (Fig. 1F) after three weeks of culture. These results show that  
all three positively correlated compounds induce mineralization in hMSCs, a hallmark 
of osteogenic differentiation. 
 
 
 
Figure 1. Withaferin 
A stimulates both 
alkaline phosphatase 
activity and 
mineralization, while 
calcium folinate and 
amylocaine stimulate 
mineralization. 
Results of ALP activity 
(A,C,E) after 1 week of 
culture and calcium 
assay after 3 weeks of 
culture (B,D,F) in 
hMSCs treated with 
various concentrations 
(shaded bars) of 
withaferin A (A,B), 
calcium folinate (C,D), 
or  amylocaine (E,F) 
when compared to 
negative control 
(control medium) 
(white bar) treated 
cells. n=3-4. * p < 
0.05, ** p < 0.01, *** p 
< 0.001. Graphs 
display 1 representative 
experiment. 
 
 
 
A         B
C         D
E         F
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3.2.3 The negatively correlated compounds, salbutamol, metaraminol, and diprophylline, have varying 
effects on osteoblastic differentiation of hMSCs in vitro 
To determine if the negatively correlated compounds, salbutamol, 
metaraminol, and diprophylline, inhibit osteoblast differentiation of hMSCs we 
cultured hMSCs with osteogenic differentiation medium, containing 100 nM dex, 
along with various concentrations of each compound. We again performed the same 
biochemical assays to determine if ALP activity or mineralization were reduced. 
Salbutamol treatment resulted in decreased levels of ALP activity (Fig. 2A) in hMSCs 
treated for one week. Salbutamol also inhibited mineralization (Fig. 2B) after three 
weeks of culture compared to dex treatment alone. Metaraminol and diprophylline 
had no effect on either ALP activity (Fig. 2C,E) or mineralization (Fig. 2D,F) at the 
doses tested (1-16 µM for both). In summary, only one of the selected negatively 
correlated compounds, salbutamol, successfully inhibited osteoblast differentiation, 
while the others had no effect.  
 
                            
Figure 2. Salbutamol 
inhibits alkaline 
phosphatase activity 
and mineralization of 
osteogenically 
differentiated 
hMSCs, but 
metaraminol or 
diprophylline have no 
effect. Results of ALP 
activity (A,C,E) after 1 
week of culture or 
calcium assay (B,D,F) 
after 3 weeks of culture 
in hMSCs treated with 
differentiation medium 
(medium+100 nM 
Dex) supplemented 
with various 
concentrations (shaded 
gray bars) of 
salbutamol (A,B), 
metaraminol (C,D), or 
diprophylline (E,F) 
when compared to 
control (differentiation 
medium alone) (black 
bar) treated cells. * p < 
0.05, ** p < 0.01, *** p      
< 0.001. Graphs 
display 1 representative 
experiment. 
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Table 3. Top Differentially Expressed Genes (DEGs). 
 
Withaferin A  Calcium Folinate 
 
Probe ID 
 
Gene ID 
Fold 
Change 
  
Probe ID 
 
Gene ID 
Fold 
Change 
203665_at HMOX1 4.88  205778_at KLK7 0.62 
213418_at HSPA6 3.76  202840_at TAF15 0.62 
117_at HSPA6 3.17  217427_s_at HIRA 0.60 
200800_s_at HSPA1A 2.72  216745_x_at - 0.59 
202581_at HSPA1A 2.55  206499_s_at RCC1 0.56 
201008_s_at TXNIP -1.57  213513_x_at ARPC2 -0.67 
201110_s_at THBS1 -1.62  212533_at WEE1 -0.72 
201109_s_at THBS1 -1.68  217586_x_at - -0.75 
202436_s_at CYP1B1 -1.75  205225_at ESR1 -0.78 
204470_at CXCL1 -1.84  214953_s_at APP -1.04 
 
Amylocaine  Salbutamol 
 
Probe ID 
 
Gene ID 
Fold 
Change 
  
Probe ID 
 
Gene ID 
Fold 
Change 
210496_at G18 0.73  204595_s_at STC1 2.34 
201041_s_at DUSP1 0.72  206924_at IL11 1.85 
213303_x_at ZBTB7A 0.71  201925_s_at CD55 1.82 
215643_at SEMA3D 0.67  201926_s_at CD55 1.78 
212501_at CEBPB 0.67  204597_x_at STC1 1.78 
218737_at SBNO1 -0.76  202627_s_at SERPINE1 -1.11 
218411_s_at MBIP -0.77  211160_x_at ACTN1 -1.13 
212934_at UBXN2B -0.77  209101_at CTGF -1.15 
204120_s_at ADK -0.88  210560_at GBX2 -1.25 
214327_x_at TPT1 -1.01  202628_s_at SERPINE1 -1.35 
 
Metaraminol  Diprophylline 
 
Probe ID 
 
Gene ID 
Fold 
Change 
  
Probe ID 
 
Gene ID 
Fold 
Change 
206924_at IL11 1.51  203944_x_at BTN2A1 1.31 
204595_s_at STC1 1.47  202699_s_at TMEM63A 1.31 
208250_s_at DMBT1 1.34  215063_x_at LRRC40 1.23 
201925_s_at CD55 1.19  215493_x_at BTN2A1 1.17 
33304_at ISG20 1.13  203935_at ACVR1 1.13 
206170_at ADRB2 -0.86  214953_s_at APP -0.69 
210560_at GBX2 -0.87  215991_s_at KIAA0090 -0.70 
210538_s_at BIRC3 -0.88  221629_x_at C8orf30A -0.71 
209101_at CTGF -0.90  215055_at B3GNTL1 -0.73 
202628_s_at SERPINE1 -1.04  215637_at TSGA14 -1.16 
 
The 5 most up-regulated and 5 most down-regulated expressed probes of each compound derived from CMAP. The 
table contains the probe ID, its gene ID and the average fold change value of the two instances (log base 2 
transformed). Top ranking DEGs are probes identified based on the average of the ratioed (instance to the control) 
normalized expression values for the two instances for each compound.  
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3.2.4 Identification of differentially expressed genes (DEG) and biological processes affected by 
positively and negatively correlated CMap compounds 
In order to gain insights into how the newly identified Cmap compounds 
influence osteogenic differentiation, we performed in silico analysis of the genes 
regulated by these compounds from the Cmap database data. We ranked differentially 
expressed genes (DEGs) by their average relative expression values for each 
compound. Table 3 displays the five most up-regulated and five most down-regulated 
genes (identified by their corresponding microarray probe) for each compound. 
Withaferin A treatment in PC3 cells resulted in the most differentially regulated genes, 
compared to control treatment, of any of the compounds. Withaferin A treatment 
strongly up-regulated stress-response genes, including heme oxygenase 1 (HMOX1), 
heat shock 70 kDa protein (HSPA1A) and heat shock protein family A member 6 
(HSPA6), with HMOX1 being the most strongly regulated (29.3-fold upregulation) 
gene of any of the Cmap compounds. Withaferin A down-regulated expression of 
thrombospondin 1 (THBS1), thioredoxin interacting protein (TXNIP), and a 
cytochrome P450 family member (CYP1B1). Calcium folinate and amylocaine 
displayed much weaker regulation (based on averaged data of the two instances) of 
genes. The top DEG for amylocaine was tumor protein, translationally-controlled 1 
(TPT1) (2 fold down-regulated) and for calcium folinate we found amyloid beta 
precursor protein (APP) to be the most regulated (also 2-fold down-regulated). Of the 
negatively correlated compounds, salbutamol demonstrated the greatest effect on 
gene expression regulation, compared to control treated cells. The strongest regulated 
genes for salbutamol included stanniocalcin 1 (STC1), interleukin 11 (IL11), CD55 
molecule (Cromer blood group) (CD55), and Serpin Family E Member (SERPINE1), 
with STC1 being the next most differentially expressed (5 fold up-regulated) gene 
after the withaferin A regulated stress response genes. IL11 and STC1 were also the 
most strongly regulated genes by metaraminol (2.9- and 2.8-fold up-regulated, 
respectively). Butyrophilin subfamily 2 member A1 (BTN2A1) and transmembrane 
protein 63A (TMEM63A) (both 2.5-fold up-regulated) topped the list of DEGs for 
diprophylline. 
 To investigate the chosen compounds biological functions, the 100 most up-
regulated and 100 most down-regulated DEGs of each compound were annotated 
and clustered through Gene Ontology (GO) analysis in DAVID. Table 4 summarizes 
the major GO terms clusters that were identified for each compound and all identified 
GO terms for each individual compound are shown in Appendix C, Table A2. DEGs 
from amylocaine and salbutamol were found to be associated with the cytosolic 
region, which DEGs from salbutamol and metaraminol were both associated with the 
extracellular region. GO terms related to apoptosis, proliferation, 
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Table 4. Top Gene Ontology (GO) terms based on gene expression profiles of CMap-derived 
compounds.   
 
Compound 
GO term 
Biological process 
GO term 
Molecular Function 
GO term 
Cellular 
component 
Withaferin A 
Response to unfolded protein 
Apoptosis (+ regulation) 
Regulation of cellular response 
to heat  
Cell proliferation 
DNA binding/transcription 
Protein binding - 
Calcium folinate - Enzyme binding - 
Amylocaine - -  Cytosol 
Salbutamol 
Wound healing 
Apoptosis (- regulation) 
Cell proliferation 
Cell signalling 
Protein C-terminus 
binding 
Extracellular region 
Cytosol 
Metaraminol - - Extracellular region 
Diprophylline - - - 
Summary of top GO term clusters that have been identified by DAVID bioinformatics resources for each compound 
using the top 100 most upregulated and 100 most downregulated probes based on the average of the ratioed (instance 
to the control) normalized expression values for the two instances for each compound. The GO terms within the 
clusters had a significance of Benjamini corrected p-value < 0.05. The headers “biological process”, “molecular 
function”, and “cellular component” stands for the GO category to which the GO term is annotated. 
 
and protein binding were shared by withaferin A and salbutamol. DEGs from calcium 
folinate annotate with the GO term enzyme binding.  
Overall, little overlap in GO terms was seen between the selected 
compounds, with only withaferin A and salbutamol sharing multiple processes. 
Withaferin A and salbutamol treatment also led to the most strongly regulated genes, 
HMOX1, HSPA1A, HSPA6, and STC1, of all the compounds; however, there was 
no overlap in genes that were most strongly expressed of repressed between them.  
 
3.2.5 HMOX1 and STC1 are important for human osteoblast differentiation 
To validate some of the results of our in silico analysis we used shRNAs to 
knockdown gene expression of two of the most strongly regulated genes by CMap 
compounds, HMOX1 and STC1, and assessed ALP activity and mineralization of 
differentiating hMSCs. Following knockdown of HMOX1, hMSCs were differentiated 
to osteoblasts using dex and after three days of treatment HMOX1 expression was 
reduced compared to scrambled control (Fig. 3A). Knockdown of HMOX resulted in 
decreased ALP activity (Fig. 3B) and mineralization (Fig. 3C). Gene expression of 
STC1 in differentiating osteoblasts was successfully reduced by shRNA treatment 
(Fig. 4A). Reduced expression of STC1 resulted in diminished ALP activity (Fig. 4B) 
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and suppression of mineralization (Fig. 4C) in hMSCs osteogenically stimulated with 
dex. These results demonstrate that two genes, HMOX1 and STC1, identified in our 
CMap analysis are essential to dex-induced human osteoblast differentiation in vitro. 
 
 
Figure 3. HMOX1 gene knockdown in differentiation hMSCs leads reduced gene expression, ALP activity 
and mineralization. (A) mRNA expression of HMOX1 was reduced 4 days after transduction with shRNA against 
HMOX1 (gray bar) compared to scrambled shRNA control (black bar). ALP activity after 1 week of culture (B) and 
mineralization after 3 weeks of culture (C) were inhibited by HMOX1 shRNA treatment (gray bar) compared to 
scrambled (black bar) in differentiating hMSCs. * p < 0.05, ** p < 0.01, *** p < 0.001. Graphs display 1 representative 
experiment. 
 
 
Figure 4. STC1 knockdown in differentiation hMSCs leads reduced gene expression, ALP activity and 
mineralization. (A) mRNA expression of STC1 was reduced 4 days after transduction with shRNA against STC1 
(gray bar) compared to scrambled shRNA control (black bar). ALP activity after 1 week of culture (B) and 
mineralization after 3 weeks of culture (C) were inhibited by STC1 shRNA treatment (gray bar) compared to 
scrambled (black bar) in differentiating hMSCs. * p < 0.05, ** p < 0.01, *** p < 0.001. Graphs display 1 representative 
experiment. 
 
3.3 Discussion 
Gene expression profiling during osteoblast differentiation provides us with 
gene activity changes contributing to cellular process and enables targets for new 
treatments to be identified. In this study, we employed gene expression profiles from 
human MSCs differentiated towards osteoblasts to identify biologically active small 
molecules capable to affect this process, both positively and negatively, using a 
computational bioinformatics method, i.e. the Connectivity Map. In a proof of 
concept study, through this approach, we recently identified parbendazole as a novel 
compound that can independently induce osteogenic differentiation of hMSCs  
leading to our scrutinization of a targetable osteogenic pathway15. Using the same 
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approach, we have now identified 3 additional positively correlated compounds, 
withaferin A, calcium folinate, and amylocaine, which stimulate osteoblast 
differentiation and mineralization of hMSCs in vitro. Conversely, we also examined 
compounds with negatively correlated gene signatures to that of differentiating 
osteoblasts, the results of which we hypothesized may reveal interesting new genes 
and processes in the osteoblast differentiation process. We also identified three 
compounds, salbutamol, metaraminol, and diprophylline, which exhibit a gene 
signature negatively correlated to our osteogenic gene signature, but only one of these 
drugs, salbutamol, inhibited dex-induced osteogenic differentiation of hMSCs. Finally, 
we analyzed the DEGs behind the CMap identified compounds and used this 
approach to identify and validate two genes, HMOX1 and STC1, as important factors 
for human osteogenesis.  
 The positively correlated compound withaferin A stimulated both ALP 
activity and mineralization in hMSCs establishing it as an osteogenic drug. These 
results are supported by two studies that have previously shown that withaferin A 
positively affects osteoblast differentiation and bone formation. Withaferin A was 
shown to promote in vitro calvarial osteoblast differentiation and proliferation by 
acting as a proteasomal inhibitor and binding to specific catalytic b subunit of the 20S 
proteasome, decreasing expression of E3 ubiquitin ligase, Smad ubiquitin regulatory 
factor 2 (Smurf2), and ultimately preventing degradation of Runt-related transcription 
factor 2 (RunX2) and relevant Smad proteins16. Oral administration of withaferin A to 
mice increased cortical bone regeneration after injury and exerted an anabolic effect 
on osteoporotic bone 16and in vivo administration in ovariectomized mice increased 
new bone formation, as well as improved bone microarchitecture and biomechanical 
strength 17. These bone anabolic properties were similar to 17-β-estradiol and 
alendronate administration, but without the estrogenic or anti-estrogenic 
consequences to the uterus. In this study different donors displayed different 
sensitivities to all of the positively correlated compounds tested, with withaferin A 
treatment being the most variable between donors. While withaferin A treatment 
induced ALP activity and mineralization in all 4 donors tests, the highest dose 
tolerated by various donors, as well as the dose that demonstrated the greatest 
response, varied between donors. These results highlight the varying sensitivity of 
various human donors, likely due to differing genetic and physiological makeup. This 
variability could also be related to the results of our DEG and GO analysis in which 
we saw that withaferin A induced changes in stress-response genes such as HSPA1A 
and HMOX1. GO analysis revealed that the DEGs were annotated to stress response 
biological processes such as “unfolded protein response”, “apoptosis” and 
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“proliferation”. In our study withaferin A treatment in hMSCs showed that it might 
have toxic effects on hMSCs after prolonged treatment at a concentration of greater 
than or equal to 0.6 µM, depending on the donor. These findings correlate with the 
known inhibitory effects of withaferin A on cell proliferation of different types of 
cancer cells by inducing cell cycle arrest at the G2/M phase18–20. The top regulated 
gene in our study, HMOX1, is an enzyme that catalyses the cleavage of heme to form 
biliverdin, carbon monoxide and free iron21 and researchers have shown that HMOX1 
has a protective role during oxidative stress22,23, which relates to our finding that 
DEGs of withaferin A correlate to various stress processes. Overexpression of 
HMOX1 has been found to increase human osteoblast stem cell differentiation, and 
shift the balance of hMSCs differentiation in favor of the osteoblast lineage24,25. Our 
HMOX knockdown experiments strongly substantiate the role of HMOX1 during 
osteogenesis. 
Calcium folinate and amylocaine both stimulated mineralization in hMSCs, 
while, interestingly, having no consistent effect on ALP activity. As mineralization is 
the defining feature of a mature osteoblast we have concluded that these two 
compounds stimulate osteogenic differentiation of hMSCs in vitro. These two 
molecules yielded a low level of gene regulation, based on DEG analysis, which could 
in part be due to a low level of correlation in the regulation of the genes between the 
two instances for both compounds. One possibility for the lower expression levels, or 
reduced number of shared DEGs between instances may be batch effects (non-
biological variations), for example the use of different microarray scanners, which has 
been reported to be commonly observed across multiple batches of microarray 
experiments26,27. As the CMap platform generated its gene profiles in multiple batches, 
we utilized a normalization step to adjust the probe data for the batch effect related to 
the use of different scanners, which should minimize the number of false positives, 
but may remove true positives as well. Amylocaine, also known as stovaine, was 
developed as a synthetic local anesthetic; however, little research has been done on 
the mechanisms of action of amylocaine and no data exists linking it to bone or 
osteoblast differentiation. Local anesthetics, including amylocaine, act by inhibiting 
voltage-sensitive Na+ channels28–30, and to a lesser extent voltage sensitive Ca2+ 
channels31, and it is plausible that the osteogenic effect observed with amylocaine 
could be related to its potential effects on ion channels, but this requires further 
investigation. Calcium folinate, otherwise known as folinic acid or by the brand name 
Leucovorin, is a derivative of tetrahydrofolic acid and is readily converted to other 
reduced folic acid derivatives, giving it the vitamin activity equivalent to that of folic 
acid. Interestingly, calcium folinate has been shown to ameliorate the negative effects 
of methotrexate chemotherapeutic on bone, including prevention of bone loss, 
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apoptosis of mesenchymal precursor cells, and bone marrow adiposity32–34 through 
up-regulating Wnt/β-catenin signaling in bone35. Only one study, to our knowledge, 
has examined the effects of calcium folinate on bone, independent of methotrexate; 
however, only tibial and femur lengths were scrutinized and no difference was found 
between calcium folinate treatment and control treatment36. Further investigations 
into the effect of both amylocaine and calcium folinate treatment on osteoblast 
differentiation and bone growth are clearly warranted.  
 Using the CMap to find compounds that could inhibit osteoblast 
differentiation proved to be less optimal, with only of the three compounds tested 
working. Treatment with the top negative correlated compound, salbutamol, reduced 
both ALP activity and mineralization in hMSCs treated with osteogenic differentiation 
medium, relative to dex only treated cells, proving its ability to inhibit the dex-induced 
differentiation of hMSCs towards osteoblasts. Salbutamol is known to be an agonist 
of adrenergic β2 receptors and is used for the relief of bronchospasm in patients 
suffering from diseases such as asthma and chronic obstructive pulmonary disease 
(COPD)37. Salbutamol has previously been shown to have  a deleterious effects on 
trabecular architecture, bone density, and mechanical strength of vertebrae and long 
bones in rats38–40. Our results are in line with this finding and suggest that the negative 
effect of salbutamol on bone may be due to reduced osteoblast differentiation. In silico 
analysis of the top DEGs following salbutamol treatment in the PC3 cell line revealed 
that a number of genes are shared by both instances of salbutamol, as well as 
metaraminol. We found STC1 to be of particular interest as it was the most strongly 
regulated gene.  STC1 encodes for a glycoprotein that may play a role in the regulation 
of calcium and phosphate transport41,42. During osteogenic differentiation of fetal rat 
calvarial cells the knockdown of STC1 expression using antisense oligonucleotides 
inhibited osteoblast differentiation, while STC1 overexpression accelerated osteogenic 
development42. This contradicts the prediction by the connectivity map, which would 
suggest STC1 to play a negative role in osteogenic differentiation, indicating that the 
differences in regulation may be due to use of different cell lines, species or culturing 
procedures and further investigation would be needed to determine the exact 
mechanism by which salbutamol negatively effects human osteoblast differentiation.  
To conclude, this study showed that CMap is able to predict compounds that 
induce osteoblast differentiation but prediction of compounds that can negatively 
regulate osteoblast differentiation was not as accurate. For this study both positively 
and negatively correlated compounds were selected based on their ability to modulate 
genes leading to inhibition or stimulation of osteoblast differentiation. In both cases, 
the regulated genes are interesting to be considered as targets for therapeutic or 
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diagnostic purposes. Moreover, the DEGs of withaferin A, salbutamol and 
metaraminol contained interesting genes, HMOX1 and STC1, involved in osteoblast 
differentiation, giving us further insights into this process and possible therapeutic 
targets. Overall, this study supports the use of the CMap for the discovery of 
compounds and underlying genes that may stimulate human osteogenic differentiation 
and constitute potential new treatments for bone diseases, such as osteoporosis. 
 
3.4 Materials and Methods 
 
3.4.1 Materials 
MSCs were purchased from Lonza (MSC; PT-2501, Walkersville, MD, USA). 
αMEM was purchased from Gibco BRL, Life Technologies (Paisley, UK). 
Dexamethasone, β-glycerophosphate, calcium folinate, metaraminol, salbutamol, the 
calcium assay kit, and triton X-100 were purchased from Sigma–Aldrich (St. Louis, 
MO, USA). Withaferin A was purchased from LKT Laboratories Inc. (St. Paul, MN, 
USA). Amylocaine was purchased from Fagron Services B.V. (Uitgeest, NL). 
Diprophylline was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Illumina Human HT-12 v3 BeadChip arrays, iScan and GenomeStudio V2010.1 
(RRID:SCR_010973) (Gene Expression Module 1.6.0) were obtained from Illumina 
Inc. (Eindhoven, The Netherlands), the 2100 Bioanalyzer from Agilent Technologies 
(Santa Clara, CA, USA). Illumina TotalPrep RNA Amplification Kit was purchased 
from Ambion (Austin, TX, USA). BCATM protein assay reagent A and B were 
purchased from Pierce (Rockford, IL, USA). Victor2 plate reader was purchased from 
PerkinElmer Life and Analytical Science (Waltham, MA, USA).  
 
3.4.2 Cell culture 
Human bone marrow-derived Mesenchymal Stromal Cells were cultured as 
described previously43,44. hMSCs were cultured in αMEM medium containing 10% 
heat-inactivated fetal calf serum and 10 mM β-glycerophosphate (control medium for 
positively correlated compound experiments). For positively correlated compound 
experiments calcium folinate (ranging from 1 to 30 µM, 8mM stock prepared in 
H2O), amylocaine (ranging from 1 to 50 µM, 15mM stock prepared in H2O), or 
withaferin A (ranging from 0.03 to 1 µM, 1mM stock prepared in 100% ETOH) were 
added to the media. For experiments with the negatively correlated compounds the 
media was supplemented with 100 nM dexamethasone (dex) alone (control medium 
for negatively correlated experiments) or in combination with salbutamol (ranging 
from 1 to 16 µM, 20mM stock prepared in 100% ETOH), metaraminol (ranging from 
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1 to 16 µM, 20mM stock prepared in H2O), or diprophylline (ranging from 1 to 16 
µM, 20mM stock prepared in 100% ETOH). Cell extracts were harvested at different 
time points during culture by scraping the cells in PBS/triton (0.1%) and storing at -
80ºC for biochemical analyses or in TRIzol and stored at -20ºC for gene expression 
analyses.  
 
3.4.3 Illumina gene chip–based gene expression 
For analysis of whole human genome expression, we used Illumina Human 
HT-12 v2 BeadChip arrays. Human MSCs (in triplicate) were treated for 6 hours with 
dexamethasone and next RNA was isolated as previously described44. RNA integrity 
of isolated RNA was assessed by RNA 6000 Nano assay on a 2100 Bioanalyzer. The 
Illumina TotalPrep RNA Amplification Kit was used for RNA amplification of each 
sample according to manufacturer's instructions. In short, T7 oligo(dT) primer was 
used to generate single-stranded cDNA, followed by a second-strand synthesis to 
generate double-stranded cDNA. Biotin-labeled cRNA was synthesized using T7 
RNA polymerase. The cRNA was column-purified and checked for quality by RNA 
6000 Nano assay. A total of 750 ng of cRNA was hybridized for each array using the 
standard Illumina protocol, using streptavidin-Cy3 for detection. Slides were scanned 
on an iScan and analyzed using GenomeStudio. 
 
3.4.4 Microarray analysis 
Background was subtracted from the raw data using GenomeStudio V2010.1 
(Gene Expression Module 1.6.0), and data were processed, using the Bioconductor 
R2.10.0 Lumi package (RRID:SCR_006442, www.bioconductor.org)45. Data were 
transformed by variance stabilization and quantile normalization. Probes that were 
detected at least once in the experiments (Illumina detection p-value < 0.01) were 
considered to be expressed and were further analyzed. Differentially expressed probes 
were identified using Bioconductor Package Limma (www.bioconductor.org)46 with p-
values adjusted to reduce the false discovery rate (FDR; p <0.001).  
 
3.4.5 Connectivity map query 
The CMap query was performed as previously described15. Briefly, to find 
compounds that have similar or opposite gene expression patterns compared to our 
human osteogenic differentiation-induced gene expression patterns, we generated 
gene signatures from microarray gene expression analyses of bone marrow-derived 
hMSCs treated with dex to stimulate osteogenic differentiation. We identified the 100 
most significantly (q<0.001) up- and downregulated probes based on log ratio of gene 
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expression during osteogenic differentiation at 6 hours following the start of 
differentiation treatment, compared to undifferentiated cells at time point 0. Illumina 
probe IDs were converted to Affymetrix probe IDs, which are required as input into 
the CMap. After removal of duplicates we ended up with 77 up-regulated genes and 
66 down-regulated genes (Appendix C, Table A1) that we submitted simultaneously 
for our CMap query (build02, http://www.broadinstitute.org/cmap/). This signature 
was queried against the CMap using the gene set enrichment analysis algorithm 
described by Lamb et al.3 and a ranked list of gene profiles was generated by CMap. 
These steps are illustrated in figure 5. 
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Figure 5: Methods flow chart. Graphical representation of the steps carried out as part of the methods for this 
work. Black boxes represent steps carried out by authors of this paper. Gray boxes represent steps performed by 
Lamb and colleagues3 as part of the CMap and results were obtained through the web based query 
(www.broadinstitute.org/cmap/). 
 
3.4.6 Alkaline phosphatase, mineralization and protein assays 
Alkaline phosphatase (ALP) and calcium measurements were performed as 
described previously47. Briefly, ALP activity is determined by an enzymatic reaction, 
where the ALP-mediated conversion of PNPP to PNP during 10 min at 37°C is 
measured colorimetrically at 405 nm. For calcium measurements, cell lysates were 
incubated overnight with 0.24 M HCl at 4°C. Calcium content was determined 
colorimetrically using a calcium assay reagent prepared by combining 1 M 
ethanolamine buffer (pH 10.6) with 0.35 mM 0-cresolphthalein complexone in a ratio 
of 1:1. ALP results were adjusted for protein content of the cell lysates. For protein 
measurement, 200 µl of working reagent was added to 25 µl of sonicated cell lysate. 
The mixture was incubated for 30 min at 37°C, cooled down to room temperature 
and absorbance was measured at 595 nm. All measurements were performed using a 
Victor2 plate reader.  
 
3.4.7 In silico analysis of connectivity map data  
The gene profiles of CMap were extracted as “instances” that include the 
gene profiles of cells treated with the compound or vehicle. The instances were 
downloaded and processed by using software environment R Project for Statistical 
Computing (https://www.r-project.org, RRID:SCR_001905). For each instance, the 
raw probe data was converted into a numerical matrix diagram with the probes as row 
headers, conditions (treatment and controls) as column headers, and each matrix cell 
contained an intensity value.  
Gene expression profiles in CMap were generated in multiple batches of 
microarrays, and thus, non-biological variation may occur between instances of a 
compound, such as the use of different array scanners. Therefore, a normalization 
step was utilised to equalize the distribution of probe intensities for every instance. 
The matrices of all instances were merged and the normalized intensity value in each 
cell was calculated by using the equation:  
Enormalized = ( Eprobe  / Econdition ) * Etotal 
The intensity value in a cell (Eprobe) was divided by the mean intensity value of the 
column (Econdition) and then multiplied by the mean intensity value of the whole matrix 
(Etotal). After normalisation, the instances were separated into individual matrices and 
plotted as a box plot for visualisation (Fig 6). 
These steps are illustrated in the methods flow chart (Fig. 5). 
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Figure 6: Gene expression box plots pre- and post-normalization. Box plots of all intensity values from multiple 
instances probe data set, before (A) and after normalization (B). The y-axis defines the probe intensity value in log 
base 2. The x-axis describes the instances. Each box plot represents the probes of a treatment or control. 
 
 
3.4.8 Differentially expressed gene (DEG) and gene ontology (GO) analysis  
For ease of understanding this process is illustrated in Figure 5. DEGs 
analysis was performed to determine which genes are highly modulated by a treatment 
compared to the control. Each instance contains one treatment probe set and multiple 
control probe sets. First the control group of each probe was averaged. The criteria 
A             B        Before Normalization       After Normalization
A             B        Before Normalization       After Normalization
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for the threshold of the probe intensity were set as follow: For each instance if the 
normalized intensity of a probe for either the treatment or the averaged control 
samples was a value of at least 100 the probe will be included. Next, the ratio between 
the treatment sample and averaged control was calculated. Subsequently, the ratio 
value was log transformed (log base 2). For the next filtering step, only if both 
instances for a single compound (there were 2 instances (biological replicates) for 
every compound identified by the CMap) met the criteria for an intensity value of 
greater than 100 that probe was included for subsequent analysis. The ratio value of 
each probe of both instances for each compound were averaged. Probes were ranked 
based on their averaged, ratioed intensity value for each compound. 
Functional annotation analysis was performed using the online application DAVID 
bioinformatics to look for functional enrichment among GO categories (biological 
process, cellular component and molecular function). For each CMap compound, the 
100 most up-regulated and 100 most down-regulated probes (based on the above 
criteria) were uploaded to DAVID (RRID:SCR_001881) and the analysis was 
performed with default settings. The results were extracted that contained the GO 
term names, the Benjamini corrected p-values, the enrichment scores, and the number 
of genes that were annotated with the particular GO term.  
 
3.4.9 Quantification of mRNA expression 
RNA isolation, cDNA synthesis and PCR reactions were performed as 
described previously44. Oligonucleotide primer pairs were designed to be either on 
exon boundaries or spanning at least one intron (Table 5). Gene expressions were 
corrected for the housekeeping gene GAPDH. Experiments were performed in at 
least duplicate for at least two separate experiments. 
 
Table 5. Oligonucleotide primers used in the study. 
Gene Forward 5'-3''  Reverse 5'-3''  
CD55 TACCCGTCTTCTATCTGGGCA AGCCCATGGTTACTAGCGTC 
STC1 CACTCAGGGAAAAGCATTCGT GAAAGTGGAGCACCTCCGAA 
HMOX1 ACTCCCTGGAGATGACTCCC GCAACTCCTCAAAGAGCTGGA 
THBS1 CAGGAGCAACCTCTACTCCG CAGCAGGGATCCTGTGTGTA 
GAPDH CCGCATCTTCTTTTGCGTCG CCCAATACGACCAAATCGTTG 
Sequences of primer sets used for qPCR in this study. All genes were detected using SYBR green. 
 
3.4.10 Lentiviral-mediated gene knockdown 
For gene knockdown of HMOX1 and STC1, constructs from the TRC-Hs1.0 
library (Thermo Scientific, Bleiswijk, Netherlands) were used (Table 6). Non-
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targeting shRNA vector with a scrambled sequence (Table 6) was used as a negative 
control. In short, lentivirus (LV) was produced by transient transfection of each LV 
construct into human embryonal kidney (HEK) 293T cells (RCB Cat# RCB2202, 
RRID:CVCL_0063) using a standard calcium phosphate precipitation technique. The 
appropriate LV vector plasmid (3 µg) and the packaging vector plasmids (9 µg of 
ViraPower mix (ThermoFisher)) were cotransfected into subconfluent HEK-293T 
cells plated in 100-mm dishes. Viral supernatants were harvested 48 and 72 hours after 
transfection, filtered through a 0.45-µm pore size filter, and used immediately for 
hMSC transduction or stored at –80°C until use. One day prior to LV transduction, 
hMSC were seeded into 12-well plates. Transduction consisted of overnight LV 
incubation, after which the medium was replaced with treatment medium and the cells 
were cultured until further analysis.  
 
Table 6. shRNA Sequences. 
ID Target Sequence 
HMOX1 CGGGCCAGCAACAAAGTGCAA 
STC1 GCATTCGTCAAAGAGAGCTTA 
Non-targeting shRNA Oligo Sequence 
Scrambled CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT 
The target sequences of shRNAs for silencing of the HMOX1 and STC1 genes and non-targeting scrambled. 
 
3.4.11 Statistics 
Biochemical analysis of hMSCs treated with positively correlated compounds 
were performed in at least four independent experiments using cells from at least 
three different donors performed at least in duplicate. Negatively correlated 
compounds were tested in at least three independent experiments using hMSCs from 
at least two different donors performed at least in duplicate. Gene expression and 
knockdown studies were performed in at least two independent experiments at least 
in triplicate. Values displayed are mean +/- SEM. Significance was calculated using 
either the Student's t-test or the one-way ANOVA followed by Tukey’s post hoc test 
for difference between all treatments or Bonferroni’s post-hoc test for differences 
between a control and each other treatment, where appropriate, using GraphPad 
Prism 6.0 (RRID:SCR_002798). P-values <0.05 were considered significant. 
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Abstract 
Osteoporosis is a common skeletal disorder characterized by low bone mass leading 
to increased bone fragility and fracture susceptibility. The bone building cells, 
osteoblasts, are derived from mesenchymal stromal cells (MSCs); however, with 
increasing age osteogenic differentiation is diminished and more adipocytes are seen 
in the bone marrow, suggesting a shift in MSC lineage commitment. Identification of 
specific factors that stimulate osteoblast differentiation from human MSCs may 
deliver therapeutic targets to treat osteoporosis. The aim of this study was to identify 
novel genes involved in osteoblast differentiation of human bone marrow–derived 
MSCs (hMSCs). We identified the gene chloride intracellular channel protein 3 
(CLIC3) to be strongly upregulated during MSC-derived osteoblast differentiation. 
Lentiviral overexpression of CLIC3 in hMSCs caused a 60% increase of matrix 
mineralization. Conversely, knockdown of CLIC3 in hMSCs using two short-hairpin 
RNAs (shRNAs) against CLIC3 resulted in a 69% to 76% reduction in CLIC3 mRNA 
expression, 53% to 37% less alkaline phosphatase (ALP) activity, and 78% to 88% 
less matrix mineralization compared to scrambled control. Next, we used an in vivo 
human bone formation model in which hMSCs lentivirally transduced with 
the CLIC3 overexpression construct were loaded onto a scaffold (hydroxyapatite-
tricalcium-phosphate), implanted under the skin of NOD-SCID mice, and analyzed 
for bone formation 8 weeks later. CLIC3 overexpression led to a 15-fold increase in 
bone formation (0.33% versus 5.05% bone area relative to scaffold). Using a Clic3-
His-tagged pull-down assay and liquid chromatography–mass spectrometry (LS/MS)-
based proteomics analysis in lysates of osteogenically differentiated hMSCs, we 
showed that CLIC3 interacts with NIMA-related kinase 9 (NEK9) and 
phosphatidylserine synthase 1 (PTDSS1) in vitro, and this finding was supported by 
immunofluorescent analysis. In addition, inhibition of NEK9 or PTDSS1 gene 
expression by shRNAs inhibited osteoblast differentiation and mineralization. In 
conclusion, we successfully identified CLIC3 to be a lineage-specific gene regulating 
osteoblast differentiation and bone formation through its interaction with NEK9 and 
PTDSS1. 
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4.1 Introduction 
Bone is a dynamic organ that throughout life undergoes constant remodeling 
through bone formation by osteoblasts and bone resorption by osteoclasts. 
Osteoporosis is a common skeletal disease characterized by reduced bone mass and 
increased fragility and fracture risk, occurring when bone remodeling is disrupted and 
bone resorption overtakes bone formation1. The vast majority of osteoporosis 
treatments, such as bisphosphonates, act through reduction of bone resorption, and 
result in modest increases in bone density; however, these treatments do not result in 
a true bone anabolic effect so patients do not regain the bone that has been lost at 
time of diagnosis. An ideal treatment would also stimulate osteoblast differentiation 
and/or bone formation to help repair the already damaged bone microarchitecture. 
Identification of novel genes or processes that stimulate osteoblast differentiation may 
therefore deliver therapeutic targets for the development of novel treatments for bone 
diseases such as osteoporosis. 
Osteoblasts are derived from the bone marrow mesenchymal stem, or 
stromal, cells (MSCs) and undergo terminal differentiation to form osteocytes2. 
Besides osteoblasts, MSCs give rise to other cell types, including adipocytes and 
chondrocytes3. Osteogenic differentiation of MSCs is a tightly regulated process that 
progresses through several phases. MSCs are driven to the osteogenic lineage by 
expression of the osteoblast-specific transcription factors Runx2 and Osterix4–6. After 
initial commitment, differentiation towards mature osteoblasts is typically 
characterized by the expression of collagen type I, osteocalcin, osteopontin, bone 
sialoprotein, and alkaline phosphatase (ALP)7; however, the precise mechanism of 
how human bone marrow–derived MSCs (hMSCs) differentiate into osteoblasts is still 
largely unknown, including the exact mechanism by which glucocorticoids stimulate 
osteoblast differentiation in vitro8,9.  
With aging there is a decrease in bone mass and increased bone fragility, 
while at the same time there is an increase in total and bone marrow adiposity10,11. As 
both the osteogenic and adipogenic lineages derive from the same progenitor, it 
appears that there is a shift in the lineage decision-making process of MSCs with 
increasing age. This theory is supported by previous work showing that bone marrow 
derived mesenchymal progenitors from aged humans, rats, and mice preferentially 
differentiate toward the adipogenic, rather than osteogenic, lineage10–14. 
Our aim was to expand the knowledge of human osteoblastogenesis by 
identifying novel genes and processes involved in differentiation of hMSCs to the 
osteogenic lineage. Gene expression analysis of hMSCs undergoing osteogenic and 
adipogenic differentiation led us to study chloride intracellular channel protein 3 
(CLIC3) as an osteogenic lineage specific candidate. CLIC proteins are a conserved 
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family of proteins first identified when a novel chloride ion channel was discovered in 
bovine kidney15,16. This family of proteins can transition between a soluble globular 
form and an integral membrane protein that is able to mediate ion conductance 
and/or ion channel formation17,18. However, their role as channel proteins under 
physiological conditions has been strongly debated. To date, six CLIC paralogues 
have been identified in vertebrates, all of which appear to have diversified in 
function18,19. CLIC3 is a largely unstudied 26.6-kDa member of the CLIC family. It 
has been implicated to be involved in cellular processes including integrin 
recycling20,21, endosome trafficking22 and cell growth via interactions with ERK723. 
 
4.2 Results 
 
4.2.1 CLIC3 is upregulated during human osteogenic differentiation and downregulated during 
adipogenesis 
  CLIC3 is dynamically expressed in human mesenchymal stromal cells 
(hMSCs) during osteogenic differentiation (Fig. 1). Figure 1 shows that expression of 
CLIC3 is increased during the osteogenic differentiation of hMSCs, peaking between 
1 and 3 days of culture, compared to non-differentiating, In addition, we saw that 
CLIC3 expression goes down in adipogenic cells compared to non-differentiating, 
showing an opposite effect to that of osteoblasts. These data led us to further 
scrutinize CLIC3 as a candidate gene for human osteoblastogenesis. 
 
 
Figure 1. CLIC3 expression is upregulated during osteoblast differentiation and downregulated during 
adipocyte differentiation. mRNA expression levels of CLIC3 in hMSCs cultured in non-differentiating (white bars), 
osteogenic (black bars), and adipogenic (grey bars) conditions over 3 weeks assessed by quantitative PCR. Graph 
displays a representative experiment. n=2.  
 
4.2.2 Overexpression of CLIC3 in hMSCs enhances in vitro osteogenic differentiation 
To determine the role CLIC3 has in human osteoblastogenesis we 
overexpressed CLIC3 in hMSCs by lentiviral transduction and studied its effect on 
classical biochemical markers of osteoblast differentiation. Efficient overexpression of 
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CLIC3 in hMSCs was determined by gene expression analysis and immunoblotting. 
Fig. 2A demonstrates successfully elevated CLIC3 mRNA expression by greater than 
100-fold at both day 1 and 7 of culture in both non-differentiating and differentiating 
hMSCs. Concordantly, protein levels of CLIC3 were also strongly increased at day 10 
of culture in non-differentiating and differentiating hMSCs (Fig. 2B). 
Immunofluorescent CLIC3 detection in differentiating hMSCs reveals that CLIC3 
overexpression (Fig. 2C) intensifies the level of CLIC3 protein in most cells, 
compared to empty vector (EV)-transduced cells (Fig. 2D). CLIC3 expression is 
predominately localized to the perinuclear region (arrow heads, Fig. 2C,D), In CLIC3-
overexpressing cells (Fig. 2C) there is increased expression in the cytoplasm (arrows) 
and nucleus (asterisk) compared to control cells (Fig. 2D). CLIC3 overexpression did 
not affect total protein levels (Fig. 2E) or ALP activity (Fig. 2F) in osteogenic hMSCs, 
but it did enhance mineralization by 60% as shown by total calcium quantification 
after 3 weeks of culture (Fig. 2G).  Overall, these results show that we have 
successfully overexpressed CLIC3 in hMSCs and that CLIC3 enhances in vitro 
mineralization. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CLIC3 overexpression enhances human osteoblast differentiation. Enhancement of CLIC3 expression 
was assessed by (A) quantification of CLIC3 mRNA expression by quantitative PCR of hMSCs transduced with empty 
vector (white bars) or CLIC3 overexpression vector (black bars) under non-differentiating (solid bars) or osteogenic 
differentiation (patterned bars) conditions at 24 hours (left 4 bars) or 7 days (right 4 bars) after the start of 
differentiation, or by (B) immunoblotting in protein lysates collected 10 days post induction of differentiation in two 
hMSC donors (A and B) using anti-CLIC3 antibody. Arrow indicates the predicted size of CLIC3 protein at 27kDa, 
last lane contains loading buffer only. In additional CLIC3 expression was visualized by immunofluorescence 
microscopy using CLIC3 antibody in hMSCs differentiated to osteoblasts and transduced with CLIC3 (C) or empty 
vector (D) at 400x total magnification after 4 days of differentiation. CLIC3, in green, is seen in the cytoplasm 
(arrows), the perinuclear region (arrow heads), and some nuclear staining (asterisk); actin cytoskeleton was visualized 
by phalloidin antibody in orange, and nuclei by DAPI in blue. Biochemical assays are shown for total protein (Day 6) 
(E), ALP activity (Day 6) (F), and mineralization (Week 3) (G) of hMSCs transduced with CLIC3 (black bars) or 
empty vector (white bars) and osteogenic culture conditions. Graphs display combined results of all experiments. 
(A) n = 8–12; (E,F) n = 18; (G) n = 19. *p < 0.05, **p < 0.01. OS = osteogenic media. CLIC3 = lentiviral transduction 
with CLIC3expression vector 1 day prior to the start of differentiation; DAPI = 4,6-diamidino-2-phenylindole. 
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4.2.3 CLIC3 is critical for in vitro human osteogenic differentiation 
To determine if CLIC3 is essential for human osteoblast differentiation we 
used short hairpin RNAs (shRNAs) against endogenous CLIC3 to knockdown its 
expression in hMSCs.  Two separate shRNAs decreased CLIC3 expression in hMSCs 
by 76% and 69% (Fig. 3A), respectively, compared to cells transduced with scrambled 
shRNA. Total protein levels were not affected by either shRNA (Fig. 3B). 
Knockdown of CLIC3 mRNA expression reduced ALP activity by 53% and 37%, 
respectively, after 1 week of culture (Fig. 3C). After 3 weeks of culture in osteogenic 
medium, CLIC3 silencing reduced mineralization by approximately 80% compared to 
the scrambled control (Fig. 3D).  
 
 
 
 
 
 
Figure 3. Knockdown of CLIC3 expression inhibits human osteoblast differentiation. Transduction of hMSCs 
with 2 shRNAs against CLIC3 (shaded bars) reduces (A) mRNA expression of CLIC3 as determined by quantitative 
PCR (day 4), (B) Total Protein (day 6), (C) ALP activity (day 6), and (D) mineralization (week 3) compared to 
scrambled control (white bar). Graphs display combined results from all experiments. A: n=4-5, B: n=7, C: n=6. ** p 
< 0.01, *** p < 0.001. 
 
4.2.4 CLIC3 enhances in vivo human bone formation 
In order to test the in vivo effect of CLIC3 manipulation on human bone 
formation we subcutaneously implanted hMSCs transduced with CLIC3 or empty 
vector (control) loaded onto a hydroxyapatite/tricalcium phosphate (HA-TCP) 
scaffold in immune-deficient mice and quantified the amount of heterotopic bone 
formed. As shown in Fig. 4, hMSCs overexpressing CLIC3 formed a significantly 
greater amount of ectopic bone compared to MSCs transduced with an empty vector. 
This is visualized in the representative Goldner-stained sections made from implants 
containing CLIC3 overexpressing hMSCs (Fig. 4A,B) containing patches of newly 
formed bone and osteoblasts compared to the control-treated hMSC-implants (Fig. 
4C,D) showing low level of newly formed bone. Quantification of the amount of new 
bone formed revealed that implants from CLIC3-overexpressing hMSCs contain 15 
times more bone compared to implants containing control-treated cells (Fig. 4E). 
These results clearly show that CLIC3 enhances in vivo bone human formation.  
 
A     B          C               D
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Figure 4. CLIC3 promotes human bone formation in vivo. Histological sections of explants of CLIC3 
overexpressing hMSCs (A, low magnification; B, high magnification) implanted under the skin of immune deficient 
(NOD-SCID) mice show more prevalent areas of new bone formation (labeled ‘B’) and osteoblasts (arrow) compared 
to empty vector-transduced cells (C, low magnification; D, high magnification). HA-TCP ceramic scaffold is labeled 
‘C’, adipocytes are labeled ‘A’. E: CLIC3 overexpression in hMSCs (black bar) increases the amount of newly formed 
bone in explants compared to control cells (white bar) based on quantification of the area of new bone formed as a 
percentage of total scaffold area, using ImageJ software. n=9-10. *** p < 0.001. 
 
4.2.5 CLIC3 pull-down identifies 52 proteins as potential interacting with CLIC3 in differentiating 
osteoblasts 
In an attempt to gain insight into the molecular interactions by which CLIC3 
acts on osteoblasts, we performed a pull-down assay followed by mass spectrometry 
(MS) analysis to identify which proteins, in cell extracts of hMSCs differentiated 
towards osteoblasts, associate with CLIC3. Table A3 (Appendix C) lists all CLIC3-
His pulled-down proteins ranked according to the average label-free quantification 
(LFQ) intensity ratio of CLIC3-His-baited samples versus control samples, which are 
based on non-specific binding. Bioinformatic analyses of these proteins were 
performed using Ingenuity Pathway Analysis and showed that “PRPP biosynthesis I”, 
“gap junction signaling”, “paxillin signaling”, “integrin signaling” and various 
endocytosis and exocytosis pathways comprise the most significant canonical 
pathways in the list of proteins (summarized in Table 1, detailed in Appendix C, 
Table A4). Using DAVID Gene Ontology (GO) analysis, the most significant GO 
terms included processes related to RNA nuclear export and localization, transport, 
cell adhesion, and localization to the nuclear periphery and pores (summarized in 
Table 1, detailed in Appendix C, Table A5). Out of the 52 proteins identified by 
CLIC3-His pull-down eight proteins were uniquely present in our CLIC3 samples, as 
compared to control samples (Table 2), and we chose to analyze 2 of these proteins 
further: NIMA-related kinase 9 (NEK9) and phosphatidylserine synthase 1 (PTDSS1). 
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Table 1: Summary of Top of Canonical Pathways and GO Terms 
Canonical Pathway1 Biological Process2 Molecular Function2 Cellular 
Component2 
-PRPP biosynthesis 
-gap junction signaling 
-paxillin signaling 
-integrin signaling 
-endocytosis/exocytosis 
-export from nucleus 
-RNA localization 
-transport 
-adhesion 
-RNA binding 
-cadherin binding 
-cell adhesion: protein 
and molecule binding 
-adherens cell 
junction 
-cytosol 
-nuclear 
periphery/pore 
Top canonical pathways determined by Ingenuity pathway analysis from the 52 proteins found to pull down with 
Clic3-His. GO term clusters that have been identified by DAVID bioinformatics resources for the same proteins. The 
GO terms within the clusters had a significance of Benjamini corrected p-value < 0.05. The headers “biological 
process”, “molecular function”, and “cellular components” stand for the GO category to which the GO term is 
annotated. 
1:determined by Ingenuity pathway analysis (http://www.ingenuity.com/) 
2:determined by DAVID Functional Annotation Analysis (http://david.ncifcrf.gov) 
 
4.2.6 CLIC3 interacts with NEK9 and PTDSS1 during osteogenic differentiation of MSCs 
To confirm the colocalization of CLIC3 with the proteins identified by the 
pull-down assay we performed immunofluorescent analysis. At day 5 of 
differentiation, CLIC3 (Fig. 5A) and NEK9 (Fig. 5B) co-localize in the perinuclear 
region (arrows, Fig. 5D) in CLIC3 overexpressing hMSCs, with some CLIC3 
expression seen in the nucleus as well (asterisk, Fig. 5A), overlapping with DAPI 
nuclear staining (5C,D). 
Similar to Figure 5A, figure 5E exhibits the cytosolic (arrowhead), perinuclear 
(arrows), and nuclear distribution of CLIC3 in osteogenically differentiated hMSCs, 
whereas PTDSS1 is localized specifically to the perinuclear (arrows) and nuclear 
(asterisk, overlapping with DAPI nuclear staining (5G)) compartments (Fig. 5F), and 
colocalization is seen in the perinuclear region (Fig. 5H).   
 
4.2.7 Inhibition of NEK9 and PTDSS1 affects osteogenic differentiation of hMSCs 
To determine if NEK9 or PTDSS1 play a role in human osteoblast 
differentiation, we studied the effects of shRNA knockdown of NEK9 and PTDSS1 
in osteogenically differentiating hMSCs. We found five shRNAs that all reduced 
NEK9 mRNA expression between 60% and 82% compared to the scrambled control 
4 days post-transduction (Fig. 6A). Four of the five shRNAs against NEK9 inhibited 
mineralization by 70% or more after 3 weeks of osteogenic differentiation (Fig. 6B). 
Although the majority of NEK9 shRNAs had no effect on total protein levels, one 
shRNA did decrease total proteins levels after 3 weeks of treatment (Fig. 6C). We 
identified five shRNAs against PTDSS1 that all reduced mRNA expression in the 
range of 48% to 75% in differentiating hMSCs (Fig. 6D). We observed that three out 
of the five shRNAs against PTDSS1 strongly inhibited mineralization, by 67% to 92% 
(Fig. 6E). The majority of shRNAs against PTDSS1 had no effect on total protein  
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Table 2: Top proteins identified in CLIC3-His pull down 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proteins identified by MS from CLIC3-His pull-down assay in hMSCs undergoing osteogenic 
differentiation. Protein lysates from osteogenically differentiated hMSCs were isolated on day 5 in 
cultures either overexpressing His-tagged CLIC3 or transduced with empty vector (EV) control, and 
subjected to protein pull-down for the His-tagged CLIC3 and proteins binding to it. Proteins were 
determined by mass spectrometry measurements (n=2). The top proteins are listed here, ranked on their 
ratio of CLIC3 versus control average LFQ intensity (i.e. present in CLIC3 overexpressing condition and 
absent in the EV condition). LFQ: Label-free quantification, nd: not detected.  
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levels; however, sh25-treated hMSCs displayed increased levels of total protein after 3 
weeks of culture (Fig. 6F). Overall these results demonstrate that both NEK9 and 
PTDSS1 play a role in supporting osteoblast differentiation of hMSCs. 
 
 
Figure 5. CLIC3 colocalizes with PTDSS1 and NEK9 in differentiating osteoblasts. Using immunofluorescence 
microscopy, CLIC3 (A,D,green) and NEK9 (B,D,red) were visualized together in hMSCs differentiated towards 
osteoblast and overexpressing CLIC3 at 630x magnification. Arrows indicate detection of both proteins in the 
perinuclear region and asterisks denote nuclear localization. Immunofluorescent detection of CLIC3 (E,H,green) and 
PTDSS1 (F,H,red) were visualized jointly in osteogenic hMSCs overexpressing CLIC3 at 400x magnification. PTDSS1 
and CLIC3 are both seen in the perinuclear (arrows) and nuclear (asterisks) compartments. C,D,G,H show nuclear 
staining by dapi in blue. PTDSS1 and CLIC3 are both seen in the perinuclear (arrows) and nuclear (asterisks) 
compartments. DAPI = 4,6-diamidino-2-phenylindole. 
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Figure 6. Knockdown of NEK9 and PTDSS1 gene expression inhibits osteogenic differentiation of hMSCs. 
mRNA expression of NEK9 (A) as determined by quantitative PCR (day 3), mineralization (B) (week 3), and total 
protein quantification (C) (week 3) after transduction of hMSCs with five shRNAs against NEK9 (shaded bars) 
compared to scrambled control (white bars). mRNA expression of PTDSS1 (D) as determined by quantitative PCR 
(day 3), mineralization (E) (week 3), and total protein quantification (F) (week 3) after transduction of hMSCs with 
five shRNAs against PTDSS1 (shaded bars) compared to scrambled control (white bars). Graphs display combined 
results from all experiments. (A) n =  4–12; (B) n = 6–12; (C) n = 6–12; (D) n = 4–12; (E) n = 5–12; (C) n = 6–12. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
 
4.3 Discussion 
CLIC3 was identified as a new gene specifically regulated in the osteogenic 
lineage of differentiating human MSCs. Lentiviral transduction-mediated 
overexpression and silencing of CLIC3 during osteogenesis revealed a crucial function 
for CLIC3 in promoting osteoblast mineralization. Overexpression of CLIC3 in 
hMSCs strongly enhanced in vivo bone formation in a mouse model for ectopic human 
bone formation, further emphasizing that CLIC3 plays an important role in human 
osteoblast differentiation. Bioinformatics analysis of proteins identified by CLIC3-His 
pull down suggests CLIC3s role during osteoblast differentiation may be related 
cytoskeletal associations and signaling, cell adhesion, and/or nuclear pore formation 
or transport of proteins or ions through nuclear pores. Finally, we identified that 
CLIC3 interacts with NEK9 and PTDSS1 during osteoblast differentiation, and 
inhibition of the NEK9 and PTDSS1 expression reduces osteogenic differentiation of 
hMSCs. 
CLICs are a diverse group of proteins, having been associated with a wide 
variety of biological processes and cellular functions including angiogenesis24, 
macrophage activation25, DNA damage26, maintenance of membrane structure27, bone 
resorption28 , cell growth, cell division and apoptosis23,29,30, and acidification of 
intracellular organelles24,31 All CLIC proteins contain a ~240 residue CLIC module 
A                B            C        
D                E            F    
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that adopts a GST superfamily fold32; within it there is conserved cysteine residue at 
what looks like an enzymatic active site18,19,33. CLIC3 was first identified based on its 
interaction with MAPK15, at the time known as ERK7, in a yeast two-hybrid assay 
and subsequently confirmed by co-immunoprecipitation in COS cells; Qian and 
colleagues23 proposed that it plays a role in controlling mammalian cell growth based 
on its association with MAPK15. This is the first report of CLIC3 being involved in 
osteoblastic differentiation of hMSCs and human bone formation. Our in vitro results 
revealed the important role for CLIC3 in osteoblast differentiation and the strong 
induction of bone formation by hMSCs after CLIC3 overexpression seen in our 
model of human ectopic bone formation in a mouse supports the strong role CLIC3 
has in ossification. It is worth noting that although this model provides an in vivo 
environment to study human bone formation, it is limited by the fact that the scaffold 
and cells are not within their native bone microenvironment and specific factors and 
vascularization may be lacking, resulting in lower bone formation overall. Our 
findings, which are in line with previous reports22,23, show that CLIC3 is 
predominately localized to the perinuclear and nuclear regions, supporting our 
bioinformatics findings suggesting a role for CLIC3 in the nuclear pore complex 
and/or export of RNA and ribonucleoprotein complexes from the nucleus. Like our 
results presented here, CLIC1, which shares a high degree of homology to CLIC1, 
with 48–49% of the protein sequences being identical23, was reported to be important 
for murine osteoblast differentiation through MSC lineage decision-making. CLIC1 
was upregulated in response to Wnt treatment and downregulated following 
adipogenic treatment in murine MSCs; overexpression of CLIC1 led to increased ALP 
activity and mineralization as well as increased expression of ALP, osterix and 
osteocalcin34. The authors showed that CLIC1 overexpression caused 
hyperpolarization of the mitochondrial membrane potential, suggesting that its role in 
osteogenic differentiation is linked to supporting energy supplementation. Based on 
their structural similarities, it would be possible to postulate that the two proteins may 
have similar functions; however, we don’t have any evidence thus far that CLIC3 
functions in regulating mitochondrial membrane potential or energy metabolism. 
Although the detailed mechanism by which CLIC3 regulates human osteoblast 
differentiation is still far from understood, the discovery of its interaction with NEK9 
and PTDSS1 during osteoblast differentiation does give us some clues to its function. 
After discovering that NEK9 associates with CLIC3 using protein pull-down 
and immunofluorescence, we confirmed that NEK9 is important in osteogenic 
differentiation by showing that NEK9 knockdown leads to reduced mineralization. 
Very recently it was reported that recessive mutations in NEK9 cause a lethal skeletal 
dysplasia characterized by fetal akinesia, multiple contractures, shortened long bones, 
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thoracic dysplasia, pulmonary hypoplasia, and protruding abdomen35. This stop-gain 
mutation results in a truncated protein that misses the majority of the RCC1-like 
domain, all of the NEK6 interaction region, and a C-terminal coiled-coil domain35. In 
fibroblasts from these patients, the NEK9 mutation results in a number of cell-cycle 
defects including reduced proliferation capability and delayed cell-cycle progression 
through G1/S boundary and S-phase. Analysis of NEK9 in patient fibroblasts also 
showed reduced cilia number and length, and in Caenorhabditis elegans expression of 
NEKL-1, the NEK9 orthologue, was restricted exclusively to a subset of ciliated cells, 
suggesting that NEK9 is involved in ciliary function35. Previous studies have shown 
the importance of primary cilia in osteoblast mechanosensing and function to enhance 
mineralization36,37, making this a potential mechanism through which CLIC3 interacts 
with NEK9; however, our CLIC3 and NEK9 immunolabelings don’t appear to be 
specific to the primary cilia. NEK9 is one of 11 Human NEK (NIMA-related kinases) 
genes that encode serine-threonine kinases with diverse biological roles including cell 
cycle control, cilia regulation, and DNA damage sensing and repair38–41, and NEK9, 
specifically, is known to be involved in regulating spindle organization, chromosome 
alignment, cytokinesis, and normal cell cycle progression42,43. Mammalian Nek9 binds 
γ-tubulin and localizes to the centrosomes and spindle poles during early cell division, 
functioning in the microtubule organizing center during mitosis41,44. Our 
immunofluorescence results demonstrate that both CLIC3 and NEK9 are most 
abundant surrounding the nucleus, suggesting that CLIC3 and NEK9 are associated 
with the microtubule-organizing center. It has been reported that CLIC3 and other 
CLIC proteins associate with the cytoskeleton or scaffolding proteins for endosome 
trafficking20–22. In addition, recent work in our lab has shown that inhibition of 
microtubules leads to dramatic cytoskeletal modifications, and an increase in focal 
adhesions and BMP2 activity causing osteogenic differentiation of hMSCs45, and 
osteogenic differentiation is associated with significant changes cytoskeletal protein in 
human osteoblasts46. In addition, our bioinformatics analysis of CLIC3-His pulled 
down proteins identified an overrepresentation of proteins involved processes related 
to cytoskeletal and integrin signaling. Collectively, we suggest that NEK9 and CLIC3 
may regulate osteoblast differentiation via cytoskeleton-associated signaling processes, 
but this requires further investigation.   
Our results show that CLIC3 and PSS1 associate in differentiating hMSCs 
and that knockdown of PTDSS1 significantly reduces osteoblast differentiation. 
PTDSS1 encodes phosphatidylserine synthase 1 (PSS1) that, along with 
phosphatidylserine synthase 2 (PSS2), promotes the biosynthesis of phosphatidyl 
serine (PS) by the exchange of L-serine with the choline moiety of 
phosphatidylcholine47. In 201448 it was discovered that de novo missense mutations in 
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the PTDSS1 gene are responsible for Lenz-Majewski hyperostotic dwarfism (LMHD), 
an extremely rare condition characterized by sclerosing bone dysplasia, intellectual 
disability and distinct craniofacial, dental, cutaneous, and distal limb anomalies 
(OMIM #151050)49,50, which was affirmed by Whyte and coworkers51 reporting 
additional LMHD patients harboring mutations in PTDSS1. These PTDSS1 
mutations result in a gain of function phenotype leading to increased synthesis of 
PTDS48,51. Bone turnover markers in a female LMHD patient, who was confirmed to 
have a mutation in PTDSS1, revealed that her osteosclerosis was a result of 
accelerated bone formation along with unremarkable rates of bone resorption51.  They 
also found elevated levels of phosphoserine in their LMHD patients’ urine, which 
could be indicative of increased PS biosynthesis. PS has unique physical and 
biochemical properties that lead to its physiological importance in roles related to 
apoptosis, coagulation, the internalization of viruses, and Ras/Rho and protein kinase 
C signaling47,52,53. CLIC proteins have also been shown to be heavily involved in Rho 
signaling in a number of cell types18,33,44 providing a potential functional link between 
the two proteins. In bone PS is known to bind calcium within matrix vesicles leading 
to hydroxyapatite crystal formation54, and enhances osteogenic differentiation of 
MSCs55 and human osteoblast progenitor cells56 to promote bone formation. In 
addition, PTDS-containing liposomes were shown to inhibit osteoclast differentiation 
and prevent trabecular bone loss57 making PS a potential candidate for osteoporosis 
treatment. Interestingly, in cultured A2780 ovarian carcinoma cells and in pancreatic 
and ovarian tumors that contain elevated levels of CLIC3, CLIC3 functions to 
mediate the return of α5β1 from late endosomes/lysosomes to the plasma 
membrane20. We hypothesize that CLIC3 may act similarly in osteoblasts to direct the 
transport of PS to the plasma membrane or to matrix vesicles. These previous 
findings, taken together with our current work, supports the idea that CLIC3 works 
together with PSS1 to increase biosynthesis of PS in osteoblast differentiation and 
bone formation. 
In conclusion, we have successfully identified CLIC3 to be a novel gene 
modulating osteoblast differentiation and enhancing bone formation. Although 
further studies are required to determine the molecular mechanisms by which CLIC3 
modulates mineralization, we postulate that CLIC3 and NEK9 both play roles in the 
microtubule organizing center to induce cytoskeletal changes important for osteoblast 
differentiation, and that CLIC3 interacts with PSS1 to enhance PS synthesis and PS 
translocation to the plasma membrane where it plays an important role in matrix 
vesicle-mediated HA formation and mineralization of the bone. The specificity of 
CLIC3 to promote the osteogenic lineage, while its expression decreases during 
adipocyte differentiation, in combination with the importance of CLIC3 during 
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human osteoblast differentiation could make it a potential target for future bone 
anabolic treatments. 
 
4.4 Materials and Methods 
 
4.4.1 Cell culture 
Human bone marrow-derived Mesenchymal Stem Cells (hMSCs) were 
cultured as described previously58. After 1 week of expansion, hMSCs were seeded 
into 12 well plates, in αMEM medium supplemented with 10% heat-inactivated fetal 
calf serum. One to two days later, to allow for attachment, osteogenic differentiation 
was initiated using 100 nM dexamethasone (dex) and 10 mM β-glycerophosphate. For 
adipogenic differentiation cells were treated with 0.1 µM dex, 60 µM indomethacin, 
and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX). Media was refreshed every 3 or 4 
days. Cell extracts were harvested at different time points during culture by scraping 
the cells either in phosphate-buffered saline containing 0.1% triton X-100 
(PBS/Triton) and stored at -80°C for biochemical analyses or in TRIzol and stored at 
-20°C for gene expression analyses. Alternatively, cells seeded on poly-L-lysine-coated 
glass coverslips were fixed in 4% phosphate-buffered paraformaldehyde for 
immunocytochemical procedures. 
 
4.4.2 Lentiviral-mediated overexpression and knockdown 
Methods for gene overexpression and silencing have been described 
previously59,60. To obtain CLIC3 overexpression, we generated full-length human 
CLIC3 cDNA (Open Biosystems, GE Dharmacon, the Netherlands) containing a 
His-tag stop codon into a pEntr vector and verified using proof reading PCR (Table 
3). To generate the CLIC3 overexpression vector E-coli were transformed with the 
construct and after culture plasmid DNA isolation was performed. The CLIC3 
construct was ligated into a pLenti6.3 vector, using Gateway Cloning (Life 
Technologies, the Netherlands) and hek cells were transfected and media containing 
virus was collected after 48 and 72 hours. 
 
Table 3. Oligonucleotide primers used for proof-reading PCR for generation of His-tagged 
CLIC3 overexpression vector 
Gene Forward (5’ - 3’) Reverse (5’ - 3’) 
CLIC3-His CACCATGGCGGAGACCAAGCTC
CA 
TCATTACTAGTGATGGTGATGGTGAT
GGCGGGGTGCACGGCGGGCC 
Sequences of forward and reverse primers used for proof reading PCR in this study. Detected using SYBR green. 
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Lentivirus (LV) was produced by transient transfection of each LV construct 
into human embryonal kidney (HEK) 293T cells using a standard calcium phosphate 
precipitation technique. The appropriate LV vector plasmid (3 µg) and the packaging 
vector plasmids (9 µg of ViraPower mix (Thermo Fisher Scientific)) were 
cotransfected into subconfluent HEK-293T cells plated in 100-mm dishes. Viral 
supernatants were harvested 48 and 72 hours after transfection, filtered through a 
0.45-µm pore size filter, and used immediately for hMSC transduction or stored until 
use at –80°C. One day prior to LV transduction, hMSC were seeded into 12-well 
plates. Transduction consisted of 24 hour LV incubation, after which the medium was 
replaced with differentiation medium and the cells were cultured until further analysis. 
hMSCs cells were transduced with the CLIC3 vector or empty vector (pLenti6.3 
vector without CLIC3 construct), as control.  For gene knockdown of CLIC3, NEK9, 
and PTDSS1, constructs from the TRC-Hs1.0 library (Sigma-Aldrich, Zwijndrecht, 
the Netherlands) were used (Table 4). A nontargeting shRNA vector with a 
scrambled sequence (Table 4) was used as a negative control.  
 
Table 4. List of shRNAs used for CLIC3, NEK9 and PTDSS1 
Target 
gene 
ID Target sequence 
CLIC3 sh9123 GCCTCGTTACAGGGAGTCCAA 
 sh9126 GCAGGAGAAAGAGTTCAAATA 
NEK9 sh10 GCCTTGATTATTGTTGCAGTT 
 sh11 CCGAGGAATGGAAGGTTTAAT 
 sh12 CCAAAGGAACTCAGACAGCAA 
 sh13 GTGAAGATCGTGCAAGGAATT 
 sh14 GTACATTTGGAGAGTGGCATT 
PTDSS1 sh25 CGAGCAGGTTAAATCTCTAAT 
 sh26 GCTAGATCCAAATCTTCGATA 
 sh27 TGGACCTATGTTCGATGGTTT 
 sh28 GCAACAACGAAAGCCATTCTT 
 sh29 GACTGAGTTGAATACCTTCTT 
Non-targeting 
shRNA 
Oligo sequence 
Scrambl
ed 
SHC0
02 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCT
TGTTGTTTTT 
Target sequences of shRNAs for gene silencing of CLIC3, NEK9 and PTDSS1, as well as the oligonucleotide 
sequence for a non-targeting scrambled control. 
 
CLIC3 mRNA overexpression or knockdown in osteoblast differentiating 
hMSCs was assessed at 24 hours and 7 days (compared to empty vector or scrambled 
shRNA-transduced cells, respectively) and mineralization was monitored at 3 weeks 
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after transduction. Western blotting of protein extracts collected 10 days after the 
start of differentiation was performed to confirm overexpression. Overexpression 
experiments were performed in at least duplicate in a minimum of two separate 
experiments in MSCs from three hMSCs donors. Knockdown experiments were 
performed in at least duplicate in a minimum of two separate experiments. 
 
4.4.3 Alkaline phosphatase, mineralization and protein assays 
Alkaline phosphatase (ALP) and calcium measurements were performed as 
described previously8,58. ALP activity is determined by an enzymatic reaction, in which 
the ALP-mediated conversion of PNPP to PNP during 10 min at 37°C was measured. 
For calcium measurements, cell lysates were incubated overnight with 0.24 M HCl at 
4°C. Calcium content was determined colorimetrically using a calcium assay reagent 
prepared by combining 1 M ethanolamine buffer (pH 10.6) with 0.35 mM 0-
cresolphthalein complexone in a ratio of 1:1. ALP results were adjusted for protein 
content of the cell lysates. For protein measurement, 200 µl of working reagent (50 
volumes BCATM reagent A and 1 volume BCA™ reagent B; Pierce, Rockford, IL) was 
added to 25 µl of sonicated cell lysate. The mixture was incubated for 30 min at 37°C, 
cooled down to room temperature (RT) and absorbance was measured at 595 nm. All 
measurements were performed using a Victor2 plate reader (PerkinElmer Life and 
Analytical Science). Staining for mineralization was performed as described 
previously8. Briefly, cells were fixed with 70% ethanol and after washing they were 
stained for 10-20 min with alizarin Red S solution. 
 
4.4.4 Western blotting 
Total protein was collected from 12-wells plate wells in RIPA lysis buffer 
(Santa Cruz), containing 10 µl 200mM PMSF/1 ml RIPA, 10 µl sodium 100mM 
orthovanadate/1 ml RIPA and 20 µl protease inhibitor cocktail (Santa Cruz)/1 ml 
RIPA. Equal amounts of protein per sample were loaded and separated by SDS-
PAGE (12% SDS-polyacrylamide gels) and transferred onto a nitrocellulose 
membrane (Hybond-ECL, Amersham Biosciences, Buckinghamshire, U.K.). After 
blocking nonspecific signal with 5% bovine serum albumin (BSA) in Tris-buffered 
saline (TBS) with 0.1 % Tween-20, the membrane was incubated with a specific 
antibody against CLIC3 (ab56364, Abcam, Cambridge, UK; 1:500). Membranes were 
probed with the secondary antibody goat anti-mouse conjugated with Alexa Fluor 680 
(1:5000, Invitrogen/Fisher Scientific, Landsmeer, Netherlands; Cat. A21057). 
Immunoreactive bands were visualized using the LI-COR Infrared Imaging System 
according to the manufacturer’s instructions (Odyssey Lincoln, NE). 
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4.4.5 Quantification of mRNA expression 
RNA isolation, cDNA synthesis and PCR reactions were performed as 
described previously58. Oligonucleotide primer pairs were designed to be either on 
exon boundaries or spanning at least one intron (Table 5). Gene expressions were 
corrected for expression of the housekeeping gene GAPDH. Experiments were 
performed in at least duplicate in a minimum of two separate experiments. 
 
Table 5. Oligonucleotide primers used in the study 
Gene Forward (5’ - 3’) Reverse (5’ - 3’) 
GAPDH CCGCATCTTCTTTTGCGTCG CCCAATACGACCAAATCGTTG 
CLIC3 CTGCCCATCCTGCTCTAT CAGCGTCTCCTCCAGAAA 
NEK9 TCAGCAATCCAGTGGAGCAG CCAGTCGTCCATATTCGCCA 
PTDSS1 TCGCCTTTACCAGGGATGAC GAGTGAACGGACCATTGGGG 
Sequences of forward and reverse primers used for qPCR in this study. All genes were detected using SYBR green. 
 
4.4.6 Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline 
(PBS) for 15 minutes at RT, washed in PBS, and excess aldehyde quenched with 10 
mM ethanolamine in PBS for 5 min. Cells were then permeabilized with 0.5% Triton-
X-100 in PBS for 10 minutes and blocked for 30 minutes at room temperature in PBS 
supplemented with 1.5% bovine serum albumin (BSA) and 0.02% Triton-X-100.  
Cells were incubated with primary antibody (anti-CLIC3 raised in mouse, 1:150 
(ab56364, Abcam, Cambridge, UK); anti-NEK9 raised in rabbit, 1:20 (11192-1-AP, 
Proteintech, Manchester, UK); anti-PTDSS1 raised in rabbit, 1:50 (HPA016852, Atlas 
Antibodies, Bromma, Sweden)) )) either overnight at 4°C or for 1 hour at RT, 
followed by secondary antibody (Alexa Fluor® 488 conjugated anti-mouse; Alexa 
Fluor® 568 conjugated anti-rabbit 1:400) for 1 hour at RT. Slides were mounted using 
Vectashield mounting medium containing DAPI and pictures were taken on a Zeiss 
Axiovert 200 MOT microscope.  
 
4.4.6 In vivo implantation assay  
All animal experiments were performed in compliance with the animal ethics 
board of the Erasmus Medical Center. Experiments were performed based on the 
protocol by Abdulla and collegues61. Five healthy, adult (2-3 months old), female 
NOD.CB17-Prkdcscid/NCrHsd (NOD-SCID) mice (Charles River Laboratories, 's- 
Hertogenbosch, Netherlands) were used for these studies. Animals were housed in a 
specific pathogen free (SPF) facility with a 12 hours day-night cycle in a controlled 
room with temperatures of 22±1°C and humidity of 50±5%. Mice were fed with 
standard rodent diet ad libitum. hMSCs transduced with CLIC3 or empty vector and 
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treated with dex for 3 days prior to being trypsinized, were loaded (5 × 105) onto 
hydroxyl-apatite/tricalcium phosphate ceramic powder (HA-TCP, 20 mg; Zimmer, 
Netherlands). After overnight incubation in sterile syringes the mixture was implanted 
subcutaneously in the dorsal surface of NOD-SCID mice. Each mouse had up to four 
implants surgically inserted subcutaneously under anesthesia. Implants were 
distributed evenly between the mice and locations within the mice (behind or in front 
of each leg). Implants were recovered after 8 weeks and fixed in 70% ethanol. After at 
least 4 hours fixation, implants were dehydrated, embedded in Methyl Methacrylate 
(MMA), and sectioned (6 µm thick). For identification of bone formed within the 
pellets we performed a Goldner stain on the sections: after sections were deacrylated 
and rehydrated they were stained in ordered steps of Weigert Haematoxylin, Ponceau 
de Xylidine/Acid Fuchsine solution, Orange G/Phosphomolybdene Acid solution, 
0.2% Light Green and then dehydrated before being mounted in Entellan62. As a 
result of this Goldner stain, bone matrix and fibrous tissue appears in green (bone 
recognizable by morphology and the bright and dense staining), osteoid in 
orange/red, nuclei in blue and the HA-TCP grey/brown. All quantitative 
measurements were performed on 2 sections of each pellet. The first was taken from 
the outer quarter of the pellet and the second from the core of the pellet. From each 
section pictures were taken with a microscope (10x magnification) covering the entire 
tissue and individual pictures were stitched together to recapitulate the entire cross-
section. Quantification was carried out using Image J software (NIH, Bethesda, MD, 
USA; https://imagej.nih.gov/ij/): ceramics areas and bone areas were determined by 
eye based on staining and morphology, the edges were hand drawn and the resulting 
pixel-measurements were calculated back to mm2. The observer assessing the pellets 
was blinded toward their identity. 
 
4.4.7 Pull-down assay 
A pull-down assay was performed to isolate proteins associating with His-
tagged CLIC3 using Dynabeads (10103D, Life Technologies, Bleiswijk, Netherlands). 
Purification of CLIC3 protein complexes was performed by a metal-based affinity 
between the Dynabeads and the His-tagged CLIC3.  The pull down was performed 
according to the manufacturers’ protocol. Bait protein was obtained from hMSCs 
differentiated with dexamethasonefor 5 days, following transduction with either His-
tagged CLIC3 or an empty vector (EV; control). Transduced cells were washed once 
with DPBS after which 1X Binding/Wash Buffer (Life Technologies) containing 
0.1% Triton X-100 (Sigma) was added to and the flasks were placed on a shaker for 
15 min at 4°C before protein extracts were collected by scraping cells on ice.  Bait 
protein was isolated by incubating the protein lysates with His-tagged Dynabeads for 
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5 minutes at 4°C before washing 4 times. Proteins interacting with His-tagged CLIC3 
were obtained from non-transduced extracts of hMSCs differentiated for 5 days with 
dex. Differentiated hMSCs were washed once with DPBS after which 1X Pull Down 
Buffer (Life Technologies) was added to and the flasks and protein extracts were 
collected as above. These samples were added to the isolated bait protein attached to 
the Dynabeads for 30 min at 4°C before washing 4 times. Finally, the isolated proteins 
were eluted in a total of 50 µl His-elution buffer. Two replicate samples from each 
condition were included for subsequent mass spectrometry assessment. 
 
4.4.8 Mass spectrometry (MS) 
The eluted His-tagged CLIC3 proteins and their interacting proteins, as well 
as the control samples, were run on NuPage Novex 4–12% Bis-Tris gel (Life 
Technologies). A total of 30 µl for each sample, containing 7.5 µl 4X sample buffer 
(Life technologies), 3 µl 10X reducing agent and 8 µg protein, diluted in 20 µl water of 
each samples was loaded onto the gel. Then the gels were run at 200V for one hour 
and washed three times with milliQ water (MQ). Proteins were stained with 50 ml 
Coomassie staining buffer (Bio-Rad) on a shaker for one hour and de-stained with 
MQ overnight. The next day, gels were fixed by incubating in 10% EtOH/ 1% Acetic 
Acid for 30 minutes at room temperature. Then the gels were washed three times with 
MQ. The 1D SDS-PAGE gel lanes were cut into 2 mm slices with an automatic gel 
slicer and subjected to in-gel reduction with dithiothreitol, alkylation with 
iodoacetamide (D4, 98%; Cambridge Isotope Laboratories Inc., Tewksbury, MA, 
USA), and digestion with trypsin (sequencing grade; Promega, Madison, WI, USA)63. 
Nanoflow liquid chromatography coupled to a tandem mass spectrometer (LC-
MS/MS) was performed on a Series 1100 capillary LC system (Agilent Technologies, 
Santa Clara, CA, USA) coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo 
Scientific, Waltham, MA, USA) operating in positive mode46. Peptide mixtures were 
trapped on a ReproSil C18 reverse-phase column (Dr. Maisch GmbH, Ammerbuch-
Entringen, Germany; 1.5 cm × 100 µm, packed in house) at a flow rate of 8 µl/min. 
Peptide separation was performed on ReproSil C18 reversed-phase column (Dr. 
Maisch GmbH; 15 cm × 50 µm, packed in house) using a linear gradient from 0 to 
80% B [A = 0.1% formic acid; B = 80% (v/v) acetonitrile, 0.1% formic acid] in 170 
min and at a constant flow rate of 200 nl/min using a splitter. The column eluent was 
directly sprayed into the electrospray ionization source of the mass spectrometer. 
Mass spectra were acquired in continuum mode, and fragmentation of the peptides 
was performed in a data-dependent mode. 
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4.4.9 Bioinformatic analysis 
The raw MS data were analyzed by MaxQuant software (version 1.3.0.5)64. A 
false discovery rate of 0.01 for proteins and peptides and a minimum peptide length 
of six amino acids were required. The Andromeda search engine65 was used to search 
the MS/MS spectra against the Uniprot database (taxonomy: Homo sapiens, release 
HUMAN_2013_04) concatenated with the reversed versions of all sequences 
(maximum of 2 missed cleavages; 0.6 Da fragment mass tolerance, enzyme specificity: 
trypsin). The data from the replicates were combined as averages. For selection of the 
most relevant interacting proteins the following criteria were set: 1) a label-free 
quantification (LFQ) value in CLIC3 samples of greater than 1 x 106, 2) number of 
unique peptides covering a protein equals 3 or more, and 3) ratio of CLIC3 samples 
versus control samples of 1.5 or greater. Proteins were then ranked based on the 
average LFQ ratio of the CLIC3 samples versus the control samples. Ingenuity 
Pathway Analysis (IPA) (www.ingenuity.com/) and Gene Ontology analysis (GO) in 
DAVID (https://david.ncifcrf.gov/) was performed using the 52 proteins identified 
by pull-down and MS. 
 
4.4.10 Statistics 
The data provided here are based on at least two independent experiments 
performed in at least in duplicate. Values displayed are mean ± SE. Significance was 
calculated using either the Student's t-test, Mann Whitney-test, or the one-way 
ANOVA with Tukey’s post-hoc test where appropriate, using GraphPad prism 6.0 
(GraphPad Software, Inc., La Jolla, CA, USA). Values of p <0.05 were considered 
significant. 
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Abstract 
Mucin1 (MUC1) encodes a glycoprotein that has been demonstrated to have 
important roles in cell-cell interactions, cell-matrix interactions, cell-signaling, 
modulating tumor progression and metastasis, and in providing physical protection to 
cells against pathogens. In this study, we investigated the bone phenotype in female 
C57BL/6 Muc1 null mice and the impact of the loss of Muc1 on osteoblasts and 
osteoclasts. We found that deletion of Muc1 results in reduced trabecular bone volume 
in 8-week-old mice compared with wild-type controls, but the trabecular bone volume 
fraction normalizes with increasing age. In mature female mice (16 weeks old), Muc1 
deletion results in stiffer femoral bones with fewer osteoblasts lining the trabecular 
surface, but increased endosteal mineralized surface and bone formation rate. The 
latter remains higher compared to wild-type females at 52 weeks of age. No difference 
was found in osteoclast numbers in vivo, and bone marrow osteoblast or osteoclast 
differentiation capacity or activity in vitro. Taken together, these results suggest that 
Muc1 depletion causes a transiently reduced trabecular bone mass phenotype in young 
mice, and later in life reduced numbers of osteoblasts with increased endocortical 
mineralization activity coincides with unaffected total bone mass and increased 
stiffness. In conclusion, our results show, for the first time, a role for Muc1 in bone 
mass and mineralization in mice in a time-dependent manner. 
Skeletal changes in Muc1 deficient mice during aging | 
 101 
5.1 Introduction 
Bone is a dynamic organ, undergoing constant remodeling that is a balancing 
act between removal of old bone by osteoclasts and formation of new bone 
controlled by osteoblasts, as well as its terminally differentiated form the osteocyte. A 
number of key factors and signaling pathways controlling osteoblast differentiation 
and activity have been identified over the last few decades. Runt-related transcription 
factor 2 (Runx2) and osterix (Osx) have been identified to be two essential 
transcription factors required for osteoblast differentiation1–3; and Wnt, bone 
morphogenetic protein (BMP), hedgehog (Hh), Notch, and transforming growth 
factor-beta (TGFβ) are key signaling pathways in osteoblasts4–9.  Still, a better 
understanding of the signaling network, their intricate interactions, and what other 
genes and pathways are involved in osteoblast function is required to develop 
approaches to enhance bone formation and promote fracture healing for patients with 
disorders such as osteoporosis and nonunion fractures. Gene expression analysis of 
differentiating osteoblasts showed an increase in Mucin 1 (MUC1) expression 
compared to undifferentiated human mesenchymal stromal cells (hMSCs)10, indicating 
a potential role for Mucin 1 in the dynamic bone formation and remodeling process.  
Mucins were first identified as being a major component of many types of 
mucus and derive their name from the Greek word for slimy. These glycoproteins are 
high in O-linked glycosylation sites creating a dense, viscous, negatively charged 
molecule. To date 21 different mucins have been identified (MUC1-21) and can be 
divided into two groups: membrane-bound mucins and secretory mucins. Mucin 1 
(MUC1) was the first mucin cloned and sequenced11–14, and it encodes a high 
molecular weight glycoprotein well known to be expressed on the apical surface of 
many epithelial cells. MUC1, like all other membrane bound mucins, is a type 1 
membrane protein and is composed of an N-terminal protein sequence, followed by a 
sequence encoding a variable number of tandem repeats (VNTR), then a 
transmembrane domain, and finally a cytoplasmic tail15. This membrane-bound 
protein can be released from the cell through proteolytic cleavage and, as a result of 
alternative splicing, a number of isoforms exist including versions that lack a 
transmembrane domain all together15,16. MUC1 falls into a family of structurally 
related mucin-like glycoproteins including CD34, CD43, CD162, CD164, GlyCAM1, 
and MAdCAM1. MUC1 has been reported to play an important role in cell-cell 
interactions, cell-matrix interactions, modulating tumor progression and metastasis15–
19, and also serves as an adhesion molecule for a number of pathogens, providing cells 
protection from bacteria18,20,21. The cytoplasmic tail of MUC1 functions in cell 
signaling, with seven evolutionary conserved tyrosine phosphorylation sites and 
| Chapter 5 
 102
cytoplasmic domains that interact with other key signaling molecules including ß-
catenin, p53, and NF-kß22,23. 
This study aimed to examine the skeletal phenotype of mice with global 
deletion of Muc1. To understand the dynamic effect Muc1 deficiency may have on the 
skeleton over time we scrutinized bone microarchitecture, strength, mineralization, 
and osteoblast and osteoclast differentiation and activity at several time points during 
aging.  
 
5.2 Results 
 
5.2.1 During aging, femoral cortical bone is increased in WT and Muc1-/- female mice 
Consistent with previous studies24, all mice developed normally, with no 
obvious abnormalities or illnesses. Additionally, to help rule out the possibility of 
bone architecture being affected by changes in overall body weight, fat deposition, or 
muscle mass, we also quantified body weight (Fig. 1A, Appendix C, Fig. A6A), 
femoral and tibial muscle weight (Appendix C, Fig. A6B,C) and subcutaneous, 
scapular and gonadal adipose weights (Appendix C, Fig. A6D,E,F) at various time 
points and found no difference between WT and KO mice for any of these 
parameters. 
 
 
Figure 1. Longitudinal analysis of body weight and cortical bone structure in wild type and Muc1 deficient 
female mice. Total body weight from 12 weeks to 47 weeks of age (A). In vivo µCT analysis of cortical bone area (C), 
marrow area (D), cortical thickness (E), periosteal perimeter (mid-shaft circumference) (F), and polar moment of 
inertia (G) were measured at diaphyseal areas. n= 9-10. Statistics: 2-way ANOVA; a-b = p<0.01. a= significant 
difference between in WT (+/+, filled squares) and Muc1 deficient (-/-, open circles) female mice with aging, b= 
significant difference with aging within a genotype. Bonferroni post hoc test: ### = p < 0.001 significant difference 
between 12-weeks and 47-weeks within genotype for both WT and KO mice. 
 
An initial study was performed into the longitudinal bone dynamics in WT 
and Muc1 KO mice in order to gain a thorough view of the changes in the cortical 
bone over time. Female mice were analyzed every 2-months throughout adult life (12-
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weeks to 47-weeks) for cortical bone architecture in the femoral diaphysis by repeated 
in vivo µCT. Aging affected all cortical bone parameters in both genotypes (Fig. 1B-G). 
Both WT and Muc1-/- mice gained cortical bone (Fig. 1C) over time, with a 22% and 
27% increase in bone from 12-weeks to 47-weeks of age in WT and KO mice, 
respectively. A similar trend was found for cortical thickness (Fig. 1E) in both 
genotypes. An overall significant difference between WT and KO mice with aging was 
found on marrow area (p = 0.002) (Fig. 1D), and cortical thickness (p = 0.001) (Fig. 
1E); however, Muc1 deletion had no significant effect on cortical bone architecture at 
any specific time point (Fig. 1B-G). No significant interaction between genotype and 
age was observed. For all parameters, no significant difference was observed between 
WT and KO mice from 12-weeks of age onward. 
 
5.2.2 Female Muc1-/- mice have temporally reduced trabecular bone mass at young age  
To scrutinize trabecular, as well as cortical, femoral bone microarchitecture of 
WT and KO mice ex vivo µCT analysis employing higher resolution (8.82 µm 
compared to 20 µm) was used at 3 time points (juvenile mice at 8 weeks, mature adult 
mice at 16-weeks, and aged mice at 52-weeks of age). For these more in depth 
analyses the chosen time points included younger and older mice compared with the 
longitudinal study to expand the picture of the bone phenotype. The femur length 
(Fig 2A) and overall morphology (Fig. 2B,C,D) of the bones did not differ between 
WT and Muc1 knockout mice at any time point.  
The trabecular bone volume fraction (BV/TV) in the metaphyseal region of 
female 8-week-old KO mice was 22% lower (p = 0.028) than that of WT mice (Fig. 
2E), which can be primarily attributed to the strong trend seen in lower number of 
trabeculae (19% of WT at 8-weeks, p = 0.051) (Fig. 2F). No difference was seen in 
trabecular thickness (Fig. 2G), but trabecular separation was increased by 7% (p = 
0.040) in KO mice compared with WT at 8-weeks of age (Fig. 2H). The difference in 
the metaphyseal phenotype between Muc1-/- and WT mice disappeared by 16-weeks of 
age (Fig. 2E-H) with an overall decrease of 88.8% (p < 0.001) and 94% (p < 0.001) in 
the trabecular bone fraction from 8 to 52 weeks in KO and WT mice, respectively. In 
the diaphyseal region, cortical parameters, such as total cortical bone (Fig. 2I), marrow 
area (Fig. 2J), cortical thickness (Fig. 2K), and periosteal perimeter (Fig. 2L) exhibited 
no difference between WT and KO mice at 8-, 16-, or 52-weeks of age. As was 
demonstrated by the in vivo µCT study, cortical bone increased with age, with a 39% 
increase (p < 0.001) in WT and 48% increase (p < 0.001) in KO mice for total cortical 
bone. 
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Figure 2. Ex vivo evaluation of macro- and microarchitecture of femoral bones from 8-, 16-, and 52-week-old 
WT and Muc1 deficient female mice. Femur length of WT (+/+, black bar) and KO mice (-/-, white bar) (A). 
Representative longitudinal (top) and transverse (bottom) cross sections show bone shape and structure of WT (left) 
and Muc1-/-(right) mice at 8 weeks (B), 16 weeks (C), and 52 weeks (D) of age. Trabecular bone fraction (E), trabecular 
number (F), trabecular thickness (G), and trabecular separation (H) were measured at the metaphyseal region. Cortical 
bone area (I), marrow area (J), cortical thickness (K), and periosteal perimeter (mid-shaft circumference) (K) were 
measured at diaphyseal areas. For bone length 8 weeks (n=7 WT, n=9 KO); 16 weeks (n=7); 52-weeks (n=8). For 
trabecular bone analysis 8 weeks (n=8 WT, n=9 KO); 16 weeks (n=9 WT, n=10 KO); 52-weeks (n=9 WT, n=10 
KO). For cortical bone analysis 8 weeks (n=8 WT, n=9 KO); 16 weeks (n=9 WT, n=9 KO); 52-weeks (n=9 WT, 
n=10 KO). Statistics: student t-test exact p value and * = p<0.05 WT vs. Muc1-/- within time point. ### = p < 0.001 
compared to 8wk WT mice. $$ = p < 0.01 compared to 8wk KO mice. $$$ = p < 0.001 compared to 8wk KO mice. 
 
Muc1 KO male mice show no difference, compared with WTs, in body 
weight (Appendix C, Fig. A7A) or femur length (Appendix C, Fig. A7B) at any time 
point, nor did they display a difference in any trabecular or cortical bone parameter at 
8 and 16 weeks (Appendix C, Fig. A7C-J). At 52-weeks of age male KO mice display 
a mild reduction in the number of trabeculae (Appendix C, Fig. A7D) and increase in 
trabecular separation (Appendix C, Fig. A7F). Trends with aging for the male mice 
were similar to the females, with the exception that the male mice showed an increase 
in trabecular thickness (WT: 23%, p = 0.0013; KO: 24%, p = 0.0052) and separation 
(WT: 87%, p < 0.0001; KO: 133%, p < 0.001) at age 52-weeks compared with age 8-
weeks. In addition, male KO mice displayed no difference in cortical thickness (p = 
0.61) between 8- and 52-weeks of age, and WT males had a less substantial increase in 
cortical thickness (10%, p = 0.0498) between 8- and 52-weeks, which result in lower 
increases in total cortical bone area (WT: 19%, p = 0.0108; KO: 11%, p = 0.0182) as 
well. 
 
Figure 2
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Skeletal changes in Muc1 deficient mice during aging | 
 105 
5.2.3 Sixteen-week-old Muc1-/- female mice have fewer trabecular osteoblasts, but endocortical bone 
formation rate is increased in 16- and 52-week-old Muc1-/- mice 
Histological sections of femurs from female WT and Muc1-/- mice were 
stained with Goldner trichrome to assess the number and distribution of cuboidal 
osteoblasts or with TRAP to assess the number and distribution of osteoclasts in the 
bone. We found that the number of osteoblasts in the femurs of 16-week-old Muc1-/- 
mice was 18% lower (p = 0.034) compared with WT mice, but the numbers did not 
differ in 8- or 52-week-old mice (Fig. 3A). Although a trend was observed in 
percentage of osteoblast-covered surface between WT and KO mice at 16 weeks of 
age (p = 0.0809), no significant difference was observed between WT and KO mice at 
any time point (Fig. 3B). Histological analysis of TRAP stained femoral sections 
showed no difference in the number of osteoclasts or the percent of bone covered by 
osteoclasts at any time point between the bones of WT and Muc1-/- mice (Fig. 3C,D).  
 
 
Figure 3. Static and dynamic histomorphometry of osteoblast and osteoclast number and osteoblast activity 
in femoral bone sections of WT (+/+, black bar) and Muc1 deficient (-/-, white bar) female mice at 8, 16, 
and 52 weeks of age. Goldner stainings were performed on bone sections and images were taken of the metaphyses 
from which we quantified osteoblast number (A) and osteoblast covered surface (B).  TRAP stainings were performed 
on femoral bone sections from WT (black bars) and Muc1-/- (white bars) mice and images were taken of the 
metaphyses. From these stainings, osteoclast number (C) and osteoclast surface (D) per bone surface area were 
quantified. Mice were injected with calcein prior sacrifice to label mineralization sites and allow for quantitative 
analyses trabecular bone mineralizing surface (E), mineral apposition rate (F) and bone formation rate (G), and of 
cortical bone endosteal mineralizing surface (H), mineral apposition rate (I), and bone formation rate (J). Statistics: 
student t-test * = p<0.05 WT vs. Muc1-/- within time point. ** = p<0.01 WT vs. Muc1-/- within time point. # = p < 
0.05 compared to 8wk WT mice.   ## = p < 0.01 compared to 8wk WT mice.  ### = p < 0.001 compared to 8wk 
WT mice. $ = p < 0.05 compared to 8wk KO mice. $$$ = p < 0.001 compared to 8wk KO mice. For osteoblast bone 
analysis 8 weeks (n=10 WT, n=9 KO); 16 weeks (n=9 WT, n=10 KO); 52-weeks (n=9 WT, n=9 KO). For osteoclast 
bone analysis and trabecular bone calcein analysis 8 weeks (n=10 WT, n=9 KO); 16 weeks (n=9 WT, n=10 KO); 52-
weeks (n=9 WT, n=10 KO). For cortical calcein analysis 8 weeks (n=8 WT, n=9 KO); 16 weeks (n=9 WT, n=10 
KO); 52-weeks (n=9 WT, n=10 KO).  
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A decrease in the percent of bone surface covered by osteoblasts (Fig. 3B) (WT p = 
0.036, KO p = 0.046) and osteoclasts (Fig. 3D) (WT p = 0.002, KO p = 0.008) 
between 8-week-old and 52-week-old mice was observed for both WT and KO 
groups. The relative number of osteoclasts on the femoral bone surface decreased 
only in KO mice between 8 weeks and 52 weeks of age (Fig. 3C) (WT p = 0.225, KO 
p = 0.022). 
To determine if Muc1 deletion affects mineralization and bone formation 
rates, dynamic histomorphometric analysis was performed in sections of femurs from 
female WT and KO mice injected twice with calcein before they were euthanized. 
Trabecular mineralizing surface fractions, mineral apposition rates, and bone 
formation rates did not differ between WT and KO mice (Fig. 3E,F,G). In both 
groups of mice, trabecular mineral apposition rates decreased over time, whereas bone 
formation rates were highest at age 16-weeks, nearly double that of rates at 8-(WT p < 
0.001, KO p < 0.001) and 52-weeks of age. The percentage actively mineralizing 
endosteal cortical bone surface was 29% higher (p = 0.002) in 16-week-old Muc1-/- 
mice compared with WT (Fig. 3H). Mineral apposition rate in cortical bone did not 
differ between WT and KO mice at any time point (Fig. 3I), but bone formation rate 
in the cortex was significantly higher in KO mice at 16-(46% higher, p = 0.021) and 
52-(28% higher, p = 0.022) weeks of age compared with WT controls (Fig. 3J). For 
both parameters, a decline with increasing age was found, with the rate decreasing 
76% (MAR p < 0.001, BFR p < 0.001) and 63% (MAR p <0.001, BFR p < 0.001) 
between 8- and 52-weeks in WT and KO mice, respectively.  
 
5.2.4 Female Muc1 knockout mice have stiffer bones at 16 weeks of age 
Structural and compositional changes in the bone can lead to changes in bone 
strength. To determine if the strength of the femurs was affected in mice lacking 
Muc1, we performed 3-point bending tests and measured three parameters: energy to 
failure, ultimate load and stiffness25. In female mice, no difference was found for 
ultimate load (Fig. 4A), but bone stiffness was increased by 15% (p = 0.028) in 16-
week-old KO compared with WT mice (Fig. 4B). Energy to failure (Fig. 4C) did not 
differ between WT and KO mice at any time point.   
As with female mice, male KO and WT mice did not differ in ultimate load 
(Appendix C, Fig. A8A) or energy to failure (Appendix C, Fig. A8C), but male KO 
mice did display stiffer femoral bones at 8 weeks of age, compared with WT males 
(21%, p = 0.0303); however, this difference disappeared by 16 weeks of age 
(Appendix C, Fig. A8B). 
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Figure 4. Mechanical testing of femurs of 8-, 16-, and 52-week old WT (+/+, black bar) and Muc1 deficient (-
/-, white bar) female mice. Three-point bending tests performed on the femurs of WT and KO mice allowed for 
quantification of the energy to failure (A), ultimate load (B), and bone stiffness (C) of the bones. Statistics: student t-
test * = p<0.05 WT vs. Muc1-/- within time point. ### = p < 0.001 compared to 8wk WT mice. $ = p < 0.05 
compared to 8wk KO mice. $$$ = p < 0.001 compared to 8wk KO mice.  8 weeks (n=9 WT, n=9 KO); 16 weeks 
(n=9 WT, n=10 KO); 52-weeks (n=9 WT, n=10 KO).  
 
5.2.5 Bone marrow-derived osteoblast differentiation does not differ between WT and KO mice 
To study the differentiation capacity of mesenchymal stromal cells (MSCs) 
toward osteoblasts, we isolated bone marrow containing MSCs and osteogenic 
progenitors from 8-, 16-, and 52-week-old female WT and Muc1-/- mice and analyzed 
their differentiation into osteoblasts in ex vivo cultures. After one week of culture, we 
counted the number of alkaline phosphatase (ALP)-positive colonies. No difference 
was observed in the number of colonies between marrow cultures from WT and KO 
mice, but a trend was found for an increased number of osteoblast colonies in bone 
marrow cells from 16-week-old KO mice (p = 0.062) (Fig. 5A,B). After 3 weeks of 
culture in osteogenic differentiation medium cells were stained with alizarin red to 
determine the level of mineralization in the bone marrow culture. No difference in 
mineralization from cells from WT and KO mice was observed (Fig. 5C,D).  
 
5.2.6 Bone marrow-derived osteoclast differentiation capacity and activity are not affected by depletion 
of Muc1  
Although our hypothesis is that Muc1 plays a role in murine bone because of 
changes in osteoblast function, Leong and colleagues26  have found that human 
monocyte/macrophage cells express moderate levels of Muc1 protein and we find 
that differentiating murine osteoclasts express low, but detectable levels of Muc1 
(Appendix C, Fig. A9). To study if Muc1 deletion affects the differentiation capacity of 
PBMCs toward osteoclasts and/or osteoclast activity, we isolated bone marrow from 
8-, 16-, and 52-week-old female WT and Muc1-/- mice and analyzed their 
differentiation into osteoclasts and their resorption capacity in ex vivo cultures. From 
the bone marrow samples we saw no difference in the relative number of small or 
large TRAP positive osteoclasts, or the total number of multinucleated osteoclasts 
(Fig. 6A,B,C), nor did the resorption capacity of osteoclasts differ between cells from 
WT or KO mice (Fig. 6D,E).  
| Chapter 5 
 108
 
Figure 5. Osteoblast cultures of bone marrow from 8-, 16-, and 52-week-old WT (+/+, black bars) and Muc1 
deficient (-/-, white bars) female mice. Analyses were performed of osteoblast differentiation capacity and activity 
in bone marrow cell cultures. Representative stainings of alkaline phosphatase (ALP) positive osteoblast colonies (C) 
in WT (top) and Muc1-/- (bottom) mice and quantification of the number of ALP positive colonies (D). 
Representative alizarin red stainings of osteoblast produced mineralization (E) in WT (top) and Muc1-/- (bottom) mice 
and quantification of alizarin red staining indicative of mineralization activity of bone marrow derived osteoblasts (F). 
Statistics: student t-test * = p<0.05 WT vs. Muc1-/-. For ALP analysis 8 weeks (n=8 WT, n=7 KO); 16 weeks (n=8); 
52-weeks (n=7 WT, n=8 KO). For alizarin red analysis 8 weeks (n=8 WT, n=7 KO); 16 weeks (n=8); 52-weeks (n=8). 
Results represent the combined results of 2 independent experiments. 
 
 
Figure 6. Osteoclast cultures of bone marrow cells from 8-, 16-, and 52-week-old WT (+/+) and Muc1 
deficient (-/-) female mice. Assessment of osteoclast differentiation capacity and activity in bone marrow cell 
cultures in WT and Muc1-/- mice was performed. Representative stainings of tartrate-resistant acid phosphatase 
(TRAP) positive osteoclasts (A) in WT (top) and Muc1-/- (bottom) mice and quantification of the distribution in 
number of nuclei contained within TRAP-positive osteoclasts (B) and the total number of multinucleated TRAP 
positive osteoclasts (C). Representative images of von kossa staining showing resorption activity of osteoclasts (D) 
from bone marrow of WT (top) and Muc1-/- (bottom) mice and quantification of surface resorption by osteoclasts of 
WT and Muc1-/- mice (E). Statistics: student t-test * = p<0.05 WT vs. Muc1-/-. 8 weeks (n=8 WT, n=7 KO); 16 weeks 
(n=8); 52-weeks (n=8). Results represent the combined results of 2 independent experiments. 
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5.3 Discussion 
 
The results of this extensive and detailed skeletal phenotype analysis 
demonstrate that deletion of Muc1 in mice leads to mild and temporally shifting 
changes in long bones and bone metabolism. 
Eight-week-old female Muc1-/- mice display decreased trabecular bone 
compared with WT females; however, this difference disappears by 16-weeks. At the 
same time, endocortical bone formation rate and femoral stiffness are increased at 16-
weeks of age in Muc1 deficient female mice, with a higher rate of endocortical bone 
formation persisting to 52-weeks of age in KO mice. Histomorphometric analysis 
demonstrated that femurs of 16-week-old Muc1-/- female mice displayed lower 
numbers of osteoblasts lining the bone surface, whereas femurs from 8- and 52-week 
old KO and WT mice did not differ in their number of osteoblasts, again 
demonstrating a temporal effect of Muc1 deletion.  
 
5.3.1 Changes in murine femoral bone with aging  
In both WT and Muc1-/- we observed a number of changes in the femoral 
bone over time. We found that the trabecular bone fraction dramatically declined 
between 8- to 52-weeks of age (88.8% in KO and 94% in WT mice). These rates of 
loss are similar to a previously published study looking at age related changes in the 
femoral bones of female wild-type C57Bl/6 mice27. We also saw that both WT and 
Muc1-/- mice gained cortical bone with aging (39% increase in WT and 48% increase in 
KO) between 8- and 52-weeks, and a similar trend was seen for cortical thickness. 
While Glatt and colleagues found that femoral cortical bone area remained steady 
between 2 and 12 months and cortical thickness in female C57Bl/6 mice increased 
markedly between 1 to 3 months of age and was then maintained through 12-
months27, our results showed an increase between each time point although the gain is 
less between 16- and 52-weeks. The difference is likely to be explained by the method 
of analysis: while Glatt used the distal femur region to assess both trabecular and 
cortical bone properties, we used the mid-shaft of the femur for our cortical 
measurements. Consistent with the increase in cortical bone with aging, all mechanical 
strength properties increased with time as well. The larger, thicker cortex of the older 
bones directly contributes to a stronger femur, requiring more force to fracture, 
assuming the material properties are the same. In this study, trabecular bone 
formation rate peaked at 16-weeks, while cortical bone formation rate declined over 
time. In concordance Glatt found that adult (5-month-old) female mice had a higher 
level of trabecular bone formation rate relative to younger (1- and 3-month old) mice; 
however, they did not see a decrease later in life (12-months)27. As the time points 
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between the two studies are not identical it is possible that this could be the reason for 
the observed difference. Cortical bone formation rate was not investigated in their 
study27. The peak in trabecular bone formation rate at 16-weeks goes along with the 
peak in osteoblast number that we also saw at 16-weeks of age. 
 
5.3.2 Muc1 deficient mice display a temporally shifting bone phenotype 
In 8-week-old Muc1 deficient mice trabecular bone volume fraction was 
reduced primarily because of lower trabecular number. Interestingly, although we 
observe a 22% decrease in the fraction of trabecular bone/ no other bone parameter 
is altered in young mice including trabecular mineralization rates, total number of 
osteoblasts, and bone strength parameters. This may indicate that osteoblast 
differentiation capacity and activity are not affected at 8-weeks of age and the reason 
for the lower amount of trabecular bone may lie in a preceding developmental defect 
or a hindrance in the growth plate in mice younger than the ages we studied. Another 
possibility is that lack of Muc1 expression in osteoblasts could cause increased 
degradation of estrogen receptor alpha (ERa) which can lead to decreased bone mass. 
Previous studies have shown that the MUC1 C-terminal subunit binds directly to the 
ERa DNA binding domain and stabilizes ERa by blocking its ubiquitination and 
degradation28. Indeed, mice lacking ERa expression in osteoblasts display decreased 
trabecular and cortical bone mass in tibial, femoral, and vertebral bones29. 
Unfortunately, they only studied mice at 12 and 18 weeks of age precluding observing 
temporal effects at ages we studied. Because we only see decreased trabecular bone in 
young Muc1-/- mice, it is possible that the temporal trabecular phenotype is overcome 
by redundancy in the system, for example by other MUC proteins. Future studies 
demonstrating how estrogen deprivation may affect the phenotype in Muc1 KO mice 
would greatly add to our understanding the role of Muc1 in bone.  
The bone phenotype of Muc1-/- mice changes over time. By 16-weeks of age 
trabecular bone volume in Muc1-/- mice has normalized to the level of wild types, but 
cortical bone formation rate and stiffness are increased. As the mice age, even though 
the total number of osteoblasts in the bone is lower in KOs, they have an increased 
capacity to produce cortical bone, as illustrated by higher endocortical mineralized 
surface and mineral apposition rate at 16- and 52-weeks of age compared with WT 
mice. It has been previously established that stiffer bones result from increased 
cortical bone and/or changes in the material properties of the bone25. The increase in 
stiffness in the KO mice is paralleled by increased cortical mineralizing surface and 
bone formation rate, which could lead to changes in the material properties of the 
bone and explain the increased stiffness. Future studies involving proteomic analysis 
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of the bone matrix proteins in mice lacking Muc1 would be useful in delineating the 
mechanism behind these changes in osteoblast activity and increased femoral 
stiffness. Two-way ANOVA analysis showed an overall significant difference in 
marrow area and cortical thickness between WT and Muc1-/- with aging, but no 
significant effect was found at any one time point by post hoc or Student-t-test. The 
mild bone architectural phenotype we observed may be partially due to the mouse 
strain; C57Bl/6 mice are known to have a lower bone mass than other strains of mice 
and this may limit observations on genetic changes in bone microarchitecture.  
Muc1 deletion also caused mild temporally shifting effects in the long bones 
of male mice; however, these effects differed somewhat from the females. Muc1-/- 
male mice show no difference, compared with WTs, in any trabecular or cortical bone 
parameter at 8- and 16-weeks. At 52-weeks of age male Muc1-/- mice display a mild 
reduction in the number of trabeculae and increase in trabecular separation. These 
data are in contrast to the female Muc1-/- data in which we found that the trabecular 
bone fraction was strongly reduced at 8 weeks of age, but no difference in trabecular 
bone parameter between Muc1-/- and WT mice later in life. Femoral stiffness was also 
temporarily increased in Muc1-/- male mice, but at 8-weeks of age, earlier than in 
females. Differences between males and females could partially be related to 
differences in estrogen regulation in males and females, and regulation of ERa as 
discussed above. Further experiments are required to determine the mechanism of 
action of Muc1 in the bones of both female and male mice; however, the male data 
supports the overall conclusion that Muc1 deletion has a temporal effect on bone 
biology. 
 
5.3.3 The importance of utilizing multiple time points when evaluating murine models for skeletal 
abnormalities  
Our results demonstrating a temporal bone phenotype in Muc1-/- mice 
underpin the importance of looking at multiple time points when investigating in vivo 
bone phenotypes. Analyzing only a single time point in our study, as is common 
routine in many mouse genetic studies, would have led to either over-interpretation or 
missing aspects of Muc1 deficiency on bone metabolism. We are not alone in 
identifying a transient or changing bone phenotype in genetically altered mice as many 
other studies report age-dependent effects following gene perturbations. Mice 
genetically engineered to overexpress epidermal growth factor receptor ligand 
amphiregulin (AREG) demonstrate greater femoral BMD and total bone in the 
metaphyseal region at 4- and 8-weeks of age compared to WT controls but after 10-
weeks of age there is no difference between the genotypes anymore30. In addition, Shi 
and colleagues identified that deletion of BMP receptor BMPR1B resulted in 
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trabecular bone loss at 8 weeks of age, which was not seen either just after birth or at 
11 weeks of age31. Our lab also previously reported a temporal difference in skeletal 
changes with age between trabecular and cortical bone in DNA repair deficient female 
Trichothiodystrophy (TTD) mice where these mice show accelerated bone aging after 
39-weeks of age32. Taken together our results suggest that the bone, and in particular 
the metaphysis of the long bones due to its relatively high bone turnover, may be 
most sensitive to gene/protein deficiency in an age-related fashion, i.e. coinciding 
with the time of most intense longitudinal growth and shows great temporal 
dynamics. 
 
5.3.4 Conclusion 
In conclusion, this study demonstrates, for the first time, a role for Muc1 in 
bone biology. Further studies are required to understand the mechanism of action by 
which Muc1 affects osteoblast differentiation and bone formation in these mice and 
the reason for the temporal dynamics of the effects on bone. Given its explicit 
expression patterns in early human osteoblast differentiation10, it will also be pivotal 
to investigate the expression patterns of MUC1 in human MSCs and osteoblasts and 
its potential role in human bone homeostasis. 
 
 
5.4 Materials and Methods 
 
5.4.1 Mice 
Muc1-/- mice were constructed as described by Spicer et al.24. The mice were 
backcrossed onto C56BL/6 and then wild-type (WT) and Muc1-/- mice were bred 
from heterozygous parents in the same facility. Mice were genotyped by PCR using 
specific primer sets as follows: wild-type allele was detected using 5’-ACC TCA CAC 
ACG GAG CGC CAG -3’ and 5’- TCC CCC CTG GCA CAT ACT GGG -3’, and 
the mutant allele was detected by 5’- ACC TCA CAC ACG GAG CGC CAG -3’ and 
5’- CAA CTG TTG GGA AGG GCG AT -3’. An amplified fragment of 260 bp 
corresponds to the WT allele and of 240 bp to the mutant allele.  
Mice were housed standard microisolator or individually ventilated cages in 
groups of 1-5 animals in specific pathogen-free (SPF) rooms at a 12-hour light-dark 
cycle and had ad libitum access to food and water. Female mice (n=9-10 per genotype) 
were sacrificed at 8-, 16- and 52-weeks of age and bones were collected for 
microcomputed tomography and histomorphometry (left femurs), 3-point bending 
tests (right femurs), and bone marrow cultures (tibiae). Male mice (n=9-10 per 
genotype) were sacrificed at 8-, 16- and 52-weeks of age and bones were collected for 
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microcomputed tomography (left femurs) and 3-point bending tests (right femurs).  
Mice were healthy for the duration of the study, with the exception of one WT female 
mouse in the longitudinal study/52-week group that was found to have a wound at 36 
weeks of age and it was deemed too severe to survive and was humanely euthanized 
and one KO male mouse in the longitudinal study/52-week group that was found 
dead at 44-weeks of age without any apparent cause. To determine the number of 
mice used in each treatment group power calculations were performed utilizing data 
from a pilot experiment assessing bone microarchitecture and strength parameters of 
bones from Muc1-/- and WT litter mates provided by the Gendler Lab group. 
Researchers were blinded to the genotype of the mice during all experimental 
procedures and at sacrifice. All animal experiments were performed in compliance 
with the animal ethics board of the Erasmus Medical Center. 
 
5.4.2 Microcomputed tomography (µCT)  
In vivo µCT of the left femur was carried out on WT and Muc1-/- mice (n = 
10) every 2 months from 3 months until 11 months of age. The scans were performed 
at 20 µm resolution using a Quantum FX system (PerkinElmer, Groningen, The 
Netherlands). Mice were anesthetized in an induction chamber by inhalation of 4% 
isoflurane. Under 4% isoflurane anesthesia the animal was placed on a specially 
constructed holder that allows for fixation of the left femur. The holder with the 
animal was fixed on the animal bed of the scanner with a nose cone supplying 1.5-
2.0% isoflurane in an air/oxygen mixture. The following scan settings were used: X-
ray power and tube current were 90 kV and 0.16 mA, respectively. Beam hardening 
and ring-artifacts were reduced, and the total scan time was 3 min. For export of 
image files, the Quantum FX generated VOX files were loaded into Analyze 12 
software (AnalyzeDirect, Overland Park, KS, USA) where a cutoff intensity of 900-
2600 (or max if less than 2600) was applied and the complete set of multiple 2D 
images were saved in BMP format for downstream analysis. Analysis only includes 
data for 9 WT females at 38- and 47-week time points due to the sacrifice of one 
mouse for a wound as described in previous methods section. During the analysis of 
the in vivo scans one scan from a KO female at the 47-week time point was found to 
have motion blurring and was excluded from the analysis. 
For ex vivo µCT analysis the left femurs from female WT and Muc1-/- mice 
sacrificed at 8, 16 and 52 weeks (n = 8-10) were scanned at a resolution of 8.82 µm, 
using a SkyScan 1076 system (Bruker MicroCT, Kontich, Belgium). According to 
guidelines recently published33, the following settings were used: X-ray power and 
tube current were 40 kV and 0.25 mA, respectively. Beam hardening (20%) was 
reduced using a 1 mm aluminum filter, ring-artifacts were reduced (set at 5), exposure 
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time was 5.9 s and an average of three pictures was taken at each angle (0.8°) to 
generate final images. 3D images were reconstructed using NRecon from Bruker 
MicroCT (Skyscan, Kontich, Belgium, 
http://www.skyscan.be/products/downloads.htm). 
For both in vivo and ex vivo µCT data analysis we used software packages from 
Bruker MicroCT, (CtAn and Dataviewer, Skyscan, Kontich, Belgium, 
http://www.skyscan.be/products/downloads.htm). Bone microarchitectural 
parameters were assessed in cortical bone for the in vivo data and in both trabecular 
and cortical bone for the ex vivo data of all mice (n = 8-10 per genotype). For ex vivo 
scans (100 sections) the metaphyseal area was selected for analysis starting 135 (8-
week-old mice), 110 (16-week-old mice), and 95 (52 week-old-mice) sections below 
our offset landmark within the epiphyseal growth plate. The diaphyseal (50 sections 
for 8.82 µm ex vivo scans, 25 sections for 20 µm in vivo scans) area was selected for at 
the mid-shaft of the femur. The trabecular bone parameters trabecular tissue volume, 
bone volume, trabecular volume fraction (BV/TV), trabecular thickness, trabecular 
number and trabecular patterning factor (connectivity of trabeculae) were determined 
in the distal metaphysis of the femur. In the mid-diaphysis, cortical volume, 
endocortical volume, cortical thickness, and perimeter were analyzed. For image 
processing, trabecular bone was manually selected and cortical bone was automatically 
selected. Global thresholding was applied for segmentation using threshold levels of 
85 (lower) and 255 (higher) for trabecular and levels of 140 and 255 for cortical bone 
measurements. 
 
5.4.3 Bone mechanical testing  
Right femurs (n = 9-10) were stored in phosphate-buffered saline at −20 °C 
until further use. The procedure was carried out as previously described in detail 34. 
Briefly, femurs were placed in a custom made 3-point bending device, with the 
loading posts 10 mm apart. Mechanical testing was performed, using a Single Column 
Lloyd LRX System (Lloyd Instruments, Fareham, UK). Displacement (mm) and force 
(N) were registered. From the resulting displacement to force graphs, ultimate force 
(N), stiffness (N/mm) and work to failure (mJ) were determined as described 
before35. 
 
5.4.4 Bone histomorphometry  
To determine the dynamic histomorphometric indices, WT and Muc1-/- mice 
(n = 8-10) were injected with calcein (15 mg/kg, Sigma, St. Louis, MO, USA) 
intraperitoneally prior to sacrifice on the following schedule: 5 and 2 days prior for 8-
week-old mice, 6 and 2 days prior for 16-week-old mice, and 8 and 2 days prior for 
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52-week-old mice. After excision, femurs were routinely embedded in 
methylmetacrylate as described previously36.  
For bone histomorphometry analysis the blocks were sectioned at 6 µm. For 
osteoblast measurements, sections were stained with a Goldner staining as described 
before37,38. For detection of osteoclasts Tartrate-resistant acid phosphatase (TRAP) 
staining was performed. Sections were rinsed in 0.2 M sodium acetate/100 mM 
tartaric acid for 20 min, after which Naphtol AS-MX (0.5 mg/ml) and Fast red TR 
salt (1.1 mg/ml) (both from Sigma, St. Louis, MO, USA) were added and incubated 
for 20 min at 37 °C. Sections were counterstained with haematoxylin for 15 sec, 
rinsed, air-dried and embedded in glycergel (Agilent, Amstelveen, The Netherlands). 
Dynamic trabecular and cortical analysis was performed separately. Cortical 
measurements were performed in the metaphysis between 0.5 mm and 2.5 mm below 
the growth plate. The trabecular measurements were performed in the entire bone 
marrow region between 0.5mm to 1.5 mm below the growth plate. Labeled surfaces 
were hand-drawn within Bioquant (Version 7.20; Bioquant image analysis corporation, 
Nashville, Tennessee, USA) resulting in the following measurements: mineral surface 
(MS), bone surface (BS), tissue volume (TV), mineral apposition rate (MAR) and bone 
formation rate (BFR).  
For TRAP and Goldner stainings at least 5 images in the trabecular area were 
taken with a Zeiss Axiovert 200 MOT system (Carl Zeiss BV, Jena, Germany) at 20x 
magnification (0.5 mm to 2.5 mm below the growth plate). All quantitative 
measurements were performed on longitudinal sections that were taken from the 
anterior-posterior middle of the bone. All measurements were performed in ImageJ 
(NIH, Bethesda, Maryland, USA, available online at https://imagej.nih.gov/ij/): 
osteoblasts, osteoclasts, osteoblast surface (contact area with the bone), osteoclast 
surface (contact surface with the bone) and bone perimeters were determined by eye 
based on staining and morphology (cuboidal cells on the bone surface). The number 
of osteoblasts and osteoclasts, as well as the surfaces were hand drawn and the 
resulting pixel-measurements were calculated back to mm2. Histomorphometric 
indices were defined and calculated according to the American Society of Bone and 
Mineral Research (ASBMR) nomenclature39 and analysis was performed blinded 
towards the genotypes.   
 
5.4.5 Bone marrow cultures 
Bone marrow cells derived from WT and Muc1-/- mice (n=7-8) were isolated 
and cultured towards osteoclasts and osteoblasts as described in detail36,40. After 7 
days of culture, TRAP staining was used to stain for osteoclasts36. Osteoclast-
generated resorption pits on calcium phosphate coating of Osteo Assay plates 
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(Corning Life Sciences BV, Amsterdam, The Netherlands) were stained by von Kossa 
after 10 days of culture. Alkaline phosphatase (ALP) and alizarin red staining were 
performed on osteoblast cultures at days 10 and 21 of culture, respectively, as 
described earlier36. Osteoclast number and the number of nuclei per cell were 
measured using the freely available ImageJ software (version 1.41; 
http://rsbweb.nih.gov/ij/). ALP positive colonies and resorption surface were 
measured using the software package Bioquant (Version 7.20; Bioquant image analysis 
corporation, Nashville, Tennessee, USA). To evaluate the mineralized nodule 
formation in vitro, cell/matrix layers were washed with PBS, fixed with 10% 
formaldehyde, and stained with alizarin red S (Sigma, St. Louis, MO, USA) solution. 
To quantify alizarin red S bound to mineralized nodules in the cultures, cultures were 
stained with alizarin red S, extensively rinsed with water, and extracted with 10% 
(w/v) acetic acid for 30 minutes at room temperature, after which the wells were 
scraped and contents added to Eppendorf tubes and vortexed for 30 sec. Mineral oil 
was added to the mixture and incubated at 85 °C for 10 min and then the tubes were 
placed on ice for 5 min. The tubes were centrifuged at 20,000 g for 15 min and 250 µl 
supernatant was pipetted into a clean tube and 100 µl 10% NaOH was added to 
neutralize the solution. The dye concentrations in the extracts were determined by 
absorbance at 540 nm using a Victor2 plate reader (PerkinElmer Life and Analytical 
Science). For each test 2-3 technical replicates (bone marrow culture wells) from each 
mouse were averaged. Results are combined from 2 independent experiments (n=3-4 
mice/experiment).  
 
5.4.6 Collection of Muscle and Adipose Tissues 
After sacrifice the musculus gastrocnemius of the tibia and the quadriceps 
muscle of the femur were dissected out from the left hindlimb and weighed 
immediately. Scapular adipose deposits (representative brown fat), subcutaneous 
adipose deposits (white adipose tissue), and gonadal adipose deposits (white adipose 
tissue) from the right side of each mouse were identified and excised as described by 
Mann et. al.41. Immediately after dissection the tissues were weighed. Weights are 
expressed as a percent of total body weight for each mouse. 
 
5.4.7 Quantification of mRNA expression 
RNA isolation, cDNA synthesis and PCR reactions were performed as 
described previously42. Oligonucleotide primer pairs were designed to be either on 
exon boundaries or spanning at least one intron (Table 1). Gene expressions were 
corrected for the housekeeping gene Hprt. Experiment was performed in triplicate. 
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Table 1. Oligonucleotide primers used in the study 
Gene Forward 5'-3'' Reverse 5'-3'' 
Muc1 CCCTATGAGGAGGTTTCGGC GTGGGGTGACTTGCTCCTAC 
Hprt TTATCAGACTGAAGAGCTACTGTAAT
GATC 
TTACCAGTGTCAATTATATCTTCAACA
ATC 
Sequences of primer sets used for qPCR in this study. All genes were detected using SYBR green. 
 
5.4.8 Statistical analysis 
Values displayed are mean ± SD. The ex vivo µCT parameters, 
histomorphometric data, femur length, mechanical loading tests, and parameters of 
cell culture analyses were compared between genotypes for all age groups separately 
using two-tailed unpaired student t-tests. For the in vivo µCT data significances were 
calculated using the two-way ANOVA with Bonferroni’s multiple comparison post-
hoc test. All statistical analyses were performed using GraphPad prism 6.0. p-values 
<0.05 were considered significant. 
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6.1. Overview 
 
Modern technologies allow us to quickly and easily probe the expression 
status of every gene in every tissue at any point in time under various conditions 
through the use of microarrays. In this thesis we utilized the results of gene 
expression microarrays performed on human mesenchymal stromal cells (hMSCs) 
differentiated towards osteoblasts to identify genes, processes and compounds 
affecting osteoblast differentiation with the ultimate goal that the knowledge gained 
could be used toward the development of a novel bone anabolic treatment for 
conditions such as osteoporosis. 
In Chapters 2 and 3 we employ the Connectivity Map (CMap) to identify 
compounds that affect osteoblast differentiation. Parbendazole was discovered as the 
compound with the most positively correlated genetic profile to osteogenically 
differentiated hMSCs and, in Chapter 2, we delved into its mechanism of action and 
determined its effects are due to profound cytoskeletal changes that up-regulate 
osteoblast specific genes, enhance BMP2 activity, and increase focal adhesion 
numbers and length. In Chapter 3 we found that the CMap can successfully identify 
other compounds that influence human osteoblast differentiation; three additional 
positively correlated compounds, withaferin A, amylocaine, and calcium folinate, 
stimulated osteogenic differentiation and one negatively correlated compound, 
salbutamol, inhibited osteoblast differentiation. We used in silico analysis to better 
understand how these compounds affect hMSCs in vitro and ascertained genes and 
processes vital to the differentiation process. In Chapter 4 we revealed a role for 
CLIC3 in human in vitro osteoblast differentiation and mineralization and in vivo bone 
formation, and discovered that NEK9 and PSS1 interact with CLIC3 to enhance 
differentiation. In Chapter 5 we showed that deletion of Muc1 in mice leads to mild 
and temporally shifting changes in long bones and bone metabolism, as well as 
highlighted changes in the murine skeleton with normal aging. Figure 1 shows some 
of the main findings and hypothesis presented in this thesis related to the cellular 
signaling involved in osteoblast differentiation. In this chapter the main findings in 
this thesis will be discussed and their importance in the field of bone biology. 
Furthermore, the prospects for the future will be considered.  
 
6.2. Using the Connectivity Map to identify new targets in bone biology 
 
The CMap database (build 02) contains profiles of 1309 FDA-approved small 
molecules. These small molecules are tested in up to five human cell lines, generating 
over 6000 expression profiles in the CMap catalog based on gene expression profiling  
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Figure 1. Proposed cell signaling processes involved in osteoblast differentiation of hMSCs.  
 
experiments carried out using Affymetrix microarrays. The instance is the basic unit 
of data in CMap and consists of each individual treatment-control pair. The fold 
change of treatment to control values was calculated for each probe set, sorted into 
decreasing order and converted to a rank vector. Thus, the probe set that is most up-
regulated will receive Rank 1 and the most down-regulated will receive Rank 22,283 
(based on the total number of probes in the microarray). Using the online tool 
(http://www.broadinstitute.org/cmap) users can query their gene signature of interest 
(i.e. genes regulated by a disease state or biological phenotype) against the chemical 
reference catalogues. The gene signature of the user is simply two lists of affymetrix 
ids, one containing up-regulated genes, up genes, and the other containing down-
regulated genes, down genes, without any expression data attached to them.  
Successful identification of true biological connections between the CMap 
reference profiles and the user’s gene signature are likely highly dependent on the 
quality of the chosen gene signature. There is no guideline for creating an optimal 
gene signature, but the conventional approach is to identify and use the differentially 
expressed genes associated with the phenotype that are statistically significant. The 
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results of Zhang1 suggest that gene signatures with between 10 to 100 genes are 
optimal. For our analysis, we used 77 up-regulated genes and 66 down-regulated 
genes, based on identification of the 100 most significantly (Z<0.001) up- and down-
regulated Illumina probes 6 hours (matching CMap treatment times) after the start of 
osteogenic differentiation of hMSCs (Illumina IDs were converted to Affymetrix IDs 
and duplicates were removed).  
The CMap uses a simple, but efficient pattern matching algorithm based on 
the non-parametric rank-ordered Kolmogorov–Smirnov statistics to compare the 
users lists of up and down regulated genes with the ranked probe sets of the instance 
gene expression profiles. A ‘connectivity score’ is generated for each instance, ranging 
from +1 to -1 to reflect the similarity, or connection, between the expression profile 
of the user’s interest and each of the drugs (instances). Positive connectivity scores 
(closest to +1) denote a high degree of similarity in gene regulation and negative 
connectivity scores (closest to -1) signify an inverse relationship. 
An important consideration when using the CMap is how to interpret the 
results. Results can be viewed for each individual test (detailed results) or as permuted 
results. The results we used for our analysis in Chapters 2 and 3 come from the 
permuted results. These results use the arithmetic means of the CMap connectivity 
scores of each compound and are ranked based on the permutation p-value. The 
permutation p-value is an estimate of the likelihood that the enrichment of a set of 
instances in the list of all instances for a given result would be observed by chance. 
This test is based on a basic resampling procedure determined empirically by 
computing the enrichment of one hundred thousand sets of instances selected at 
random from the set of all instances in the result. Using the permuted results for 
selection of drug candidates decreases the likelihood of selecting false positives. 
Zhang and colleagues found that at the individual treatment instance level, the CMap 
does not provide effective safeguards against possible false connections; however, 
when they compared the CMap permuted results using the permutation p-value to 
their results obtained using a more rigorous null hypothesis Hset0 equation applied to 
original CMap data, both results controlled for false connections equally well1.  
The permuted results can be further divided, with the choice to view the 
individual compounds (all cell lines combined, yielding a greater replicate number), 
each compound separated by cell line, or by ATC code (Anatomical Therapeutic 
Chemical Classification System). When we examined the individual and the permuted 
results separated by cell line we found that individual compounds ranked quite 
differently based on the cell line tested in and the majority of our top hits were in the 
human prostate cancer cell line (PC3). Examples of individual instance CMap scores 
and rankings of the top positively correlated compound, parbendazole, and most  
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Table 1: Examples of Individual Instances in Detailed Results 
Instance ID Compound Cell Line Rank (1 to 6100) Score (+1 to -1) 
4535 parbendazole PC3 5 0.87 
3799 parbendazole PC3 7 0.841 
4357 parbendazole MCF7 5247 -0.468 
3881 parbendazole MCF7 5357 -0.487 
     
2344 salbutamol HL60 891 0.308 
2306 salbutamol MCF7 2995 0 
7376 salbutamol PC3 6008 -0.682 
4700 salbutamol MCF7 6047 -0.728 
3677 salbutamol PC3 6073 -0.784 
 
negatively correlated compound, salbutamol, based on the permuted results can be 
seen in Table 1. While the individual instances of both parbendazole and salbutamol 
in the PC3 cell line have strong and similar scores to their respective replicates, 
instances in the other cell lines can differ greatly from these. We have hypothesized 
that there is a resemblance in the genomic profiles of both osteogenic hMSCs and the 
bone metastatic PC3 cells, which potentially link both of their abilities to thrive in the 
bone environment. This finding highlights one of the limitations of the CMap, which 
requires an assumption that the genetic response of the cell lines utilized will be 
similar to those studied by individual CMap users. It also does not account for the 
dynamics associated with a disease or phenotype or in vivo multi-organ effects. While 
using the cell line based permuted results excludes any compound that was not tested 
multiple times in any cell line (their permuted p-value is quantified as 0 when only 1 
replicate exists), we felt this extra level of security was necessary. 
The methodology behind the CMap is fairly simple, notably the original 
Kolmogorov–Smirnov (KS) statistics used as the ‘similarity metric’ and the lack of 
true null hypothesis testing, and has been criticized for a high level of noise and failure 
to apply a comprehensive measure to validate the significance of a gene signature 
when queried against reference profiles. Several studies have increased the specificity 
and reliability of the CMap by creating new methods of data normalization and 
scoring algorithms which can be applied to the original KS statistics, or by 
incorporating additional models and data sources into the CMap2,3. That being said, 
the utility of the CMap is undeniable. The CMap has been successfully used to 
identify compounds and combination therapies that show promise in the treatment of 
osteoarthritic pain4, adenocarcinoma5, skeletal muscle atrophy6,7, emphysema-related 
lung disease8, kidney disease9, gliomas10, natural killer (NK) cell neoplasms11, 
Parkinson's disease related neurodegeneration12 and medulloblastomas13. Our results 
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add proof to the value of the CMap approach and methodology. All four selected 
positively correlated compounds instigated osteoblast differentiation of hMSCs. The 
rest of the top-ranking compounds were predominately made up of glucocorticoid 
receptor (GR) binding ligands, including dexamethasone (dex), which was expected, 
as dex is the compound that we used to stimulate osteoblast differentiation and 
glucocorticoid-mediated activation of the glucocorticoid receptor is the classical 
stimulus for human osteoblast differentiation in vitro. The connectivity map proved to 
be less successful when selecting compounds that we hoped would inhibit osteoblast 
differentiation of hMSCs. Only one, salbutamol, out of three negatively correlated 
compounds proved to successfully inhibit differentiation as determined by 
biochemical assays for alkaline phosphatase (ALP) activity and mineralization. The 
fact that metaraminol shares six out of 10 top differentially expressed genes with 
salbutamol makes this finding even more intriguing. These results could indicate that 
inhibiting the dex-induced osteoblast differentiation is a complicated process that 
requires a more sensitive experimental setup that facilitates the effectiveness of the 
compound, for example pre-treatment with the prospective inhibitors or treatment 
with a stronger dose.  
Our results highlight the valuable role bioinformatics approaches, such as the 
CMap, have as tools in expanding our knowledge of bone biology and providing 
potential novel treatments for disorders such as osteoporosis, but validation of these 
results through experimental approaches is critical. 
 
6.3. The cytoskeleton is a major influence in regulating osteoblast 
differentiation  
 
One of the key highlights that can be gained from this research is the 
importance of the cytoskeleton in osteoblast differentiation. This became clear in 
Chapter 2, where we showed that the osteogenic effect of CMap identified 
compound, parbendazole, is a result of changes to the cytoskeleton owing to 
parbendazole’s ability to depolymerize the microtubules. Further use of the CMap 
identified Withaferin A as another osteogenic stimulator in Chapter 3, and previous 
studies have demonstrated that Withaferin A also exerts its influence, at least in part, 
by causing changes to the actin cytoskeleton. In Chapter 4 we demonstrated a novel 
role for CLIC3 in osteoblast differentiation and bone formation which, based on our 
bioinformatic analysis of proteins identified by CLIC3-His pull down and literature, 
also potentially coupled to microtubule associations and signaling. Remarkably, 15 of 
the top differentially expressed genes from the successful CMap-identified 
compounds are known to affect cytoskeletal organization or signaling (DUSP114, 
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SEMA3D15, UBXN2B16, TPT117, HMOX118, HSPA1A19, TXNIP20, THBS121, 
CXCL122, RCC123, ARPC224, APP25, CD5526, ACTN127,28, CTGF29), providing 
additional support for the role of the cytoskeletal in osteoblast differentiation. In 
addition, three out of seven of the top proteins identified by CLIC3-pull down 
(NEK930, PLCB331, NUP16032) have been proven to alter cytoskeletal elements.  
Microtubules are highly dynamic cytoskeletal elements that undergo 
continuous assembly and disassembly to maintain normal function33,34. They play a 
role in a variety of cellular processes including mitosis, cell motility, and intra- and 
inter-cellular trafficking35, but are also playing a functional role in signal transduction, 
through interaction with members of sonic hedgehog, Wnt, Indian 
hedgehog/parathyroid hormone-related protein and MAPK signaling pathways33,36,37. 
In hMSCs, parbendazole's inhibitory effect on the microtubules leads to enhancement 
of actin stress fibers, increases focal adhesions, and up-regulates bone morphogenetic 
protein (BMP2) gene expression and activity (Fig. 1). Our elucidation of 
parbendazole's cytoskeletal driven osteoblast differentiation is supported by previous 
works that together demonstrate that inhibition of microtubules leads to increased cell 
contractility, cytoskeletal tension and f-actin stress fiber formation through 
RhoA/ROCK signaling, which ultimately leads to enhanced osteoblast 
differentiation38–43.  
The actin cytoskeleton supports a great variety of cellular processes, such as 
endocytosis, oriented growth, adhesion and migration, and is an important factor in 
osteogenic, adipogenic and chondrogenic differentiation of MSCs40. As we saw with 
parbendazole, disruption of microtubules leads quickly to changes in the actin 
microfilaments40. In our study, microtubule depolymerization lead to a large, 
widespread appearance and increased actin stress fibers. Experiments using cultured 
hMSCs and murine pre-ostoblast calls have also demonstrated that osteoblast 
differentiation alters the actin cytoskeleton, transforming from numerous, thin actin 
filaments running parallel along the long axis of the cell, to fewer, thicker fibers criss-
crossing strands; furthermore, disruption of the actin cytoskeleton inhibits osteogenic 
differentiation39,44–46. In addition, Mishra et. al. recently demonstrated through real-
time labeling and tracking of F-actin turnover dynamics that there is quickly (within 
minutes) divergence in the dynamics of the actin cytoskeleton between hMSCs 
stimulated with osteogenic, adipogenic or chondrogenic media, and these changes 
precedes the lineage specific morphological changes (seen after 24 hours)47. They 
propose that these early changes in the actin network could serve as a marker of 
lineage divergence. Actin stress fibers are one of the stiffest structures within hMSCs48 
and osteogenic differentiation appears to require a stiff, spread actin cytoskeleton40, 
which seems logical because, in vivo, osteoblasts are generally found as flat cells, sitting 
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on the surface of the bone. This idea is further strengthened by the finding that stiffer 
biomaterials promote osteogenic differentiation of MSCs, while softer materials 
stimulate chondrogenic and adipogenic differentiation49,50. 
Evidence of withaferin A’s effect on the cytoskeleton comes from Falsey et al. 
who demonstrated that withaferin A covalently binds annexin II and stimulates basal 
F-actin cross-linking activity51 (Fig. 1). In addition, withaferin A disrupts the vimentin 
cytoskeleton52. Vimentin, is an intermediate filament protein of the cytoskeleton. 
Interestingly, vimentin is proven to suppress ATF4-dependent osteocalcin 
transcription and osteoblast differentiation53, but in the case of withaferin A treatment 
ATF4 expression is enhanced, in turn stimulating osteoblast differentiation.  
It has been reported that CLIC3 and other CLIC proteins associate with the 
cytoskeleton or scaffolding proteins for endosome trafficking54–56. In addition, our 
bioinformatics analysis of CLIC3-His pulled down proteins identified an 
overrepresentation of proteins involved in processes related to cytoskeletal and 
integrin signaling. CLIC3 protein pull-down identified NEK9 as a binding partner and 
in vitro shRNA knockdown experiments proved that NEK9 is required for hMSC 
osteoblast differentiation and mineralization. NEK9 is known to be involved in 
regulating spindle organization, chromosome alignment, cytokinesis, and normal cell 
cycle progression57,58. Mammalian Nek9 binds gamma-tubulin and localizes to the 
centrosomes and spindle poles during early cell division and functions in the 
microtubule organizing center during mitosis30,59. Recessive mutations in NEK9 cause 
a lethal skeletal dysplasia and analysis of NEK9 mutations in patient fibroblasts that 
also showed reduced cilia number and length, suggesting that NEK9 is involved in 
ciliary function60. Another role for primary cilia in bone was demonstrated by 
Oliazadeh et al. who investigated the role of the cilia in patients with idiopathic 
scoliosis, which causes abnormal curvature of the spine and of which nearly half (38% 
to 65% in different cohorts) suffer from osteopenia and/or osteoporosis. They found 
that the bone cells of idiopathic scoliosis patients had significant elongation of the 
primary cilia and after mechanical stimulation the bone-derived cells had reduced 
responses of BMP2, RUNX2, and PTGS261. The primary cilium is a microtubule-
based organelle that has emerged as a novel extracellular sensor in bone. It is able to 
sense mechanical stimulus and transduce them into biochemical responses, which 
regulate bone adaptation, increasing osteogenic gene expression and bone 
formation62. Taken together, these findings suggest that NEK9 and CLIC3 may 
regulate osteoblast differentiation via cytoskeleton-associated signaling processes (Fig. 
1).  
The research presented in this thesis, along with others, confirms that 
dynamic cytoskeletal changes appear to be one of intracellular signals that control 
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osteoblast differentiation. The changes that we see in the balance between the tension 
forces of the actin microfilaments and the compression forces of the microtubules 
that further elicit changes in cell shape, function, gene expression, and fate, are in line 
with the cellular tensegrity model63,64 and with previous findings that changes in cell 
shape and cytoskeleton can strongly influence hMSC fate65. A fundamental aspect 
within the cellular tensegrity model is that every structural element within the system 
is poised to sense and immediately respond to physical stimuli from both inside and 
outside the cell64. Meaning that, for example, when mechanical forces are applied to 
the bone, bone cells respond by coordinated changes in the extracellular matrix, cell, 
cytoskeleton and without producing any structural breakage or disconnection between 
these parts. The dynamic nature of the cytoskeleton makes it difficult to study 
changes in the cytoskeleton and determine the roles of the many accessory molecules 
that modulate organization of it, but this work is vital to fully understand the 
differentiation process and develop new bone anabolic treatments. The evidence 
presented in this thesis significantly strengthens the concept that cytoskeletal changes 
strongly influence hMSC lineage allocation and osteoblast differentiation. 
 
6.4. Focal Adhesion Complexes and Integrin Signaling influence osteoblast 
differentiation 
 
Focal adhesions complexes are clusters of transmembrane integrin molecules 
associated with a complex network of plaque proteins that connect to actin filaments. 
Focal adhesions are used by cells to respond to the external environment through a 
variety of signaling cascades. The complexes can regulate cell adhesion, migration, 
proliferation, and differentiation66. 
We discovered that parbendazole treatment in hMSCs leads to an increase in 
focal adhesion number and length (Fig. 1). Other groups have also shown that 
disruption of microtubules by microtubule-depolymerizing agents, similar to 
parbendazole, leads to a substantial increase in the size and the number of mature 
focal adhesions67,68, and reestablishment of microtubule polymerization causes a 
transient decrease in size or even the disappearance of focal adhesions69. Osteogenic 
differentiation is promoted in MSCs with a stiff, spread actin cytoskeleton and greater 
numbers of focal adhesions40. Focal adhesions are also important in differentiation 
and MSC lineage decision making. Osteogenesis requires larger numbers of focal 
adhesions, while differentiation towards adipocytes or chondrocytes are encouraged 
by preventing focal adhesion attachment40. 
CLIC3 has been previously shown to associate with integrins in cultured 
A2780 ovarian carcinoma cells and in pancreatic and ovarian tumors that contain 
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elevated levels of CLIC3, where it functions to mediate the transport and recycling of 
α5β1 integrins from late endosomes/lysosomes to the plasma membrane54. Our 
bioinformatics pathway analysis of CLIC3-His pulled down proteins in Chapter 4 
identified an overrepresentation of proteins involved in paxillin and integrin signaling 
and gene ontology (GO) analysis showed “protein binding involved in cell adhesion” 
and “cell adhesion molecule binding” to be significant GO terms associated with 
molecular function. As discussed above, the CLIC3-associated protein NEK9 
localizes to the primary cilium. Integrins are also localized to the primary cilium70 and 
it has been demonstrated previously that mechanical stimuli modulates integrin-
mediated signals, which are transferred through focal adhesion complexes and actin 
microfilaments71 (Fig. 1).  
In Chapter 3, we demonstrated that the CMap-identified compound 
salbutamol inhibited osteoblast differentiation and that the gene CTGF/CCN2 was 
consistently down-regulated by salbutamol treatment in PC3 cells. The work of 
Hendesi and colleagues revealed that osteoblast differentiation and matrix 
mineralization is enhanced in osteoblasts cultured on CTGF containing matrix. It was 
shown that adhesion to CTGF was mediated through integrin binding, which 
promoted cytoskeletal reorganization, cell spreading and Rac activation in the 
osteoblasts, ultimately leading to increased Runx2 binding of the osteocalcin gene 
promoter, and increased expression of osteogenic genes that are regulated by Runx229. 
Based on these results we can hypothesize down-regulation of CTGF by salbutamol 
contributes to its inhibitory effects on osteoblast differentiation through integrin 
binding and signaling (Fig. 1). 
Taken together these results support the importance of focal adhesion 
complexes and integrin signaling in osteoblast differentiation. Increases in focal 
adhesion number and length can influence osteoblast differentiation through 
enhanced extracellular matrix binding and/or integrin mediated signaling. Cytoskeletal 
rearrangements may also affect osteoblast differentiation though enhanced integrin 
signaling. Focal adhesion complexes and integrins are known to directly interact with 
extracellular matrix proteins, including SPP1 and IBSP who play a critical role in 
osteoblast survival and differentiation40,72–74. This increase in the number of focal 
adhesion complexes and interaction with matrix proteins allows for enhanced 
adhesion to the extracellular matrix74,75, which may also contribute to osteogenic 
differentiation (Fig. 1). Due to the direct signaling and binding of integrins with the 
extracellular matrix and actin cytoskeleton, integrins may play a direct role in 
regulating osteoblast differentiation and mineralization. Targeting of integrin signaling 
could make an attractive candidate for development of future bone anabolic 
treatments.  
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6.5. Consideration of timing for in vitro and in vivo bone models 
 
A remarkable theme among these works is the significance of temporal 
properties in bone formation and osteoblast differentiation and importance of 
considering the cell type, stage of differentiation, and age of an organism when 
planning experiments and examining data. 
In Chapter 5 we demonstrated that deletion of Muc1 results in a mild, but also 
transient phenotype in the femoral bones of female mice. We found that the 
trabecular bone volume was reduced in 8-week-old mice compared to wild type (WT) 
controls, but this normalizes with increasing age. As the mice age, Muc1 deletion 
results in stiffer femoral bones with fewer osteoblasts lining the trabecular surface, but 
increased endosteal mineralized surface and bone formation rate (16 weeks of age). 
While the cortical bone formation rate remains higher in knockout mice compared to 
wild type females at 52 weeks of age, all other parameters normalize. These results 
demonstrate the importance of examining multiple time points when investigating in 
vivo bone phenotypes. Analyzing only a single time point or a single parameter of bone 
morphology/strength in our study, as is common routine in many mouse genetic 
studies, would have led to either over-interpretation or missing aspects of Muc1 
deficiency on bone metabolism.  
Data from the study of Muc1 deficiency in mice also emphasizes the dramatic 
effect aging has on the femoral bone over time. Trabecular bone fraction dramatically 
declined (over 90% in WT mice), while cortical bone area (roughly 40% in WT mice), 
thickness, and periosteal perimeter increased during aging between 8 and 52 weeks of 
age. All mechanical strength properties increased with time, which is expected given 
that the larger, thicker cortex of the older bones directly contributes to a stronger 
femur, requiring more force to fracture, assuming the material properties do not 
change. With regards to histomorphometry measurements, trabecular bone formation 
rate and osteoblast numbers peaked at 16 weeks, while cortical bone formation rate 
declined over time. Our results suggest that different components of the bone may be 
more sensitive to perturbagens and/or may react differently depending on the age of 
the organism. For example, the metaphysis of the long bones has a relatively high rate 
of bone turnover compared to diaphyseal cortical bone and developmental phases 
involving intense longitudinal growth may show greater temporal dynamics. While our 
Muc1 studies are limited due to the use of the mouse model and potential differences 
in bone biology between mice and humans, evidence from human studies also 
supports the idea of age-related changes in bone. In humans after the attainment of 
peak bone mass in early adulthood, bone remodeling is balanced and bone mass is 
| Chapter 6 
 132
stable for a decade or two until age-related bone loss begins. In healthy adults, 
increased resorptive activity is linked to complementary increased bone formation; 
however, in postmenopausal women and elderly men the balance between resorption 
and subsequent formation at each bone remodeling unit is negative with increased 
resorptive activity leading to irreversible bone loss that is irreversible76. Understanding 
this dynamic process of bone metabolism over time is greatly important to planning in 
vivo experiments related to bone biology and interpreting the results. Our results in 
studying the in vivo function of Muc1 in mice highlights the issue of bone loss during 
aging and could be an interesting model to delve into this topic more fully.  
In Chapter 2 we found that different populations of human cell types react 
differently to parbendazole treatment in vitro. When hMSCs were cultured with 
parbendazole we found an increase in both proliferation and in apoptosis. This 
indicates that there are at least two populations of cells within our bone marrow 
derived MSCs with different sensitivity to parbendazole. One population, likely the 
true stem cells, is resistant to the apoptotic effects of parbendazole and are induced to 
proliferate and eventually differentiate and mineralize, and another population, the 
pre-committed cells, that undergoes apoptosis. This hypothesis is supported by the 
observation that human pre-osteoblast cells, SV-HFOs, treated with parbendazole did 
not display an increase in ALP activity or mineralization. Based on these data we 
proposed that parbendazole acts at the stage of lineage allocation in hMSCs. These 
findings are important in strengthening the role for cytoskeletal changes influences 
hMSC lineage decision making and furthering the need for understanding how to 
target these processes for therapeutic development. 
In Chapter 3 we used the CMap to identify calcium folinate, otherwise known 
as folinic acid or by the brand name Leucovorin, as a potential stimulator of 
osteoblast differentiation and confirmed its ability to induce osteogenic differentiation 
of hMSCs through in vitro experiments. Calcium folinate, a derivative of 
tetrahydrofolic acid, is already used clinically to help ameliorate some of the negative 
side effects of the chemotherapeutic agent methotrexate, which functions as a 
dihydrofolate reductase inhibitor in soft tissues through its capacity to readily be 
converted to folic acid derivatives without the action of dihydrofolate reductase. 
Interestingly, research in rodent models has demonstrated that calcium folinate 
reduces bone loss and damage to the growth plate and bone marrow compartments 
normally seen with methotrexate treatment77–80. Furthermore, it has been observed 
that there is an increase in bone marrow adiposity following methotrexate treatment 
alone, and when calcium folinate is administered concurrently these effects are 
amended and an increase in bone marrow MSC proliferation is also observed78,81. 
These effects are proposed to be due to up-regulation of Wnt/ß-catenin signaling in 
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the bone through normalizing the level of the Wnt antagonist sFRP-1 that was 
elevated by methotrexate alone81. However, whether these effects are a direct effect of 
calcium folinate on Wnt/ß-catenin signaling or an indirect outcome of changes to 
cellular folate metabolism requires further investigation, as in-depth studies on the in 
vivo bone effect of calcium folinate alone are still lacking. Combining our observations 
that calcium folinate can independently stimulate differentiation of hMSCs in vitro with 
the available in vivo results demonstrating that calcium folinate can prevent 
methotrexate induced bone marrow adiposity while preserving bone, strongly 
indicating that calcium folinate alone acts at the stage of lineage allocation in 
osteoblast differentiation.  
Another observation related to the study of differences in cell type response 
and its relationship to stages of differentiation include the likely role of HMOX1 in 
withaferin A-induced osteoblast differentiation. As we described in Chapter 3, 
withaferin A induces osteoblast differentiation of hMSCs and the gene we found to be 
most up-regulated by withaferin A treatment, HMOX1, was also required for 
osteoblast differentiation. Previous work has shown that overexpression of HMOX1 
increases human osteoblast stem cell differentiation, and shifts the balance of hMSCs 
differentiation in favor of the osteoblast lineage82,83. It has been observed that certain 
cell types are more sensitive to the same doses of withaferin A treatment, with some 
cell lines demonstrating higher levels of apoptosis and cell death52. We used bone 
marrow hMSCs as our cell of choice to test the CMap compound and we speculate, 
based on these previous results, that the true MSCs are responsible for the effect we 
see and that if we had used a committed cell line we might not see the same effect. 
Our choice of cell comes from our interest in understanding lineage 
commitment of hMSC as an important part of understanding osteoblast 
differentiation and our original selection of genes for further studies considered 
differential regulation of them in the osteoblast versus adipocyte lineages during 
differentiation of hMSCs. Since it has been observed that the there is an increase in 
the adiposity of the bone marrow in osteoporosis patients84–86 and that bone marrow-
derived mesenchymal progenitors from aged humans and mice preferentially 
differentiate toward the adipogenic, rather than osteogenic, lineage87–90, I believe that 
one avenue for the development of novel therapeutics for osteoporosis should target 
the lineage commitment of hMSCs.  
 
6.6. Therapeutic potential 
 
All four compounds we identified using the CMap as having positively 
correlating gene expression profiles to that of osteogenically differentiated hMSCs, 
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parbendazole, withaferin A, amylocaine, and calcium folinate, successfully stimulated 
in vitro osteoblast differentiation. This alone gives us reason to consider each of them 
as possible candidates for bone anabolic treatments. Parbendazole and withaferin A 
produced the strongest response in our cultures, both stimulating alkaline 
phosphatase activity and mineralization, and there is mounting in vitro and in vivo data 
demonstrating the osteo-anabolic effect of microtubule inhibitors91,92 and on 
withaferin A93,94 treatment. However, in vitro testing of compounds in a cell culture 
environment is very different from testing in an in vivo environment and we must 
consider the fact that these compounds may have varying and/or negative effects on 
other cell types and organ systems. Both parbendazole and withaferin A have been 
shown to have cytotoxic effects in certain cell types making them poor candidates as 
bone anabolic therapies, but development of a drug that harnesses the mechanisms 
that drive the osteogenic effect of these compounds at the level of MSC lineage 
decision making, such as integrin signaling, enhancing cytoskeletal tension and up-
regulation of expression of HMOX1 and HSPA1A, could provide us with the most 
beneficial new treatments for osteoporosis or other disorders requiring bone 
(re)generation.  
Calcium folinate and amylocaine both stimulated mineralization in hMSCs, 
while, interestingly, having no consistent effect on ALP activity. As mineralization is 
the defining feature of a mature osteoblast we have concluded that these two 
compounds stimulate osteogenic differentiation of hMSCs in vitro. There is little 
research and date annotated to amylocaine, also known as stovaine, and it was 
developed as a synthetic local anesthetic; however, no data exists linking it to bone or 
osteoblast differentiation. Its anesthetic properties are attributed to the ability to 
inhibit voltage-sensitive Na+ channels95–97, and to a lesser extent voltage sensitive Ca2+ 
channels98, and it is plausible that the osteogenic effect observed with amylocaine 
could be related to its potential effects on ion channels, but this requires further 
investigation. Calcium folinate, as we discussed previously, is currently used in the 
clinic to ameliorate the negative effects of methotrexate chemotherapeutic on a 
variety of tissues including bone77–79. Unfortunately, data is lacking with regard to 
calcium folinate's effect on osteoblast differentiation and bone formation independent 
of methotrexate treatment. Only one study has examined the effects of calcium 
folinate on bone, independent of methotrexate; however, only tibial and femur 
lengths were scrutinized and no difference was found between calcium folinate 
treatment and control treatment80. In addition there is evidence for a potential role in 
a preference for osteoblast lineage allocation through up-regulating Wnt/β-catenin 
signaling in bone81. Further investigation into the effects of calcium folinate and 
amylocaine on in vivo bone formation and regulation of osteoblast differentiation as 
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potential bone anabolic treatments, particular in models of osteoporosis such as 
ovariectomy mouse models, are highly warranted. Both of these compounds have 
been used in humans for other proposes, which further strengthens the cause of 
studying them more in depth for use in osteoporosis treatments 
Our discovery of CLIC3 and MUC1 as novel genes involved in bone 
formation makes them potential candidates as targets for development of bone 
anabolic therapeutics as well. While more research is required to understand the role 
MUC1 may play in human bone formation in order to seriously consider it for drug 
development, CLIC3 is a particularly interesting candidate. The specificity of CLIC3 
to promote the osteogenic lineage, while its expression decreases during adipocyte 
differentiation, in combination with the importance of CLIC3 during human 
osteoblast differentiation could make it a potential target for future bone anabolic 
treatments. Our discovery that CLIC3 interacts with two proteins, PTDSS1 and 
NEK9, that are both known to cause severe human skeletal defects when they are 
mutated60,99,100 further strengthens its importance in bone. Development of a drug 
that could target CLIC3 and in turn regulate PTDSS1 and NEK9 to enhance 
osteoblast differentiation and bone production would be ideal. 
 
6.7. Final conclusion and future outlook 
 
This thesis has presented a number of novel findings in the bone biology 
field and highlights the complexity of the biology and study of osteoblast 
differentiation. Through the use of gene expression analysis of hMSCs undergoing 
osteogenic differentiation we have identified important genes and processes 
controlling osteoblast differentiation. These studies, and studies like it, are vital 
gaining greater knowledge about MSC lineage decision making and osteoblasts 
differentiation which is required to develop much needed bone anabolic therapeutics. 
Although the overall aim of this project was to identify novel factors enhancing 
osteoblast differentiation and bone production that could ultimately lead to new 
treatments for osteoporosis patients, this research is also useful in the field of bone 
(re)generation in general. Bone has the ability to regenerate and repair itself, but large 
bone defects or disease states can impair this process. By enhancing these innate 
properties of bone, we can improve treatments and recovery times for patients 
suffering from serious bone defects and bone loss.  
The work presented here has demonstrated the power of the CMap as an 
effective tool to discover novel bone anabolic compounds. All of the top positively 
correlating compounds we tested in our human osteoblast differentiation model using 
hMSCs induced mineralization independent of any additional stimulus. Amylocaine 
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and calcium folinate hold promise as novel bone anabolic treatments and additional 
studies into their mechanism of action and in vivo effects are required.  
The evidence presented here supports the concept that cytoskeletal changes 
strongly influence hMSC lineage allocation and osteoblast differentiation. I envisage 
that cytoskeletal manipulation, or the down-stream processes that results from it, hold 
promise as novel anti-osteoporotic treatments, but this will need to be studied further.  
We identified two novel lineage specific genes that influence osteoblast 
differentiation, CLIC3 and MUC1. Very little evidence exists pertaining to CLIC3s 
function or role in other tissues and more research is required to understand if our 
hypothesis that CLIC3 regulates osteoblast differentiation through interactions with 
NEK9 in the microtubule organizing center to induce cytoskeletal changes or in the 
function of the primary cilia and/or working together with PTDSS1 to increase 
biosynthesis of phosphatidylserine enhancing osteoblast differentiation and matrix 
vesicle-mediated hydroxyapatite formation and mineralization of the bone (Fig. 1).   
Although deletion of Muc1 resulted in only subtle changes in the bone, we 
were intrigued that the phenotype changed over time. I believe that it is worthwhile to 
investigate the role of MUC1 in bone further, particularly in regards to what role it 
might have in younger mice (less than 8 weeks of age), situations where estrogen is 
depleted, given the known links it has to estrogen receptor beta signaling, and in bone 
fracture models. Based on our discovery of MUC1 as explicitly expressed in the 
osteogenic lineage in early human osteoblast differentiation104, it will also be pivotal to 
further investigate the function of MUC1 in human MSCs and osteoblasts and its 
potential role in human bone homeostasis. Another remarkable finding of MUC1s 
function comes from Kitamoto and collegues101, who reported that MUC1 enhances 
hypoxia driven angiogenesis through studies showing that increased MUC1 
expression in pancreatic cancer cells derived from metastatic tumors cultured in 
hypoxic conditions promoted angiogenesis of endothelial cells. Within bone MSCs 
reside in stem cell niches of low-oxygen atmospheres and local levels of oxygen are 
reduced at the site of fractures102,103. Based on this I wonder whether MUC1 may play 
an additional role in the bone to stimulate angiogenesis via secretion from MSCs 
and/or osteoblasts during times in hypoxic conditions, which could be investigated in 
bone fracture models.  
Bone biology is a complicated and fascinating field of study. All models have 
limitations and advantages. When studying osteoblast differentiation in the context of 
looking for bone anabolic treatments for conditions such as osteoporosis, considering 
the cell type and stage of differentiation affected by a candidate is important as well as 
the reality of not studying these cells in their natural environment. In my opinion, the 
knowledge that a switch in lineage decision making of MSCs could be a major 
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contributor to the development of osteoporosis is of the utmost importance. With 
this information in mind we should consider that different pathways, drugs and genes 
affect varying stages of the differentiation process and candidates should target the 
very early stages of differentiation, i.e. at the level of the MSC. Our discovery of novel 
genes, compounds and processes that play a role in osteoblast differentiation, in 
particular in the lineage decision making of MSCs, constitute potential therapeutic 
targets for the development of novel treatments for bone diseases, such as 
osteoporosis, and should be investigated further. 
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A. Summary 
 
Bone is a dynamic organ that throughout life undergoes constant remodeling 
controlled in a balancing act between removal of old bone by osteoclasts and 
formation of new bone controlled by osteoblasts, as well as its terminally 
differentiated form the osteocyte. The process of building bone starts with the 
mesenchymal stromal cell (MSC), a multipotent cell that has the ability to differentiate 
into a number of cell types including osteoblasts, chondrocytes, and adipocytes. A 
number of key factors and signaling pathways controlling osteoblast differentiation 
and activity have been identified over the last few decades; however, a better 
understanding of the signaling network, their intricate interactions, and what other 
genes and pathways are involved in osteoblast function is required to develop 
approaches to enhance bone formation and promote fracture healing for patients with 
disorders such as osteoporosis. The overall aim of this thesis, through a combined use 
of bioinformatic, genomic, molecular, and proteomic approaches, was to identify 
novel factors (compounds, genes, and processes) involved osteoblast differentiation 
and bone formation to expand the basic knowledge of osteoblast differentiation 
which can ultimately be used the development of a novel bone anabolic treatment for 
conditions such as osteoporosis. 
In chapters 2 and 3 we demonstrated the use of the web-based Connectivity 
Map (CMap) tool to find compounds with correlating gene expression profiles to that 
of human MSCs (hMSCs) undergoing osteoblast differentiation that can affect 
osteoblast differentiation. The CMap identified parbendazole as the top positively 
correlating compound and in chapter 2 we showed that parbendazole, independent 
of an additional osteogenic stimulus, was able to stimulate in vitro human osteoblast 
differentiation as evidenced by increased ALP activity, mineralization and 
upregulation of genes important in osteoblast differentiation and extracellular matrix 
production. Mechanistically, it was found that the osteogenic effect of parbendazole 
occurs independent of glucocorticoid receptor signaling, but rather via affecting 
microtubule formation, cytoskeletal organization, focal adhesion distribution, and 
BMP2 activity. In chapter 3, three additional positively correlated compounds, 
withaferin A, calcium folinate, and amylocaine, which stimulate osteoblast 
differentiation and mineralization of hMSCs in vitro were identified. Conversely, 
compounds with negatively correlated gene signatures to that of differentiating 
osteoblasts, the results of which we hypothesized may reveal interesting new genes 
and processes in the osteoblast differentiation process, were examined. Three 
compounds, salbutamol, metaraminol, and diprophylline, which exhibit a gene 
signature negatively correlated to our osteogenic gene signature were identified, but 
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only one of these drugs, salbutamol, inhibited dexamethasone-induced osteogenic 
differentiation of hMSCs were identified Finally, the differentially expressed genes 
behind the CMap identified compounds and used this approach to find and validate 
two genes, HMOX1 and STC1, as important factors for human osteogenesis were 
analyzed. 
In chapter 4, CLIC3 was identified as a new gene specifically regulated in the 
osteogenic lineage of differentiating hMSCs. Lentiviral transduction-mediated 
overexpression and silencing of CLIC3 during osteogenesis revealed a crucial function 
for CLIC3 in promoting osteoblast mineralization. Overexpression of CLIC3 in 
hMSCs strongly enhanced in vivo bone formation in a mouse model for ectopic 
human bone formation further emphasizing that CLIC3 plays an important role in 
human osteoblast differentiation. Bioinformatics analysis of proteins identified by 
CLIC3-His pull down suggests CLIC3s role during osteoblast differentiation may be 
related cytoskeletal associations and signaling, cell adhesion, and/or nuclear pore 
formation or transport through. Finally, it was identified that CLIC3 interacts with 
NEK9 and PTDSS1 during osteoblast differentiation, and inhibition of the NEK9 
and PTDSS1 expression reduces osteogenic differentiation of hMSCs. 
Chapter 5 describes a novel and temporally shifting role for Muc1 in bone 
biology. It was showed that deletion of Muc1 in female mice leads to decreased 
trabecular bone volume in 8-week-old compared to wild type (WT) females; however, 
this difference disappears by 16 weeks. At the same time, endocortical bone formation 
rate and femoral stiffness are increased at 16 weeks of age in Muc1 deficient female 
mice, with a higher rate of endocortical bone formation persisting to 52 weeks of age 
in Muc1-/- mice. Histomorphometric analysis demonstrated that femurs of 16-week-
old Muc1-/- female mice displayed lower numbers of osteoblasts lining the bone 
surface, while femurs from 8- and 52-week old KO and WT mice did not differ in 
their number of osteoblasts.  
 In conclusion, this thesis has presented a number of novel findings in the 
bone biology field and highlights the complexity of the biology and study of 
osteoblast differentiation. These studies, and studies like it, are vital in gaining greater 
knowledge about MSC lineage decision making and osteoblasts differentiation, which 
is required to develop much needed bone anabolic therapeutics. The findings 
presented in this thesis highlight the importance of the cytoskeleton in regulating and 
influencing osteoblast differentiation, and may hold promise as novel anti-
osteoporotic treatments, with further research.   The discovery of a number of novel 
factors affecting osteoblast differentiation, including the CMap identified compounds 
and CLIC3 and MUC1, opens up new avenues in the bone biology field for 
development of bone anabolic therapeutics.
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B. Samenvatting 
 
Bot is een dynamisch orgaan dat gedurende het hele leven een constante 
remodellering ondergaat, gecontroleerd in een evenwichtsoefening tussen 
verwijdering van oud bot door osteoclasten en vorming van nieuw bot gecontroleerd 
door osteoblasten, evenals zijn terminaal gedifferentieerde vorm de osteocyt. Het 
proces van het bouwen van bot begint met de mesenchymale stromale cel (MSC), een 
multipotente cel die het vermogen heeft om te differentiëren in een aantal celtypen, 
waaronder osteoblasten, chondrocyten en adipocyten. De afgelopen decennia zijn een 
aantal sleutelfactoren en signaalroutes vastgesteld die de differentiatie en activiteit van 
osteoblast beheersen; een beter begrip van het signaalnetwerk, hun ingewikkelde 
interacties en welke andere genen en routes betrokken zijn bij de osteoblastfunctie is 
echter vereist om benaderingen te ontwikkelen om de botvorming te verbeteren en 
fractuurgenezing te bevorderen voor patiënten met aandoeningen zoals osteoporose. 
Het algemene doel van dit proefschrift was, door een gecombineerd gebruik van 
bioinformatische, genomische, moleculaire en proteomische benaderingen, om 
nieuwe factoren (verbindingen, genen en processen) te identificeren die te maken 
hadden met osteoblastdifferentiatie en botvorming om de basiskennis van 
osteoblastdifferentiatie uit te breiden welke uiteindelijk kan worden gebruikt voor de 
ontwikkeling van een nieuwe botanabole behandeling voor aandoeningen zoals 
osteoporose. 
In de hoofdstukken 2 en 3 is het gebruik van het webgebaseerde 
Connectivity Map-hulpmiddel (CMap) aangetoond om verbindingen te vinden met 
correlerende genexpressieprofielen met die van menselijke MSC's (hMSC's) die 
osteoblastdifferentiatie ondergaan welke de osteoblastdifferentiatie kunnen 
beïnvloeden. De CMap identificeerde parbendazol als de bovenste positief 
correlerende verbinding en in hoofdstuk 2 is aangetoond dat parbendazol, 
onafhankelijk van een extra osteogene stimulus, in vitro humane 
osteoblastdifferentiatie kon stimuleren zoals bewezen door verhoogde ALP-activiteit, 
mineralisatie en opregulatie van genen die belangrijk zijn in osteoblast differentiatie en 
extracellulaire matrixproductie. Mechanistisch is gevonden dat het osteogene effect 
van parbendazol onafhankelijk van de glucocorticoïdereceptorsignalering optreedt, 
maar eerder via het beïnvloeden van de vorming van microtubuli, 
cytoskeletorganisatie, focale adhesieverdeling en BMP2-activiteit. In hoofdstuk 3 zijn 
drie extra positief gecorreleerde verbindingen geïdentificeerd; metaferine A, 
calciumfolinaat en amylocaïne, die osteoblast differentiatie en mineralisatie van 
hMSC's in vitro stimuleren. Omgekeerd zijn ook verbindingen met negatief 
gecorreleerde gensignaturen met die van differentiërende osteoblasten, waarvan de 
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resultaten waarvan verondersteld is dat ze interessante nieuwe genen en processen in 
het osteoblastdifferentiatieproces kunnen onthullen onderzocht. Ook zijn drie 
verbindingen geïdentificeerd, salbutamol, metaraminol en diprophylline, die een 
gensignatuur vertonen die negatief gecorreleerd is met onze osteogene gensignatuur, 
maar slechts één van deze geneesmiddelen, salbutamol, remde door dexamethason 
geïnduceerde osteogene differentiatie van hMSC's. Ten slotte, zijn de de differentieel 
tot expressie gebrachte genen achter de CMap-geïdentificeerde verbindingen 
geanalyseerd, en deze benadering gebruikt om twee genen, HMOX1 en STC1, te 
vinden en te valideren, als belangrijke factoren voor menselijke osteogenese. 
In hoofdstuk 4 is CLIC3 geïdentificeerd als een nieuw gen dat specifiek 
wordt gereguleerd in de osteogene lijn van differentiërende hMSC's. Lentivirale 
transductie-gemedieerde overexpressie en “silencing” van CLIC3 tijdens osteogenese 
onthulde een cruciale functie voor CLIC3 bij het bevorderen van 
osteoblastmineralisatie. Overexpressie van CLIC3 in hMSC's verhoogde de in vivo 
botvorming sterk in een muismodel voor ectopische menselijke botvorming en 
benadrukte verder dat CLIC3 een belangrijke rol speelt bij de differentiatie van 
menselijke osteoblasten. Bioinformatica-analyse van eiwitten, geïdentificeerd door 
CLIC3-His pull-down suggereert dat CLIC3s rol tijdens osteoblastdifferentiatie 
gerelateerd kan zijn aan cytoskeletale associaties en signalering, celadhesie en / of 
nucleaire porievorming of transport doorheen. Ten slotte hebben is vastgesteld dat 
CLIC3 een interactie aangaat met NEK9 en PTDSS1 tijdens osteoblastdifferentiatie, 
en remming van de expressie van NEK9 en PTDSS1 vermindert de osteogene 
differentiatie van hMSC's. 
Hoofdstuk 5 beschrijft een nieuwe en in tijd veranderende rol voor Muc1 in 
botbiologie. Er is aangetoond dat verwijdering van Muc1 bij vrouwelijke muizen leidt 
tot een verminderd trabeculair botvolume bij 8 weken oude dieren in vergelijking met 
wildtype (WT) vrouwtjes; dit verschil verdwijnt echter na 16 weken. Tegelijkertijd 
neemt de snelheid van de endocorticale botvorming en de stijfheid van het dijbeen toe 
op de leeftijd van 16 weken bij Muc1-/- vrouwelijke muizen, met een hogere snelheid 
van de endocorticale botvorming tot 52 weken bij de Muc1-/- muizen. 
Histomorfometrische analyse toonde aan dat femora van 16-weken oude Muc1-/- 
vrouwelijke muizen lagere aantallen osteoblasten vertoonden langs het botoppervlak, 
terwijl femora van 8- en 52-weken oude KO- en WT-muizen niet verschilden in hun 
aantal osteoblasten. 
Concluderend heeft dit proefschrift een aantal nieuwe bevindingen op het 
gebied van botbiologie gepresenteerd en de nadruk gelegd op de complexiteit van de 
biologie en studie van osteoblastdifferentiatie. Deze onderzoeken, en dergelijke 
studies, zijn van vitaal belang om meer kennis te vergaren over MSC-besluitvorming 
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en osteoblasten differentiatie, die nodig is om de hoognodige anabole therapeutica te 
ontwikkelen. De bevindingen in dit proefschrift benadrukken het belang van het 
cytoskelet bij het reguleren en beïnvloeden van osteoblastdifferentiatie, en kunnen 
veelbelovend zijn als nieuwe anti-osteoporotische behandelingen, met verder 
onderzoek. De ontdekking van een aantal nieuwe factoren die de 
osteoblastdifferentiatie beïnvloeden, waaronder de CMap-geïdentificeerde 
verbindingen en CLIC3 en MUC1, opent nieuwe wegen op het gebied van 
botbiologie voor de ontwikkeling van botanabole therapeutica.
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C. Supplementary Tables and Figures 
 
Table A1: Probes used for CMap query 
Up-regulated Probes  Down-regulated Probes 
 Affymetrix Probe ID HG-U133A Gene symbol   
Affymetrix Probe 
ID HG-U133A Gene symbol 
1 205730_s_at ABLIM3  1 222162_s_at ADAMTS1 
2 201963_at ACSL1  2 201034_at ADD3 
3 207589_at ADRA1B  3 218631_at AVPI1 
4 204174_at ALOX5AP  4 204907_s_at BCL3 
5 221009_s_at ANGPTL4  5 207510_at BDKRB1 
6 206029_at ANKRD1  6 201169_s_at BHLHB2 
7 206176_at BMP6  7 211518_s_at BMP4 
8 218723_s_at C13orf15  8 216598_s_at CCL2 
9 218309_at CAMK2N1  9 203666_at CXCL12 
10 219398_at CIDEC  10 212977_at CXCR7 
11 221541_at CRISPLD2  11 202434_s_at CYP1B1 
12 209283_at CRYAB  12 204977_at DDX10 
13 214724_at DIXDC1  13 218858_at DEPDC6 
14 204602_at DKK1  14 201340_s_at ENC1 
15 203810_at DNAJB4  15 215704_at FLG 
16 201041_s_at DUSP1  16 204948_s_at FST 
17 209457_at DUSP5  17 203925_at GCLM 
18 214445_at ELL2  18 221576_at GDF15 
19 201324_at EMP1  19 206614_at GDF5 
20 205521_at ENDOGL1  20 210640_s_at GPER 
21 208962_s_at FADS1  21 218468_s_at GREM1 
22 204560_at FKBP5  22 206432_at HAS2 
23 206860_s_at FLJ20323  23 202934_at HK2 
24 205021_s_at FOXN3  24 203665_at HMOX1 
25 202723_s_at FOXO1  25 209905_at HOXA9 
26 203592_s_at FSTL3  26 201565_s_at ID2 
27 209892_at FUT4  27 201631_s_at IER3 
28 203725_at GADD45A  28 206332_s_at IFI16 
29 207574_s_at GADD45B  29 214059_at IFI44 
30 201841_s_at HSPB1  30 205207_at IL6 
31 206375_s_at HSPB3  31 201625_s_at INSIG1 
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32 218934_s_at HSPB7  32 201464_x_at JUN 
33 209184_s_at IRS2  33 210261_at KCNK2 
34 201389_at ITGA5  34 201650_at KRT19 
35 204301_at KBTBD11  35 206969_at KRT34 
36 208960_s_at KLF6  36 206481_s_at LDB2 
37 212442_s_at LASS6  37 206953_s_at LPHN2 
38 218574_s_at LMCD1  38 218559_s_at MAFB 
39 215322_at LONRF1  39 212530_at NEK7 
40 212859_x_at MT1E  40 206814_at NGF 
41 204745_x_at MT1G  41 220132_s_at NPM1 
42 217546_at MT1M  42 203708_at PDE4B 
43 204326_x_at MT1X  43 220343_at PDE7B 
44 203036_s_at MTSS1  44 203131_at PDGFRA 
45 218330_s_at NAV2  45 217996_at PHLDA1 
46 213012_at NEDD4  46 203354_s_at PSD3 
47 201502_s_at NFKBIA  47 207017_at RAB27B 
48 218786_at NT5DC3  48 202677_at RASA1 
49 205960_at PDK4  49 209568_s_at RGL1 
50 212239_at PIK3R1  50 204337_at RGS4 
51 207290_at PLXNA2  51 212724_at RND3 
52 204285_s_at PMAIP1  52 213236_at SASH1 
53 206631_at PTGER2  53 202656_s_at SERTAD2 
54 204748_at PTGS2  54 205856_at SLC14A1 
55 206157_at PTX3  55 205396_at SMAD3 
56 204916_at RAMP1  56 208127_s_at SOCS5 
57 202388_at RGS2  57 202935_s_at SOX9 
58 212099_at RHOB  58 203217_s_at ST3GAL5 
59 202082_s_at SEC14L1  59 210612_s_at SYNJ2 
60 204541_at SEC14L2  60 203083_at THBS2 
61 202627_s_at SERPINE1  61 209386_at TM4SF1 
62 201739_at SGK1  62 206025_s_at TNFAIP6 
63 214719_at SLC46A3  63 204932_at TNFRSF11B 
64 209453_at SLC9A1  64 215111_s_at TSC22D1 
65 212797_at SORT1  65 204881_s_at UGCG 
66 219257_s_at SPHK1  66 220976_s_at KRTAP1-1 
67 220983_s_at SPRY4     
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68 219315_s_at TMEM204     
69 207001_x_at TSC22D3     
70 205480_s_at UGP2     
71 206796_at WISP1     
72 221029_s_at WNT5B     
73 205883_at ZBTB16     
74 212704_at ZCCHC11     
75 211962_s_at ZFP36L1     
76 204131_s_at ZNF286C     
77 212742_at ZNF364     
List of up-regulated and down-regulated genes at 6 hours after start of osteogenic differentiation in hMSCs and their 
associated affymetrix probe IDs used for initial CMap query. 
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Table A2. Gene Ontology (GO) terms associated with CMap compound genes 
 
Withaferin A  
Category Term Fold Enrichment Count 
Benjamini 
corrected p-
value 
BP GO:0006986~response to unfolded protein 34.88 13 1.90E-12 
BP GO:0043065~positive regulation of apoptotic process 5.63 15 3.33E-04 
BP GO:1900034~regulation of cellular response to heat 12.02 8 2.23E-03 
MF GO:0005515~protein binding 1.35 105 2.53E-03 
MF GO:0051082~unfolded protein binding 8.18 8 4.77E-03 
BP GO:0008284~positive regulation of cell proliferation 3.87 16 4.95E-03 
MF GO:0051087~chaperone binding 9.73 7 5.68E-03 
MF GO:0031625~ubiquitin protein ligase binding 4.71 12 5.77E-03 
MF GO:0031072~heat shock protein binding 16.08 6 5.78E-03 
BP 
GO:0045944~positive regulation of 
transcription from RNA polymerase II 
promoter 
2.76 24 6.15E-03 
BP GO:0042127~regulation of cell proliferation 6.09 10 1.00E-02 
BP GO:0045766~positive regulation of angiogenesis 7.84 8 1.56E-02 
BP GO:0048008~platelet-derived growth factor receptor signaling pathway 19.43 5 1.98E-02 
BP GO:0071372~cellular response to follicle-stimulating hormone stimulus 40.98 4 2.02E-02 
MF GO:0008083~growth factor activity 5.56 8 3.41E-02 
BP GO:0042026~protein refolding 30.05 4 4.29E-02 
BP GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling 30.05 4 4.29E-02 
 
 
Calcium Folinate 
Category Term Fold Enrichment Count 
Benjamini 
corrected p-value 
MF GO:0019899~enzyme binding 3.99 13 3.84E-02 
 
 
Amylocaine  
Category Term Fold Enrichment Count 
Benjamini 
corrected p-value 
CC GO:0005829~cytosol 1.67 52 2.75E-04 
 
 
Salbutamol  
Category Term Fold Enrichment Count 
Benjamini 
corrected p-value 
CC GO:0005615~extracellular space 2.59 31 4.09E-04 
BP GO:0042060~wound healing 10.83 8 1.06E-02 
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BP GO:0043066~negative regulation of apoptotic process 3.81 16 1.20E-02 
MF GO:0008022~protein C-terminus binding 5.87 10 1.73E-02 
BP GO:0042127~regulation of cell proliferation 5.86 10 2.17E-02 
BP GO:0008283~cell proliferation 3.85 13 3.49E-02 
BP GO:0007267~cell-cell signaling 4.69 11 3.64E-02 
BP GO:0001525~angiogenesis 4.86 10 3.80E-02 
BP GO:0001666~response to hypoxia 5.67 9 3.83E-02 
BP GO:0030335~positive regulation of cell migration 5.30 9 4.51E-02 
CC GO:0005737~cytoplasm 1.44 67 4.59E-02 
 
 
Metaraminol  
Category Term Fold Enrichment Count 
Benjamini 
corrected p-value 
CC GO:0005615~extracellular space 2.46 30 1.82E-03 
 
All GO terms that were identified by DAVID bioinformatics in the DEGs derived from the CMAP-gene profiles. For 
the search the 100 most upregulated and 100 most downregulated probes were selected based on the average of the 
ratioed (instance to the control) normalized expression values for the two instances for each compound. The GO terms 
within the clusters had a significance of Benjamini corrected p-value < 0.05. The headers “biological process”, 
“molecular function”, and “cellular component” stands for the GO category to which the GO term is annotated. 
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Table A3: All proteins found by CLIC3-His pull down 
 
Protein name Gene ID Ratio LFQ  
CLIC3 / EV 
Chloride intracellular channel protein 3 CLIC3 1227400000 
Serine/threonine-protein kinase Nek9 NEK9 5714650 
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 PLCB3 3564350 
Aminoacyl tRNA synthase complex-interacting multifunctional 
protein 1 
AIMP1 2891250 
Casein kinase II subunit alpha 3; 
Casein kinase II subunit alpha 
CSNK2A1; 
CSNK2A3 2350900 
40S ribosomal protein S28 RPS28 1803250 
Phosphatidylserine synthase 1 PTDSS1 1471350 
Nuclear pore complex protein Nup160 NUP160 1106150 
Rho guanine nucleotide exchange factor 7 ARHGEF7 2.72 
Lipoamide acyltransferase component of branched-chain alpha-keto 
acid dehydrogenase complex 
DBT 2.39 
Centrosomal protein of 170 kDa CEP170 2.24 
Cytosolic acyl coenzyme A thioester hydrolase ACOT7 2.20 
LIM domain only protein 7 LMO7 2.08 
Splicing factor, proline- and glutamine-rich SFPQ 2.03 
cAMP-dependent protein kinase type I-alpha regulatory subunit PRKAR1A 2.03 
BTB/POZ domain-containing protein KCTD12 KCTD12 2.00 
Serine/arginine repetitive matrix protein 1 SRRM1 1.96 
Phostensin PPP1R18 1.95 
Heterogeneous nuclear ribonucleoprotein D0 HNRNPD 1.89 
Actin, aortic smooth muscle; 
Actin, gamma-enteric smooth muscle 
ACTA2; 
ACTG2 1.85 
Kinectin KTN1 1.80 
Mesoderm-specific transcript homolog protein MEST 1.79 
Sorting nexin-33 SNX33 1.78 
Transitional endoplasmic reticulum ATPase VCP 1.76 
Nucleoporin NUP188  NUP188 1.76 
5-nucleotidase NT5E 1.74 
26S proteasome non-ATPase regulatory subunit 4 PSMD4 1.72 
Heterogeneous nuclear ribonucleoprotein U-like protein 2 HNRNPUL2-
BSCL2 1.72 
Pinin PNN 1.69 
Heterogeneous nuclear ribonucleoprotein M HNRNPM 1.68 
Formin-binding protein 1-like FNBP1L 1.68 
RuvB-like 1 RUVBL1 1.66 
Nexilin NEXN 1.66 
E3 SUMO-protein ligase RanBP2 RANBP2 1.65 
LIM and SH3 domain protein 1 LASP1 1.65 
Sorbin and SH3 domain-containing protein 2 SORBS2 1.65 
Lamin-B2 LMNB2 1.65 
Caveolin-1; Caveolin CAV1 1.62 
H/ACA ribonucleoprotein complex subunit 4 DKC1 1.61 
Importin subunit beta-1 KPNB1 1.61 
Caldesmon CALD1 1.58 
Ribose-phosphate pyrophosphokinase 1;  
Ribose-phosphate pyrophosphokinase 2;  
Ribose-phosphate pyrophosphokinase 3 
PRPS1; 
PRPS2; 
PRPS1L1 
1.58 
Protein FAM98B FAM98B 1.58 
Plasminogen activator inhibitor 1 SERPINE1 1.57 
THO complex subunit 2 THOC2 1.55 
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Heterogeneous nuclear ribonucleoproteins C1/C2; Heterogeneous 
nuclear ribonucleoprotein C-like 1; Heterogeneous nuclear 
ribonucleoprotein C-like 2 
HNRNPC; 
HNRNPCL1; 
HNRNPCL2 
1.53 
Pentraxin-related protein PTX3 PTX3 1.52 
Nuclear RNA export factor 1 NXF1 1.52 
Alpha-parvin PARVA 1.52 
Casein kinase I isoform delta;  
Casein kinase I isoform epsilon 
CSNK1E; 
CSNK1D 1.51 
Oxysterol-binding protein 1 OSBP 1.51 
Glia-derived nexin SERPINE2 1.50 
All proteins found by His-tagged CLIC3 pull down that met our selection criteria: 1) LFQ value in CLIC3 samples of 
greater than 1 x 106, 2) number of unique peptides covering a protein equals 3 or more, and 3) ratio of CLIC3 samples 
versus control samples of 1.5 or greater. Protein lysates from osteogenically differentiating hMSCs were isolated on day 
5 in cultures either overexpressing His-tagged CLIC3 or transduced with empty vector (EV) control, and subjected to 
protein pull-down for the His-tagged CLIC3 and proteins binding to it. Proteins were determined by mass spectrometry 
measurements (n=2). The top proteins are listed here, ranked on their ratio of CLIC3 versus control average LFQ 
intensity (i.e. present in CLIC3 overexpressing condition and absent in the EV condition). LFQ: Label-free 
quantification.  
 
 
 
 
 
Table A4: Canonical Pathways associated with CLIC3-His pull-down proteins 
 
Rank Ingenuity Canonical Pathways p-value 
1 PRPP Biosynthesis I 0.00000002 
2 Gap Junction Signaling 0.00005623 
3 Paxillin Signaling 0.00015136 
4 Mechanisms of Viral Exit from Host Cells 0.00017783 
5 Integrin Signaling 0.00019055 
6 Cellular Effects of Sildenafil (Viagra) 0.00038019 
7 Agrin Interactions at Neuromuscular Junction 0.00081283 
8 Caveolar-mediated Endocytosis Signaling 0.00089125 
9 RAN Signaling 0.00091201 
10 FAK Signaling 0.00162181 
11 Virus Entry via Endocytic Pathways 0.00169824 
12 Stearate Biosynthesis I (Animals) 0.00389045 
13 RhoA Signaling 0.00416869 
14 MSP-RON Signaling Pathway 0.00660693 
15 Epithelial Adherens Junction Signaling 0.00691831 
16 Amyloid Processing 0.00812831 
All canonical pathways determined by Ingenuity pathway analysis of the 52 proteins obtained from CLIC3-His pull 
down. Cutoff for selection set at p < 0.01 
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Table A5: Gene Ontology (GO) terms associated with CLIC3-His pull-down proteins 
 
GO term: Biological Process Benjamini corrected  
p-value 
Fold Enrichment 
RNA localization 0.000351 14.16 
transport of virus 0.000698 29.13 
multi-organism localization 0.000767 27.55 
multi-organism transport 0.000767 27.55 
ribonucleoprotein complex localization 0.000776 19.03 
RNA export from nucleus 0.000942 19.34 
ribonucleoprotein complex export from nucleus 0.001107 20.16 
nuclear export 0.002483 12.86 
establishment of RNA localization 0.002626 12.93 
biological adhesion 0.002811 3.37 
cell adhesion 0.002987 3.38 
nucleic acid transport 0.003287 13.14 
RNA transport 0.003287 13.14 
mRNA-containing ribonucleoprotein complex export from 
nucleus 
0.003353 19.80 
mRNA export from nucleus 0.003353 19.80 
endomembrane system organization 0.003963 6.12 
viral life cycle 0.005063 6.68 
nucleobase-containing compound transport 0.005094 11.01 
interspecies interaction between organisms 0.005137 4.03 
symbiosis, encompassing mutualism through parasitism 0.005137 4.03 
multi-organism cellular localization 0.005237 24.99 
multi-organism intracellular transport 0.005237 24.99 
RNA processing 0.005512 4.48 
intracellular transport of virus 0.005597 25.36 
mRNA transport 0.007155 13.59 
regulation of protein catabolic process 0.008455 7.33 
positive regulation of protein catabolic process 0.008496 9.26 
RNA splicing 0.011931 6.83 
multi-organism cellular process 0.014118 3.80 
mitotic cell cycle process 0.014203 4.21 
viral process 0.014511 3.83 
regulation of cellular component organization 0.014704 2.61 
mitotic nuclear envelope disassembly 0.020010 30.89 
positive regulation of catabolic process 0.023241 7.12 
nucleocytoplasmic transport 0.023247 5.80 
nuclear transport 0.023529 5.70 
cell cycle process 0.023977 3.25 
cell-cell adhesion 0.024154 3.48 
mitotic cell cycle 0.024168 3.87 
membrane disassembly 0.024965 28.32 
nuclear envelope disassembly 0.024965 28.32 
regulation of catabolic process 0.033027 5.33 
mRNA metabolic process 0.033389 4.57 
regulation of proteolysis 0.047213 4.30 
GO term: Molecular Function Benjamini corrected  
p-value 
Fold Enrichment 
poly(A) RNA binding 0.000003 4.92 
RNA binding 0.000007 3.90 
cadherin binding 0.002150 8.04 
protein binding involved in cell adhesion 0.002475 8.09 
protein binding involved in cell-cell adhesion 0.002786 8.23 
cadherin binding involved in cell-cell adhesion 0.002993 8.51 
Appendix C: Supplementary Tables and Figures | 
 157 
cell adhesion molecule binding 0.022222 5.35 
organic cyclic compound binding 0.048282 1.58 
GO term: Cellular Component Benjamini corrected  
p-value 
Fold Enrichment 
anchoring junction 0.000198 5.47 
adherens junction 0.000513 5.20 
cytosol 0.002340 2.16 
cell junction 0.003319 3.24 
nuclear periphery 0.003662 13.61 
cell-cell adherens junction 0.006602 6.72 
nuclear pore 0.006943 17.22 
nucleoplasm 0.022067 2.05 
nuclear body 0.043307 5.47 
cell-cell junction 0.044715 3.89 
GO terms that were identified by DAVID bioinformatics analysis of the 52 proteins obtained from CLIC3-His pull 
down. Cutoff for selection set at benjamini corrected p < 0.05 
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Figure A6. Cross sectional study of body, muscle and adipose depot weights from WT (+/+, black bar) and 
Muc1 deficient (-/-, white bar) mice at 8, 16, and 52 weeks of age. Total body weight (A). Femoral (B) and tibial 
(C) muscle weight relative to total body weight. Relative weights of subcutaneous (D), scapular (E), and gonadal (F) 
adipose deposits. Statistics: student t-test * = p<0.05 WT vs. Muc1-/- comparing WT versus KO at each time point. For 
body weight 8 weeks (n=10 WT, n=9 KO); 16 weeks (n=9 WT, n=10 KO); 52 weeks (n=9 WT, n=10 KO). For muscle 
weights 8 weeks (n=10 WT, n=9 KO); 52 weeks (n=8 WT, n=9 KO). For subcutaneous and scapular adipose weights 
16 weeks (n=7 WT, n=8 KO); 52 weeks (n=8 WT, n=10 KO). For gonadal adipose weights 16 weeks (n=7 WT, n=8 
KO). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7. Body weight, femur length, and ex vivo evaluation of microarchitecture of femoral bones from 8-, 
16-, and 52-week-old WT and Muc1 deficient male mice. Total body weight of WT (+/+, black bar) and KO (-/-, 
white bar) male mice (A). Femur length of WT and KO male mice (B). Trabecular bone fraction (C), trabecular number 
(D), trabecular thickness (E), and trabecular separation (F) were measured at the metaphyseal region. Cortical bone area 
(G), marrow area (H), cortical thickness (I), and periosteal perimeter (mid-shaft circumference) (J) were measured at 
diaphyseal areas. For body weight 8 weeks (n=10); 16 weeks (n=9); 52-weeks (n=10 WT, n=9 KO). For bone length 8 
weeks (n=9 WT, n=10 KO); 16 weeks (n=9 WT, n=8 KO); 52-weeks (n=8 WT, n=7 KO). For trabecular and cortical 
bone analysis 8 weeks (n=10); 16 weeks (n=9); 52-weeks (n=10 WT, n=8 KO). Statistics: student t-test exact p value, * 
= p<0.05 WT vs. Muc1-/- within time point, and ** = p<0.01 WT vs. Muc1-/- within time point. # = p < 0.05 compared 
to 8wk WT mice, ## = p < 0.01 compared to 8wk WT mice, ### = p < 0.001 compared to 8wk WT mice. $ = p < 
0.05 compared to 8wk KO mice, $$ = p < 0.01 compared to 8wk KO mice, $$$ = p < 0.001 compared to 8wk KO 
mice. 
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Figure A8: Mechanical testing of femurs of 8-, 16-, and 52-week old WT (+/+, black bar) and Muc1 deficient 
(-/-, white bar) male mice. Three-point bending tests performed on the femurs of WT and KO mice allowed for 
quantification of the energy to failure (A), ultimate load (B), and bone stiffness (C) of the bones. Statistics: student t-test 
* = p<0.05 WT vs. Muc1-/- within time point. ### = p < 0.001 compared to 8wk WT mice. $ = p < 0.05 compared to 
8wk KO mice. $$ = p < 0.01 compared to 8wk KO mice.  8 weeks (n=10 WT, n=9 KO); 16 weeks (n=9 WT, n=10 
KO); 52-weeks (n=10 WT, n=9 KO). 
 
 
 
 
 
Figure A9: Muc1 expression in osteoclasts. mRNA expression levels of Muc1 in differentiation murine osteoclasts at 
day 3 (black bar) and 7 (white bar) as assessed by quantitative PCR. Results are presented as relative to the housekeeping 
gene Hrpt. n = 3 donor mice.  
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D. Abbreviation Index 
 
 
αMEM  alpha minimum essential medium 
µCT  micro–computed tomography 
ALP   alkaline phosphatase (enzyme/activity) 
ALPL   alkaline phosphatase liver/bone/kidney (gene) 
ATF4  Activating Transcription Factor 4  
BFR  bone formation rate 
BGLAP  osteocalcin (gene) 
BMD   bone mineral density  
BMP   Bone Morphogenetic Protein 
BRU   bone remodeling unit 
BSA  bovine serum albumen 
BV  bone volume 
BV/TV  bone volume fraction  
CBFA1  core-binding factor subunit alpha-1 
CLIC3  Chloride Intracellular Channel Protein 3 
CMap   Connectivity Map  
COL1A1 collagen type I alpha 1 chain 
cRNA  complementary RNA 
DAPI  4',6-diamidino-2-phenylindole 
DEG  Differentially Expressed Gene 
dex   dexamethasone  
DNA  deoxyribonucleic acid 
DXA   Dual energy X-ray absorptiometry  
ECM   extracellular matrix  
ERa  estrogen receptor alpha  
EV   empty vector  
FA  focal adhesion 
FACS   Fluorescence-Activated Cell Sorting  
FGF  Fibroblast Growth Factor  
FITC  fluorescein isothiocyanate 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GO   Gene Ontology  
GR   glucocorticoid receptor 
HMOX1  heme oxygenase 1 
Hprt  hypoxanthine Phosphoribosyltransferase 1 
IBSP   bone sialoprotein  
IGF-I   Insulin-like Growth Factor I  
kDa  kilodalton 
KO  knockout 
LFQ  label-free quantification  
LMHD   Lenz-Majewski hyperostotic dwarfism  
LS/MS   liquid chromatography–mass spectrometry  
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MAR  mineral apposition rate 
M-CSF   macrophage-Colony Stimulating Factor  
mRNA  messenger RNA 
MSC   Mesenchymal stromal cell 
MUC1  Mucin 1  
NEK9  NIMA-related kinase 9  
OPG   osteoprotegerin  
OSX   Osterix  
PBMC  peripheral blood mononuclear cell 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PNP   p-nitrophenol 
PNPP   p-nitrophenyl phosphate 
PPAR-γ2 peroxisome proliferator-activated receptor-gamma 2  
PS   phosphatidyl serine  
PSS  phosphatidylserine synthase   
PTDSS1 phosphatidylserine synthase 1  
PTH   Parathyroid hormone 
RANKL  Receptor Activator of Nuclear kappa B Ligand  
RFU  relative fluorescence units 
RLU  Relative Light Unit 
RNA  Ribonucleic acid 
RUNX2 Runt-related transcription factor 2  
SATB2  Special AT-rich Binding 2  
SEM (or SE) standard error of the mean 
SD  standard deviation 
shRNA  short hairpin RNA 
SOX9  Sex determining region Y-box 9  
SP7  Osterix (gene) 
SPP1  osteopontin 
STC1  Stanniocalcin-1 
SV-HFO  Simian virus-immortalized human fetal osteoblasts  
TGFß   transforming growth factor-ß  
TRAcP (TRAP) Tartrate-resistant acid phosphatase  
WT  wild type
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